CLINICAL STUDY PROTOCOL

Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed

Sponsor: Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

IND Number: 125589
EudraCT Number: 2017-000308-17
Clinical Trials.gov Identifier: TBD

Indication: HIV-1 Infection


Gilead Study Clinical Program Manager: Name: PPD
Telephone: PPD
Fax: PPD

Gilead Medical Monitor: Name: PPD
Telephone: PPD
Fax: PPD

Protocol Version/Date: Original: 06 February 2017
Amendment 1: 20 March 2017
Amendment 2: 28 June 2018

CONFIDENTIALITY STATEMENT

The information contained in this document, particularly unpublished data, is the property or under control of Gilead Sciences, Inc., and is provided to you in confidence as an investigator, potential investigator, or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies of the investigational drug described in the protocol. You will not disclose any of the information to others without written authorization from Gilead Sciences, Inc., except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered.
TABLE OF CONTENTS

TABLE OF CONTENTS ................................................................................................................................. 2
LIST OF IN-TEXT TABLES ................................................................................................................................ 5
LIST OF IN-TEXT FIGURES ............................................................................................................................... 5
PROTOCOL SYNOPSIS ....................................................................................................................................... 6
GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS ..................................................................... 13
1. INTRODUCTION .............................................................................................................................................. 16
  1.1. Background .................................................................................................................................................. 16
  1.2. Bictegravir .................................................................................................................................................. 17
      1.2.1. General Information .......................................................................................................................... 17
      1.2.2. Preclinical Pharmacology and Toxicology ......................................................................................... 17
      1.2.3. Clinical Studies of BIC ....................................................................................................................... 19
  1.3. Information About Emtricitabine/Tenofovir Alafenamide (Descovy®, F/TAF) ...................................... 31
  1.4. Information about B/F/TAF ......................................................................................................................... 31
      1.4.1. GS-US-141-1233: Relative Bioavailability of BIC, FTC, and TAF between B/F/TAF and BIC+F/TAF .... 31
  1.5. Information about Dolutegravir (DTG, Tivicay®) ..................................................................................... 32
  1.6. Rationale for this Study ............................................................................................................................... 32
  1.7. Risk/Benefit Assessment for the Study ...................................................................................................... 33
  1.8. Rationale for Dose Selection ..................................................................................................................... 33
  1.9. Compliance ............................................................................................................................................... 35
2. OBJECTIVES .................................................................................................................................................. 36
3. STUDY DESIGN ............................................................................................................................................... 37
  3.1. Endpoints ................................................................................................................................................... 37
  3.2. Study Design ........................................................................................................................................... 37
  3.3. Study Treatments .................................................................................................................................... 37
  3.4. Duration of Treatment ............................................................................................................................... 37
  3.5. Biomarker Testing .................................................................................................................................. 38
      3.5.1. PPD ....................................................................................................................................................... 39
      3.5.2. Additional Sample Storage ............................................................................................................... 39
4. SUBJECT POPULATION ............................................................................................................................. 40
  4.1. Number of Subjects and Subject Selection ............................................................................................. 40
  4.2. Inclusion Criteria ..................................................................................................................................... 40
  4.3. Exclusion Criteria ..................................................................................................................................... 42
5. INVESTIGATIONAL MEDICINAL PRODUCTS (IMP) .................................................................................... 44
  5.1. Randomization, Blinding and Treatment Codes ......................................................................................... 44
      5.1.1. Procedures for Breaking Treatment Codes ......................................................................................... 44
  5.2. Description and Handling ......................................................................................................................... 45
      5.2.1. Formulation ........................................................................................................................................ 45
      5.2.2. Packaging and Labeling ................................................................................................................... 46
      5.2.3. Storage and Handling ....................................................................................................................... 47
  5.3. Dosage and Administration of B/F/TAF and DTG+F/TAF .................................................................... 47
  5.4. Prior and Concomitant Medications ....................................................................................................... 47
  5.5. Accountability for IMP ............................................................................................................................ 48
      5.5.1. IMP Return or Disposal .................................................................................................................. 49

CONFIDENTIAL Page 2 28 June 2018
6. STUDY PROCEDURES................................................................................................................ 50
   6.1. Subject Enrollment and Treatment Assignment ................................................................. 50
   6.2. Pretreatment Assessments ................................................................................................... 50
       6.2.1. Screening Visit ........................................................................................................... 50
       6.2.2. Day 1 Assessments ................................................................................................... 51
   6.3. Randomization ....................................................................................................................... 51
   6.4. Treatment Assessments (Week 4 - 48) .................................................................................. 52
   6.5. Treatment Assessments (Post Week 48 until the End of Blinded Treatment Visit) .................. 53
       6.5.1. Post Week 48 Assessments ....................................................................................... 53
       6.5.2. End of Blinded Treatment Visit Assessments ............................................................. 53
       6.5.3. OL Extension Assessments ....................................................................................... 54
   6.6. Post-treatment Assessments .................................................................................................. 55
       6.6.1. Early Study Drug Discontinuation Assessments ........................................................... 55
       6.6.2. 30-Day Follow-Up Visit ............................................................................................ 56
   6.7. Criteria for Discontinuation of Study Treatment .................................................................... 56
   6.8. End of Study ........................................................................................................................... 57
   6.9. Post Study Care ....................................................................................................................... 57
   6.10. Clinical Laboratory Assessments ........................................................................................ 57
       6.10.1. Blood Samples ......................................................................................................... 57
       6.10.2. Urine Samples ......................................................................................................... 59
       6.10.3. PPD .......................................................................................................................... 59
   6.11. Virologic Failure ................................................................................................................. 59
       6.11.1. Management of Virologic Rebound ........................................................................... 59
       6.11.2. Subjects with HIV-1 RNA ≥ 50 copies/mL at Study Drug Discontinuation, or Week 48 ......................................................................................................................... 61
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT ................................................................ 62
   7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events ....................... 62
       7.1.1. Adverse Events ........................................................................................................... 62
       7.1.2. Serious Adverse Events ............................................................................................. 62
       7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious Adverse Events ......................................................................................... 63
   7.2. Assessment of Adverse Events and Serious Adverse Events ................................................. 63
       7.2.1. Assessment of Causality for Study Drugs and Procedures ........................................... 63
       7.2.2. Assessment of Severity .............................................................................................. 64
   7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious Adverse Events to Gilead ........................................................................................................... 64
       7.3.1. Adverse Events .......................................................................................................... 64
       7.3.2. Serious Adverse Events ............................................................................................ 65
   7.4. Gilead Reporting Requirements ............................................................................................ 66
   7.5. Toxicity Management ............................................................................................................ 66
       7.5.1. Grades 1 and 2 Laboratory Abnormality or Clinical Event .......................................... 66
       7.5.2. Grade 3 Laboratory Abnormality or Clinical Event ..................................................... 66
       7.5.3. Grade 4 Laboratory Abnormality or Clinical Event ..................................................... 67
       7.5.4. On-Treatment ALT Flare ............................................................................................ 67
       7.5.5. Management of Potential Hepatobiliary Toxicity ......................................................... 68
       7.5.6. On-Treatment Hepatitis C Management ...................................................................... 68
   7.6. Special Situations Reports ..................................................................................................... 69
       7.6.1. Definitions of Special Situations .................................................................................. 69
       7.6.2. Instructions for Reporting Special Situations ............................................................... 69
8. STATISTICAL CONSIDERATIONS ........................................................................................... 71
   8.1. Analysis Objectives and Endpoints ....................................................................................... 71
8.1. Analysis Objectives..................................................................................................................71
8.1.2. Primary Endpoint ....................................................................................................................71
8.1.3. Secondary Endpoint ................................................................................................................71
8.2. Analysis Conventions..................................................................................................................71
8.2.1. Analysis Sets ..........................................................................................................................71
8.3. Data Handling Conventions ......................................................................................................72
8.4. Demographic Data and Baseline Characteristics .....................................................................73
8.5. Efficacy Analysis ........................................................................................................................73
8.5.1. Primary Analysis .........................................................................................................................73
8.5.2. Secondary Analyses ...................................................................................................................74
8.6. Safety Analysis ............................................................................................................................75
8.6.1. Extent of Exposure ......................................................................................................................75
8.6.2. Adverse Events ........................................................................................................................75
8.6.3. Laboratory Evaluations .........................................................................................................76
8.6.4. Other Safety Evaluations .......................................................................................................76
8.7. Patient Reported Outcomes (PRO) ............................................................................................76
8.8. Sample Size ...............................................................................................................................76
8.9. Data Monitoring Committee .....................................................................................................77
8.10. Analysis Schedule ......................................................................................................................77
9. RESPONSIBILITIES ......................................................................................................................78
9.1. Investigator Responsibilities .........................................................................................................78
9.1.1. Good Clinical Practice .............................................................................................................78
9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) Review and Approval ........................................................................................................................................78
9.1.3. Informed Consent .......................................................................................................................78
9.1.4. Confidentiality ........................................................................................................................79
9.1.5. Study Files and Retention of Records .....................................................................................79
9.1.6. Case Report Forms ..................................................................................................................80
9.1.7. Investigational Medicinal Product Accountability and Return ................................................81
9.1.8. Inspections ................................................................................................................................81
9.1.9. Protocol Compliance ...............................................................................................................81
9.2. Sponsor Responsibilities ..............................................................................................................82
9.2.1. Protocol Modifications ............................................................................................................82
9.2.2. Study Report and Publications ................................................................................................82
9.3. Joint Investigator/Sponsor Responsibilities ..................................................................................82
9.3.1. Payment Reporting ................................................................................................................82
9.3.2. Access to Information for Monitoring ..................................................................................83
9.3.3. Access to Information for Auditing or Inspections ................................................................83
9.3.4. Study Discontinuation ............................................................................................................83
10. REFERENCES ................................................................................................................................84
11. APPENDICES ................................................................................................................................86

Appendix 1. Investigator Signature Page .................................................................................................87
Appendix 2. Study Procedures Table ....................................................................................................88
Appendix 3. Management of Clinical and Laboratory Adverse Events ..................................................92
Appendix 4. Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities .......93
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines) .......................115
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements...117
LIST OF IN-TEXT TABLES

Table 1-1. GS-US-141-1218: BIC Mean (%CV) PK Parameters Following Single Doses of BIC in Healthy Subjects (BIC PK Analysis Set; Part A: Single Dosing). ........................................... 22
Table 1-2. GS-US-141-1218: BIC Plasma Pharmacokinetic Parameters by BIC Dose Following Multiple-Dose Administration of BIC (Analysis Set: BIC PK Part B: Multiple-Dose) ........................................................................................................ 23
Table 1-4. Trough BIC Plasma Concentrations at Steady State Following BIC Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values (BIC PK Analysis Set). ........................................................................................................ 25
Table 1-5. GS-US-141-1475: Virologic Outcome at Week 48 Using the US FDA-Defined Snapshot Algorithm and HIV-1 RNA < 50 copies/mL (FAS) ................................................................................. 28
Table 1-6. GS-US-141-1219: Trough BIC Plasma Concentrations at Steady State Following BIC Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values ........................................................................................................ 34
Table 5-1. Prior and Concomitant Medications ............................................................................. 48

LIST OF IN-TEXT FIGURES

Figure 1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA (log_{10} copies/mL) (PP Analysis Set). .................................................................................. 25
Figure 3-1. Study Schema ......................................................................................................... 38
Figure 6-1. Virologic Rebound Schema ................................................................................. 60
PROTOCOL SYNOPSIS

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404

Study Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed

IND Number: 125589
EudraCT Number: 2017-000308-17
Clinical Trials.gov Identifier: TBD

Study Centers Planned: Approximately 100 centers in North America and Europe

Objectives:
The primary objective of this study is:

- To evaluate the efficacy of switching from a regimen of either dolutegravir (DTG) and emtricitabine/tenofovir alafenamide (F/TAF) or DTG and emtricitabine/tenofovir disoproxil fumarate (F/TDF) to a fixed dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus DTG+F/TAF in virologically suppressed HIV-1 infected subjects with or without antiretroviral (ARV) resistance as determined by the proportion of subjects with virologic failure HIV-1 RNA ≥ 50 copies/mL at Week 48

The secondary objective of this study is:

- To evaluate the safety and tolerability of the two treatment groups through Week 48

Study Design: Randomized, double-blind, multicenter, active-controlled study to evaluate the safety and efficacy of switching to a FDC of B/F/TAF versus DTG+F/TAF in HIV-1 infected subjects who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable regimen of DTG+F/TAF or DTG+F/TDF for ≥ 6 months prior to screening (if there is documented or suspected nucleos(t)ide reverse transcriptase inhibitor [NRTI] resistance), or ≥ 3 months prior to screening (if there is no documented or suspected NRTI resistance).
Subjects who provide written consent and meet all eligibility criteria will be randomized in a 1:1 ratio to switch to one of the following 2 treatment groups:

**Treatment Group 1 (n=260):** FDC of B/F/TAF (50/200/25 mg) + placebo to match DTG 50 mg + placebo to match FDC of F/TAF (200/25 mg) administered orally, once daily (QD), without regard to food (total of 3 tablets)

**Treatment Group 2 (n=260):** DTG 50 mg + FDC of F/TAF (200/25 mg) + placebo to match FDC of B/F/TAF (50/200/25 mg) administered orally, QD, without regard to food (total of 3 tablets)

Randomization will be stratified by prior NRTI use (F/TAF vs. F/TDF) and documented or suspected history of NRTI resistance. The following NRTI-associated mutations will be considered as having NRTI resistance: M41L, K65R/E/N, D67N, T69 insertions, K70R, L74I/V, Y115F, Q151M, M184I/V, L210W, T215F/Y, K219Q/E/R/N, T69D, K70E/G/M/Q/S/T, V75A/S/M/T. NRTI resistance will be stratified by the following categories:

1) K65R/E/N, or 3 or more thymidine analogue mutations (TAMs) that include M41L or L210W, or T69 insertions, (TAMs are: M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/R/N)


3) None of these mutations/No NRTI resistance

For subjects that qualify for more than one resistance category, stratification will be prioritized by category 1, then 2, then 3 above. Subjects taking F/TDF prior to study entry will discontinue F/TDF and will switch to an F/TAF-containing regimen (blinded B/F/TAF or DTG+F/TAF). Subjects taking F/TAF prior to study entry will remain on an F/TAF-containing regimen (blinded B/F/TAF or DTG+F/TAF).

**Number of Subjects Planned:**
Approximately 520 subjects in total.
260 subjects in each Treatment Group 1 and Treatment Group 2

**Target Population:**
HIV-1 infected adult subjects who are virologically suppressed (HIV-1 RNA < 50 copies/mL) for ≥ 6 months (if there is documented or suspected NRTI resistance), or ≥ 3 months (if there is no documented or suspected NRTI resistance) prior to screening, on a stable regimen of DTG+F/TAF or DTG+F/TDF.
Duration of Treatment: Subjects will be treated for at least 48 weeks during the blinded treatment phase.

After Week 48, all subjects will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Once the last subject completes the Week 48 visit and Week 48 analysis is completed, all subjects will return to the clinic (preferably within 30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF FDC is demonstrated following review of unblinded data, subjects in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label (OL) extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead Sciences elects to discontinue the study in that country, whichever occurs first.

All subjects participating in the OL extension phase, without regard to their blinded treatment regimen, will return for study visits at Week 12 OL and every 12 weeks thereafter for up to 96 weeks.

Subjects who complete the study through the End of Blinded Treatment Visit and do not continue on the open-label B/F/TAF FDC extension phase, will be required to return to the clinic 30 days after the End of Blinded Treatment Visit for a 30-Day Follow-Up Visit.

Treatment assignments will be provided to the investigators within 30 days of the last subject completing the End of Blinded Treatment Visit.

Diagnosis and Main Eligibility Criteria: Medically stable HIV-1 infected subjects who meet the following criteria:

- Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:
  - ≥ 6 months (if there is documented or suspected NRTI resistance prior to the screening visit),
  - ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)
Documented plasma HIV-1 RNA < 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the Screening Visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)

- The last two HIV-1 RNA measurements prior to screening must be < 50 copies/mL; however, unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or “blip”) in the past are acceptable.

- If the lower limit of detection of the local HIV-1 RNA assay is < 50 copies/mL (eg, < 20 copies/mL), the plasma HIV-1 RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests after < 50 copies/mL has been achieved.

- HIV-1 RNA levels < 50 copies/mL at Screening Visit.

- Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance

- No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure (2 consecutive HIV-1 RNA ≥ 50 copies/mL after achieving < 50 copies/mL while on an INSTI-containing regimen)

- Eligible subjects with the following historical ARV resistance are permitted to enroll:
  - Any NRTI resistance mutations
  - Any non-nucleoside reverse transcriptase mutations
  - Any protease inhibitor mutations
  - Subjects with resistance to 2 or more classes of antiretrovirals must be reviewed by the Gilead Medical Monitor to confirm eligibility

- Eligible subjects with chronic HBV and/or HCV infection are permitted to enroll

Study Procedures/Frequency: After screening procedures, eligible subjects will be randomized 1:1 to Treatment Group 1 or Treatment Group 2, and treated for at least 48 weeks. Following the Day 1 visit, subjects will return for study visits at Weeks 4, 8, and 12, and then every 12 weeks through the End of Blinded Treatment Visit.
For all eligible subjects, blood and urine will be collected at Day 1, Weeks 4, 8, 12, and then every 12 weeks through the End of Blinded Treatment Visit. Laboratory analyses (hematology, chemistry, and urinalysis), HIV-1 RNA, CD4+ cell count and percentage, and complete or symptom-directed physical examinations will be performed at the Screening, Day 1, and all subsequent study visits.

Adverse events and concomitant medications will be assessed at each visit.

Historical HIV-1 RNA genotypes (from resistance testing) will be collected, if available.

<table>
<thead>
<tr>
<th>Test Product, Dose, and Mode of Administration:</th>
<th>FDC of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily without regard to food.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reference Therapy, Dose, and Mode of Administration:</td>
<td>Dolutegravir 50 mg (DTG) plus an FDC of emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) administered orally, once daily without regard to food.</td>
</tr>
</tbody>
</table>

Criteria for Evaluation:

Safety: Adverse events, clinical laboratory tests, and tolerability of treatment regimens

Efficacy: The primary efficacy endpoint is:

- The proportion of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm

The secondary endpoints include:

- The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm
- The change from baseline in CD4+ cell count at Week 48
Patient Reported Outcome: Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity and Activity Impairment Questionnaire (WPAI), and Pittsburgh Sleep Quality Index (PSQI) will be administered at Day 1, Weeks 4, 12, and 48.

Statistical Methods: The primary analysis will consist of a non-inferiority test of switching to B/F/TAF FDC versus DTG+F/TAF, with respect to the proportion of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48, as defined by the US FDA-defined snapshot algorithm. It will be concluded that B/F/TAF FDC is non-inferior to DTG+F/TAF if the upper bound of the 2-sided 95% confidence interval (CI) of the difference between treatment groups [B/F/TAF – (DTG+F/TAF)] in the percentage of subjects with HIV-1 RNA ≥ 50 copies/mL is less than 4% (ie, a margin of 4% is applied to non-inferiority assessment). The 2-sided 95% CIs will be constructed based on the exact method.

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm will also be summarized. The 95% CIs will be constructed in the same manner as described for the primary efficacy endpoint.

The change from baseline in CD4+ cell count at Week 48 will be summarized by treatment using descriptive statistics. The differences and the associated 95% CIs will be constructed using an Analysis of Variance (ANOVA) model, including treatment (B/F/TAF vs. DTG+F/TAF), prior NRTI use (F/TAF vs. F/TDF), and documented or suspected history of NRTI resistance as fixed effects in the model.

Adverse events and clinical laboratory assessment will be summarized using descriptive statistics.

Patient reported outcome instrument assessments may be summarized using descriptive statistics.

A total of approximately 520 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment groups (260 subjects per treatment group), achieves at least 90% power to detect a non-inferiority margin of 4% in difference in percentage in subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 between the 2 treatment groups.
For sample size and power computation, it is assumed that both treatment groups have 2% of subjects with HIV-1 RNA $\geq 50$ copies/mL at Week 48 (based on the historical Gilead Genvoya® and Stribild® studies), that a non-inferiority margin is 4%, and that the significance level of the test is at a one-sided 0.025 level.

This study will be conducted in accordance with the guidelines of Good Clinical Practice (GCP) including archiving of essential documents.
## GLOSSARY OF ABBREVIATIONS AND DEFINITION OF TERMS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>°C</td>
<td>degrees Celsius</td>
</tr>
<tr>
<td>°F</td>
<td>degrees Fahrenheit</td>
</tr>
<tr>
<td>AE</td>
<td>adverse event</td>
</tr>
<tr>
<td>AhR</td>
<td>aryl hydrocarbon receptor</td>
</tr>
<tr>
<td>AIDS</td>
<td>acquired immune deficiency syndrome</td>
</tr>
<tr>
<td>ALT</td>
<td>alanine aminotransferase</td>
</tr>
<tr>
<td>ANOVA</td>
<td>analysis of variance</td>
</tr>
<tr>
<td>ARV</td>
<td>antiretroviral</td>
</tr>
<tr>
<td>AST</td>
<td>aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>area under the plasma/serum/peripheral blood mononuclear cell concentration versus time curve</td>
</tr>
<tr>
<td>BA</td>
<td>bioavailability</td>
</tr>
<tr>
<td>BIC, B</td>
<td>bictegravir</td>
</tr>
<tr>
<td>B/F/TAF</td>
<td>bictegravir/emtricitabine/tenofovir alafenamide</td>
</tr>
<tr>
<td>BMD</td>
<td>bone mineral density</td>
</tr>
<tr>
<td>BUN</td>
<td>blood urea nitrogen</td>
</tr>
<tr>
<td>CBC</td>
<td>complete blood count</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CK</td>
<td>creatine kinase</td>
</tr>
<tr>
<td>CL_{cr}</td>
<td>creatinine clearance</td>
</tr>
<tr>
<td>C_{max}</td>
<td>the maximum observed serum/plasma/peripheral blood mononuclear (PBMC)</td>
</tr>
<tr>
<td></td>
<td>concentration of drug</td>
</tr>
<tr>
<td>C_{tmax}</td>
<td>the observed drug concentration at the end of the dosing interval</td>
</tr>
<tr>
<td>CPK</td>
<td>creatine phosphokinase</td>
</tr>
<tr>
<td>CRO</td>
<td>contract (or clinical) research organization</td>
</tr>
<tr>
<td>CSR</td>
<td>clinical study report</td>
</tr>
<tr>
<td>CYP</td>
<td>cytochrome P450</td>
</tr>
<tr>
<td>DHHS</td>
<td>Department of Health and Human Services</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DTG</td>
<td>dolutegravir, Tivicay®</td>
</tr>
<tr>
<td>ECG</td>
<td>electrocardiogram</td>
</tr>
<tr>
<td>eCRF</td>
<td>electronic case report form(s)</td>
</tr>
<tr>
<td>eGFR</td>
<td>estimated glomerular filtration rate</td>
</tr>
<tr>
<td>EVG</td>
<td>elvitegravir</td>
</tr>
<tr>
<td>E/C/F/TAF</td>
<td>elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide, Genvoya®</td>
</tr>
<tr>
<td>FAS</td>
<td>full analysis set</td>
</tr>
<tr>
<td>FDA</td>
<td>(United States) Food and Drug Administration</td>
</tr>
<tr>
<td>FDC</td>
<td>fixed dose combination</td>
</tr>
<tr>
<td>F/TAF</td>
<td>emtricitabine/tenofovir alafenamide, Descovy®</td>
</tr>
</tbody>
</table>
F/TDF  emtricitabine/tenofovir disoproxil fumarate
FTC, F  emtricitabine, Emtriva®
GCP  Good Clinical Practice (Guidelines)
GGT  gamma glutamyl transferase
GLSM  geometric least squares mean
GSI, Gilead  Gilead Sciences, Inc.
HAART  highly active antiretroviral therapy
HBV  hepatitis B virus
HBcAb  hepatitis B core antibody
HBeAb  hepatitis B virus e-antibody
HBsAb  hepatitis B surface antibody
HBsAg  hepatitis B surface antigen
HCV  hepatitis C virus
HDPE  high-density polyethylene
hERG  human Ether-à-go-go-Related Gene
HIV  human immunodeficiency virus
HLA  human leukocyte antigen
HLGT  high-level group term
HLT  high-level term
ICH  International Conference on Harmonisation
IDMC  Independent Data Monitoring Committee
IEC  Independent Ethics Committee
IMP, study drug  investigational medicinal products
IND  Investigational New Drug (Application)
INSTI  integrase strand-transfer inhibitor
IRB  institutional review board
IWRS  interactive web response system
KS  Kaposi’s sarcoma
LLN  lower limit of the normal range
LLT  lower level term
LSM  least-squares mean
MAD  multiple ascending dose
MedDRA  Medical Dictionary for Regulatory Activities
mg  milligram
min  minute
mmHg  millimeters mercury
NNRTI  non-nucleoside reverse transcriptase inhibitor
NOEL  no observed effect level
NRTI  nucleoside/nucleotide reverse transcriptase inhibitor
N(t)RTI  nucleos(t)ide reverse transcriptase inhibitor
<table>
<thead>
<tr>
<th>Acronym</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>OCT2</td>
<td>organic cation transporter 2</td>
</tr>
<tr>
<td>OL</td>
<td>open label</td>
</tr>
<tr>
<td>PBMC</td>
<td>peripheral blood mononuclear cell</td>
</tr>
<tr>
<td>PI</td>
<td>protease inhibitor</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PP</td>
<td>per-protocol</td>
</tr>
<tr>
<td>PRO</td>
<td>patient reported outcomes</td>
</tr>
<tr>
<td>PSQI</td>
<td>Pittsburgh Sleep Quality Index</td>
</tr>
<tr>
<td>PT</td>
<td>preferred term</td>
</tr>
<tr>
<td>PTM</td>
<td>placebo-to-match</td>
</tr>
<tr>
<td>PVE</td>
<td>Pharmacovigilance and Epidemiology</td>
</tr>
<tr>
<td>PXR</td>
<td>pregnane X receptor</td>
</tr>
<tr>
<td>RAL</td>
<td>raltegravir</td>
</tr>
<tr>
<td>rBA</td>
<td>relative bioavailability</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>SAD</td>
<td>single ascending dose</td>
</tr>
<tr>
<td>SADR</td>
<td>serious adverse drug reaction</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SF-36</td>
<td>Short Form 36 Health Survey</td>
</tr>
<tr>
<td>SmPC</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>SOC</td>
<td>system organ class</td>
</tr>
<tr>
<td>SOP</td>
<td>standard operating procedures</td>
</tr>
<tr>
<td>STR</td>
<td>single tablet regimen</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>TAF</td>
<td>tenofovir alafenamide</td>
</tr>
<tr>
<td>TAM</td>
<td>thymidine analogue mutations</td>
</tr>
<tr>
<td>TDF</td>
<td>tenofovir disoproxil fumarate, Viread®</td>
</tr>
<tr>
<td>TFV</td>
<td>tenofovir</td>
</tr>
<tr>
<td>TFV-DP</td>
<td>tenofovir diphosphate (TFVpp)</td>
</tr>
<tr>
<td>UGT1A1</td>
<td>uridine 5'-diphospho-glucuronosyltransferase</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of the normal range</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
<tr>
<td>WPAI</td>
<td>Work Productivity and Activity Impairment Questionnaire</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

1.1. Background

Human immunodeficiency virus-1 (HIV-1) infection is a life-threatening and serious disease that is of major public health interest around the world. There are approximately 2.4 million people in North America and Western and Central Europe living with HIV-1 and 37 million people worldwide {Joint United Nations Programme on HIV/AIDS (UNAIDS) 2016}. The infection, if left untreated or suboptimally treated, is characterized by deterioration in immune function, ultimately resulting in death. Therapeutic strategies for the treatment of HIV-1 disease have been significantly advanced by the availability of highly active antiretroviral therapy (HAART); the introduction of HAART was associated with a dramatic decrease in acquired immune deficiency syndrome (AIDS)-related morbidity and mortality {Palella 1998}, {Mocroft 1998}, {Sterne 2005}. The success of potent and well-tolerated antiretroviral therapy (ART) means that morbidity and mortality in the HIV-infected population is increasingly driven by non-AIDS–associated comorbidities. Clinical attention has become more focused on the optimization of tolerability, long-term safety, and adherence of potent ART regimens {Costagliola 2014}. In addition, there remains a significant medical need for new, effective therapies that take into consideration HIV genetic variability, the aging HIV-infected population, antiretroviral (ARV) resistance, non-HIV comorbidities, and regimen simplification.

For ART-naive HIV-infected patients, current treatment guidelines suggest that initial therapy consist of 2 nucleos(t)ide reverse transcriptase inhibitors (N[t]RTI) and either an integrase strand-transfer inhibitor (INSTI) or the boosted protease inhibitor darunavir {Panel on Antiretroviral Guidelines for Adults and Adolescents 2016}. Virologically suppressed, HIV-infected patients may switch from their current regimen because of safety or tolerability concerns or for regimen simplification. All patient populations may benefit from once-daily fixed-dose combination (FDC) regimens as these have been shown to provide increased adherence and improved clinical and virologic outcomes {Sterrantino 2012}, {Aldir 2014}

Tenofovir (TFV) is a nucleotide analog that inhibits HIV-1 reverse transcription. While tenofovir disoproxil fumarate (TDF), an oral prodrug of TFV, is a preferred NtRTI for initial therapy, nephrotoxicity is an identified risk, and reductions in bone mineral density (BMD) have been shown that are larger than those seen with other nucleoside/nucleotide reverse transcriptase inhibitor (NRTIs). Tenofovir alafenamide (TAF) is also an oral prodrug of TFV. TAF is more stable in plasma than TDF, provides higher intracellular levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP), and approximately 90% lower circulating levels of TFV relative to TDF at the clinical doses. The distinct metabolism of TAF offers the potential for an improved clinical profile compared with TDF.
Bictegravir (BIC) (previously referred to as GS-9883) is a potent inhibitor of HIV-1 integrase that is being evaluated for the treatment of HIV-1 infection. Antiviral testing has shown that BIC is active against a broad panel of HIV-1 viral lab strains and clinical isolates. BIC is fully active against a panel of mutant viruses with resistance to NRTIs, non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs). Integrase mutant viruses that are resistant to the INSTIs raltegravir (RAL) and elvitegravir (EVG) remain largely sensitive to BIC.

Gilead Sciences (Gilead) has coformulated BIC with the NRTI emtricitabine (FTC; F) and the NtRTI TAF into an FDC tablet that is suitable for once-daily use. This bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC may provide a potent, convenient, tolerable, and practical regimen for the long-term treatment of patients with HIV infection.

1.2. Bictegravir

1.2.1. General Information

BIC, a potent inhibitor of HIV-1 integrase is being evaluated for the treatment of HIV infection.

1.2.2. Preclinical Pharmacology and Toxicology

A core battery of safety pharmacology studies have been conducted with BIC. These include assessments of cytotoxicity, off-target receptor and ion-channel binding, effects on human Ether-à-go-go-Related Gene (hERG) potassium current and papillary muscle action potential, and in vivo studies in rats and dogs that evaluated effects of BIC on all major organ systems. The volume of distribution of BIC ranged between 0.09 and 0.22 L/kg in the preclinical species, which indicates that the distribution of BIC is limited to the extracellular compartment due to its high binding to plasma proteins. The projected half-life of BIC in humans is approximately 20 hours based upon the estimates of clearance and volume of distribution.

1.2.2.1. Pharmacology

BIC has IC\textsubscript{50} values ranging from 1.5 to 2.4 nM, similar to the inhibitory effect of dolutegravir (DTG) and EVG. BIC is highly potent against HIV replication in MT4 cells with an EC\textsubscript{50} (50\% effective inhibitory concentration) value of 1.9 nM and a protein adjusted EC\textsubscript{95} value of 361 nM. BIC does not show significant cytotoxicity against dividing and non-dividing human peripheral blood mononuclear cell (PBMCs), primary human hepatocytes and various non-target human cell lines.

BIC is mainly metabolized by uridine 5'-diphospho-glucuronosyltransferase (UGT1A1) and cytochrome P450 enzyme (CYP)3A. BIC does not inhibit major human CYP isoforms or UGT1A1 at concentrations up to 25 \( \mu \text{M} \). Consequently, BIC is unlikely to be a clinically relevant inhibitor of these enzymes, and is not expected to inhibit the metabolic clearance of drugs metabolized by these enzymes. BIC only modestly inhibits renal transporter organic cation transporter 2 (OCT2) (IC\textsubscript{50} = 0.42 \( \mu \text{M} \)). As a result, BIC is not expected to significantly interfere
with the key transporter responsible for creatinine tubular elimination at the clinically projected $C_{\text{max}}$. Additionally, the risk that BIC will affect the OCT2-mediated excretion of co-administered drugs is considered to be low.

BIC does not activate aryl hydrocarbon receptor (AhR) and only weakly activates pregnane X receptor (PXR) at concentrations up to 50 $\mu$M (less than 5% and 40% of activation, respectively, compared to positive control compound). Therefore, BIC is not expected to act as an inducer through PXR- or AhR-mediated pathways at the doses and exposure levels projected in clinical use.

1.2.2.2. Toxicology

Single oral doses of BIC up to 1000 mg/kg were well-tolerated in rats (AD-141-2286). The increase in exposure was limited (< 2-fold) between 100 and 300 mg/kg and similar exposure was observed between 300 and 1000 mg/kg suggesting saturation of absorption at 300 mg/kg ($\text{AUC}_{0-24} 2205 \, \mu\text{g} \cdot \text{h/mL}$ and 1931 $\mu$g·h/mL, respectively). In monkeys, single oral doses of BIC up to 1000 mg/kg were well-tolerated (AD-141-2284). The increase in exposure was limited (< 2-fold) between 300 to 1000 mg/kg ($\text{AUC}_{0-24} 803 \, \mu\text{g} \cdot \text{h/mL}$ and 1078 $\mu$g·h/mL, respectively).

In 2-week (TX-141-2029) and 26-week (TX-141-2031) oral toxicity studies in rats at doses up to 300 mg/kg/day, BIC was well-tolerated with no BIC-related effects on clinical observations, body weight, food consumption, ophthalmic examinations, and anatomic pathology. The high dose of 300 mg/kg/day was considered the maximum feasible dose based upon saturation of absorption. The no observed effect level (NOEL) in the 26-week study was considered to be the high dose of 300 mg/kg/day. At the NOEL, BIC exposures in the rat were considered to be approximately 12-/31-fold higher (males/females) than the projected steady state human exposure of BIC following administration of B/F/TAF (50/200/25 mg) once daily under fed conditions.

In a 39-week study in monkeys (TX-141-2032), following administration of 1000 mg/kg/day (high dose) of BIC for 39 weeks, pathology data indicated minimal to marked bile duct hyperplasia and minimal or moderate hepatocyte hypertrophy in both sexes, and minimal regenerative hyperplasia and minimal or slight neutrophil infiltrate in males. The macroscopic finding of rough surface on the liver in one male administered 1000 mg/kg/day correlated with moderate hepatocyte hypertrophy and marked bile duct hyperplasia. After a 4-week recovery period, BIC-related microscopic liver findings included marked bile duct hyperplasia, slight hepatocyte hypertrophy, minimal regenerative hyperplasia, and slight lymphocyte infiltrate in one male and slight bile duct hyperplasia in one female administered 1000 mg/kg/day, while the other two animals in the high dose group had no hepatobiliary findings. Minimally to mildly increased alanine aminotransferase (ALT) activities ($\leq 3.5$-fold versus baseline values), likely associated with liver findings, exhibited reversibility. There were no other adverse findings in the study, including clinical observations, or effects on body weight, body weight change, food consumption, ECGs, hematology, coagulation, clinical chemistry, urinalysis, and ophthalmoscopy.
No BIC-related effects were observed in the mid-dose group (200 mg/kg/day) which was considered the NOEL. The estimated margin of exposure at the NOEL was approximately 5.1-fold based on expected human exposure with the once daily dosing of the B/F/TAF (50/200/25 mg) tablet.

A standard battery of in vitro and in vivo studies was performed to assess the genotoxic potential of BIC. There was no evidence of mutagenic or clastogenic activity in an in vitro bacterial reverse mutation assay (Study TX-141-2026), a chromosomal aberration assay in human lymphocytes (Study TX-141-2027), or in a rat micronucleus test (Study TX-141-2029).

1.2.3. Clinical Studies of BIC

Clinical studies entailing the use of BIC include:

- GS-US-141-1218, a Phase 1 double blind, randomized, placebo-controlled, first-in-human, single- and multiple-ascending dose study evaluating the safety, tolerability, and PK of oral GS-9883 in healthy subjects and a randomized, open-label, 2-cohort, 3-period, crossover, PK study evaluating the drug interaction potential between emtricitabine/tenofovir alafenamide (F/TAF) FDC tablet and GS-9883 in healthy subjects (completed)

- GS-US-141-1219, a Phase 1b randomized, double-blinded, sequential cohort placebo-controlled study of the safety, PK, and antiviral activity of GS-9883 in HIV-1 infected subjects (5 mg, 25 mg, 50 mg, 100 mg) (completed)

- GS-US-141-1233, a Phase 1, Open-label, Two-Cohort, Multiple-Period, Fixed-Sequence, Crossover Study to Evaluate 1) the Relative Bioavailability of Two GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg) Fixed-Dose Combination Tablets Versus a GS-9883 (75 mg) Tablet and a Emtricitabine/Tenofovir Alafenamide (200/25 mg) Fixed-Dose Combination Tablet Administered Simultaneously and 2) the Effect of Food on the Pharmacokinetics of GS-9883, Emtricitabine and Tenofovir Alafenamide When Administered as GS-9883/Emtricitabine/Tenofovir Alafenamide (75/200/25 mg and 50/200/25 mg) Fixed-Dose Combination Tablets (completed)

- GS-US-141-1478, a Phase 1, Open Label, Parallel Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects with Normal and Impaired Hepatic Function (completed)

- GS-US-141-1479, a Phase 1, open-label, parallel-group, adaptive single-dose study to evaluate the PK of GS-9883 in subjects with normal and impaired renal function (completed)

- GS-US-141-1480, a Phase 1 partially-blinded, randomized, placebo- and positive-controlled study to evaluate the effect of GS-9883 on the QT/QTc interval in healthy subjects (completed)
- GS-US-141-1481, a Phase 1 study to evaluate the pharmacokinetics, metabolism, and excretion of GS-9883 in healthy subjects (completed)

- GS-US-141-1485, a Phase 1 adaptive study to evaluate transporter, CYP-mediated and UGT1A1 drug-drug interactions between GS-9883 and probe drugs (completed)

- GS-US-141-1487, a Phase 1 randomized, Blinded, Placebo-Controlled Phase 1 Study Evaluating the Effect of GS-9883 on Renal Function as Assessed by Markers of Glomerular Filtration Rate (completed)

- GS-US-311-1790, a Phase 1 Randomized, Open Label, Drug Interaction Study Evaluating the Effect of F/TAF FDC Tablet or GS-9883 on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol (completed)

- GS-US-380-1761, a Phase 1 Study to Evaluate Pharmacokinetic Drug-Drug Interaction Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate (B/F/TAF) and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) Tablets (completed)


- GS-US-380-1999, a Phase 1 Multiple Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Potential between GS-9883/Emtricitabine/Tenofovir Alafenamide Fumarate and Sofosbuvir/Velpatasvir/GS-9857 in Healthy Subjects (completed)

- GS-US-380-3908, a Phase 1, Blinded, Placebo-controlled, Two-period Crossover Drug Interaction Study to Assess the Effect of GS-9883/F/TAF on Metformin Pharmacokinetics in Healthy Subjects (completed)

- GS-US-380-3909, a Phase 1, Open Label, Multiple-Cohort, Multiple-Period, Fixed-Sequence, Drug Interaction Study to Evaluate the Effect of Antacid and Mineral Supplements on GS-9883 Pharmacokinetics (completed)

- GS-US-141-1475, a Phase 2 Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (ongoing)

Please refer to the B/F/TAF Investigators’ Brochure for further information about these studies.

1.2.3.1. Phase 1 Safety and Pharmacokinetics (PK)

Study GS-US-141-1218 was a four part, first-in-human study. Parts A and B were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies of BIC in healthy male and female subjects. Part C was an open label, fixed sequence food effect study evaluating
the effect of food on the PK of BIC. Part D was a randomized, open-label, 2-cohort, 3-period, crossover PK study evaluating the drug interaction potential between FTC/TAF FDC tablet and BIC in healthy subjects.

There was no difference in the overall incidence or type of adverse events (AEs) when BIC was administered in the fasted and fed states. There was no difference in the overall incidence of AEs when BIC or FTC/TAF was each administered alone or in combination.

No deaths or pregnancies were reported. No Grade 3 or 4 AEs or serious adverse events (SAEs), were reported in any cohort.

Increases in serum creatinine were observed in this study, presumably via inhibition of the renal transporter OCT2. In the multiple ascending dose (MAD) cohorts (fasted), serum creatinine change at Day 14 ranged from 0.05 mg/dL for the 5 mg cohort to 0.18 mg/dL for the 300 mg/dL cohort. In Part D (DDI), conducted in the fed state (regular meal), subjects received 100 mg BIC monotherapy for 7 days and 100 mg BIC with FTC/TAF for 7 days, the mean serum creatinine change at Day 7 was 0.14 mg/dL following BIC and 0.17 mg/dL following BIC + FTC/TAF. All changes returned to baseline after discontinuation of BIC.

The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. Grade 3 laboratory abnormalities included 10 subjects with Grade 3 urine dipstick tests for blood. All of these subjects were female, none of the labs were considered by the Investigator to be clinically significant, and all were associated with menstruation. No other Grade 3 or 4 laboratory abnormalities were observed.

Based on results in Study GS-US-141-1218, pharmacokinetic profile of BIC was characterized by rapid absorption with time to peak plasma concentrations (median $T_{\text{max}}$ of cohorts) ranging between 1 and 4 hours following administration under fasted conditions. BIC exposures were appropriately dose proportional following single dose 25-100 mg dose administration, with decreasing dose proportional at higher doses. The half-life of BIC was approximately 18 hours, with no changes observed across studied dose range as evidenced by parallel terminal phase slopes. A high-fat meal increased $AUC_{\text{inf}}$ and $C_{\text{max}}$ (geometric mean, 84% and 101%, respectively) following 100 mg single dose administration. Steady state was achieved after 4-6 days of once daily dosing of BIC with average accumulation ratios for $AUC_{24\text{hr}}$ of 1.6.
Table 1-1. GS-US-141-1218: BIC Mean (%CV) PK Parameters Following Single Doses of BIC in Healthy Subjects (BIC PK Analysis Set; Part A: Single Dosing)

<table>
<thead>
<tr>
<th>BIC PK Parameter</th>
<th>5 mg (N=6)</th>
<th>25 mg (N=6)</th>
<th>50 mg (N=6)</th>
<th>100 mg (N=6)</th>
<th>300 mg (N=6)</th>
<th>600 mg (N=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>691.2 (22.1)</td>
<td>1618.3 (26.7)</td>
<td>3965.0 (40.1)</td>
<td>6998.3 (36.1)</td>
<td>14605.0 (27.1)</td>
<td>20050.0 (7.5)</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (hr)</td>
<td>1.25 (1.00-1.50)</td>
<td>2.00 (1.00-3.00)</td>
<td>3.00 (1.50-4.00)</td>
<td>2.25 (1.50-3.00)</td>
<td>3.50 (2.00-6.00)</td>
<td>3.5 (2.00-4.00)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;inf&lt;/sub&gt; (ng.hr/mL)</td>
<td>13059.7 (25.1)</td>
<td>35718.2 (21.3)</td>
<td>78399.5 (29.7)</td>
<td>163028.2 (24.3)</td>
<td>355917.3 (32.9)</td>
<td>454446.8 (19.9)</td>
</tr>
<tr>
<td>T&lt;sub&gt;1/2&lt;/sub&gt; (hr)</td>
<td>18.51 (16.81-19.99)</td>
<td>18.08 (16.63-19.64)</td>
<td>16.72 (15.77-17.11)</td>
<td>18.90 (17.96-20.05)</td>
<td>18.14 (17.86-20.53)</td>
<td>17.89 (16.38-19.52)</td>
</tr>
</tbody>
</table>

T<sub>1/2</sub> and T<sub>max</sub>: Median (Q1, Q3)

Table 1-2 presents BIC plasma PK parameters following administration of BIC (5, 25, 50, 100, and 300 mg) once daily for 7 days. Following administration of either BIC (5, 25, 50, 100, or 300 mg) once daily for 7 days, the PK absorption profile observed on Days 1 and 7 was similar to that observed in Part A single ascending dose (SAD). The median T<sub>max</sub> values ranged from 1.5 to 2.5 hours on Day 1 and 1.5 to 4.0 hours on Day 7. Linearity was observed comparing BIC AUC and C<sub>max</sub> on Days 1 and 7 over the dose range of 25 to 50 mg. Steady state levels of BIC were achieved between Study Days 4 to 6 of dosing and maintained through Day 14. Accumulation is approximately 1.6-fold, which is consistent with the observed half-life of the BIC (approximately 18 hours).
Table 1-2. GS-US-141-1218: BIC Plasma Pharmacokinetic Parameters by BIC Dose Following Multiple-Dose Administration of BIC (Analysis Set: BIC PK Part B: Multiple-Dose)

<table>
<thead>
<tr>
<th>BIC PK Parameter Mean (%CV)*</th>
<th>5 mg (N = 6)</th>
<th>25 mg (N = 6)</th>
<th>50 mg (N = 6)</th>
<th>100 mg (N = 6)</th>
<th>300 mg (N = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC&lt;sub&gt;0-24&lt;/sub&gt; (hr*ng/mL)</td>
<td>9033.6 (8.2)</td>
<td>27,775.1 (28.3)</td>
<td>58,371.4 (18.9)</td>
<td>79,773.8 (19.9)</td>
<td>180,714.3 (17.6)</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>709.7 (9.5)</td>
<td>2220.0 (35.6)</td>
<td>4648.3 (18.7)</td>
<td>6248.3 (26.8)</td>
<td>13,716.7 (19.1)</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (hr)</td>
<td>1.50 (1.50, 1.50)</td>
<td>1.75 (1.00, 3.00)</td>
<td>1.50 (1.00, 2.00)</td>
<td>2.50 (2.00, 3.00)</td>
<td>2.50 (2.00, 4.00)</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;tau&lt;/sub&gt; (hr*ng/mL)</td>
<td>14,392.0 (16.7)</td>
<td>50,008.2 (26.6)</td>
<td>89,710.1 (22.7)</td>
<td>126,785.8 (23.7)</td>
<td>277,200.2 (16.7)</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>982.5 (7.9)</td>
<td>3455.0 (24.1)</td>
<td>6538.3 (17.6)</td>
<td>9396.7 (20.8)</td>
<td>19,900.0 (21.2)</td>
</tr>
<tr>
<td>C&lt;sub&gt;tau&lt;/sub&gt; (ng/mL)</td>
<td>400.83 (26.9)</td>
<td>1322.00 (27.8)</td>
<td>2241.67 (28.2)</td>
<td>3145.00 (26.1)</td>
<td>6758.33 (21.6)</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (hr)</td>
<td>1.50 (1.00, 2.00)</td>
<td>3.00 (2.00, 3.00)</td>
<td>1.75 (1.50, 2.00)</td>
<td>1.75 (1.50, 3.00)</td>
<td>4.00 (2.00, 4.00)</td>
</tr>
<tr>
<td>Accumulation Ratio of AUC (%)</td>
<td>160.5 (19.0)</td>
<td>182.2 (17.1)</td>
<td>154.0 (15.9)</td>
<td>158.5 (12.1)</td>
<td>157.5 (22.6)</td>
</tr>
</tbody>
</table>

Table 1-3 presents the geometric least squares mean (GLSM) ratios and associated 90% confidence intervals (CIs) for the test (fed) versus reference (fasted) treatments for the primary plasma PK parameters of BIC. Administration of a single dose of BIC 100 mg with food (high-calorie/high-fat breakfast) increased the GLSM values of C<sub>max</sub> and AUC<sub>inf</sub> 101% (90% CI of GLSM ratio 165.93% to 242.74%) and 84% (90% CI of GLSM ratio 152.05% to 222.59%), respectively. There were no apparent changes in clearance and T<sub>1/2</sub> following administration with food, indicating that food enhanced the bioavailability of BIC by improving its solubility and/or absorption.

<table>
<thead>
<tr>
<th>BIC PK Parameter</th>
<th>Mean (%CV)</th>
<th>Test BIC 100 mg Fed (n = 8)</th>
<th>Reference BIC 100 mg Fasted (n = 8)</th>
<th>% GLSM Ratio (90% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC&lt;sub&gt;int&lt;/sub&gt; (hr*ng/mL)</td>
<td>214,146.3 (15.9)</td>
<td>117,777.1 (23.3)</td>
<td>183.97 (152.05, 222.59)</td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;last&lt;/sub&gt; (hr*ng/mL)</td>
<td>209,259.9 (15.1)</td>
<td>115,681.7 (24.0)</td>
<td>183.58 (151.91, 221.86)</td>
<td></td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (ng/mL)</td>
<td>11,268.8 (15.1)</td>
<td>5885.0 (34.9)</td>
<td>200.69 (165.93, 242.74)</td>
<td></td>
</tr>
</tbody>
</table>

CI = confidence interval; GLSM = geometric least squares mean

1.2.3.2. Phase 1b Proof of Concept

The first HIV-1 positive human subjects were dosed in the fasted state with 10 days of BIC in Study GS-US-141-1219. Four cohorts of 5 subjects each were randomized 4:1 to receive BIC or placebo to match (PTM) at doses of 5 mg, 25 mg, 50 mg, and 100 mg once daily for 10 days.

BIC was generally well tolerated at the doses evaluated. A total of 9 of 20 subjects had an AE in this study. The most frequently reported AEs across all subjects were diarrhea (2 subjects), and headache (3 subjects). No other AE was reported in more than 1 subject. There was no increase in the incidence of AEs with increasing doses of BIC.

The majority of AEs were considered by the investigator to be not related to study drug. A total of 2 subjects experienced mild diarrhea that was considered related to study drug (1 in the 5 mg cohort, 1 in the 100 mg cohort).

No deaths or pregnancies were reported. No Grade 3 or 4 AEs, SAEs, or AEs leading to discontinuation of study drug were reported in any cohort.

The majority of laboratory abnormalities were Grade 1 or Grade 2 in severity. No Grade 3 treatment emergent laboratory abnormalities were observed. Median serum creatinine changes at Day 10 were: 0.05 mg/dL (5 mg), 0.04 mg/dL (25 mg), 0.06 mg/dL (50 mg), and 0.15 mg/dL (100 mg). These changes in serum creatinine appeared to be transient and returned close to baseline values on discontinuation of study drug. One Grade 4 new onset laboratory abnormality was seen in 1 subject who received 5 mg BIC. This was a Grade 4 creatine phosphokinase (CPK) seen on Day 17, 7 days following his last dose of study medication. The subject was asymptomatic. The Investigator felt that this was unrelated to study medication and was due to resumption of crystal methamphetamine use by the subject. An adverse event of elevated creatine kinase (CK) was reported unrelated to study medication.

Based on PK information collected in Study GS-US-141-1219, which was in line with PK observed in Study GS-US-141-1218, the median IQ for each dose were calculated and are presented in Table 1-4 below.
Table 1-4. Trough BIC Plasma Concentrations at Steady State Following BIC Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ95 Values (BIC PK Analysis Set)

| BIC dose | n | Median (range) $C_{\text{ss}}$ (ng/mL) | Median (range) paiIQ95 | a |
|----------|---|----------------------------------------|------------------------|
| 5 mg     | 4 | 206.5 (146.0 to 342.0)                 | 1.3 (0.9 to 2.1)       |
| 25 mg    | 4 | 797.5 (714.0 to 1900.0)                | 4.9 (4.4 to 11.7)      |
| 50 mg    | 4 | 2170.0 (852.0 to 3020.0)               | 13.4 (5.3 to 18.6)     |
| 100 mg   | 4 | 4190.0 (3730.0 to 5970.0)              | 25.9 (23.0 to 36.9)    |

a. The protein-adjusted IQ95 (paiIQ95) value is estimated based on steady-state Ctau values and the in vitro paiC95 value for wild-type HIV-1 (162 ng/mL).

The mean and 95% CIs of change from baseline in HIV-1 ribonucleic acid (RNA) (log10 copies/mL) are presented in Figure 1-1.

Figure 1-1. GS-US-141-1219: Mean and 95% CIs of Change from Baseline in HIV-1 RNA (log10 copies/mL) (PP Analysis Set)

NOTE: Baseline value was the last available value collected prior to the time of the first dose of study drug.
Mean viral load change on Day 11 was $-2.08 \log_{10}$ in the 25 mg cohort, $-2.06 \log_{10}$ in the 50 mg cohort, and $-2.43 \log_{10}$ in the 100 mg cohort. Time weighted average change from baseline at Day 11 (DAVG11) was $-0.92 \log_{10}$ in the 5 mg cohort, $-1.33 \log_{10}$ in the 25 mg cohort, $-1.37 \log_{10}$ in the 50 mg cohort and $-1.61 \log_{10}$ in the 100 mg cohort. Viral suppression (HIV-1 RNA < 50 copies/mL) was ever achieved by the end of the study (Day 17) by 1 subject (25.0%) in the BIC 50 mg group and 2 subjects (50%) in the BIC 100 mg group.

1.2.3.3. Summary of Phase 2 Study (GS-US-141-1475)

Study GS-US-141-1475 is an ongoing Phase 2, randomized, double-blind, multicenter, active-controlled study to assess the safety and efficacy of a regimen containing BIC+F/TAF versus DTG+F/TAF in HIV-infected, ART-naive adult subjects.

Eligible subjects were randomized in a 2:1 ratio to one of the following treatment groups, stratified by HIV-1 RNA level ($\leq 100,000$ copies/mL, $> 100,000$ copies/mL to $\leq 400,000$ copies/mL, or $> 400,000$ copies/mL) at screening:

- Treatment Group 1: BIC 75 mg + F/TAF (200/25 mg) + placebo-to-match DTG 50 mg once daily
- Treatment Group 2: DTG 50 mg + F/TAF (200/25 mg) + placebo-to-match BIC 75 mg once daily

Week 48 interim data are summarized below.

Subject Disposition and Baseline Characteristics

A total of 98 subjects were randomized and treated in the study: 65 subjects in the BIC+F/TAF group and 33 subjects in the DTG+F/TAF group. At the time of the Week 48 data analysis, 5 subjects (5.1%) had prematurely discontinued study drug, 3 in the BIC+F/TAF group and 2 in the DTG+F/TAF group. The reasons for study drug discontinuation were as follows (one subject each): AE, withdrawal of consent, and lost to follow-up in the BIC+F/TAF group, and noncompliance with study drug and lost to follow up in the DTG+F/TAF group.

Demographic and baseline characteristics were similar between the 2 treatment groups. Key baseline disease characteristics (ie, viral load, CD4+ cell count, and estimated glomerular filtration rate [eGFR]$_{CG}$) were similar between the 2 treatment groups.

Median (Q1, Q3) baseline HIV-1 RNA was $4.45 \ (3.96, \ 4.79) \log_{10} \text{ copies/mL}$, with 82.7% having $\leq 100,000 \text{ copies/mL}$ at baseline. Five subjects (5.1%) had $> 400,000 \text{ copies/mL}$ at baseline; of these, 4 subjects were randomized to BIC+F/TAF and 1 subject was randomized to DTG+F/TAF.

Median (Q1, Q3) baseline CD4+ cell count was 444 (316, 595) cells/μL, with 41.8% of subjects having $\geq 500 \text{ cells/μL}$ at baseline. Median (Q1, Q3) baseline eGFR$_{CG}$ was 125.3 (105.7, 147.0) mL/min.
**Efficacy Results**

The primary efficacy endpoint was the proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 24 as determined by the United States (US) Food and Drug Administration (FDA)-defined snapshot algorithm. The percentages of subjects with HIV-1 RNA < 50 copies/mL at Week 24 was high in both groups, as follows: BIC+F/TAF 96.9%; DTG+F/TAF 93.9%; difference in percentages: 2.9%, 95% CI: −8.5% to 14.2%. Because the lower bound of the 95% CI for the difference in response rate (BIC+F/TAF – DTG+F/TAF) was greater than the prespecified −12% margin, BIC+F/TAF was determined to be noninferior to DTG+F/TAF.

The percentages of subjects with HIV-1 RNA < 50 copies/mL at Week 48 were similar between the 2 treatment groups when assessed using the US FDA-defined snapshot algorithm based on the full analysis set (FAS) (Table 1-5), as follows: BIC+F/TAF 96.9%; DTG+F/TAF 90.9%; difference in percentages: 6.4%, 95% CI: −6.0% to 18.8%.

As expected for an INSTI-containing regimen, HIV-1 RNA levels decreased rapidly in the first 4 weeks following initiation of study drug in both treatment groups. After Week 4, HIV-1 RNA values were stable and similar between the 2 treatment groups through Week 48; mean (SD) decreases from baseline at Week 48 using the FAS were as follows: BIC+F/TAF −3.09 (0.752) log_{10} copies/mL; DTG+F/TAF −3.11 (0.852) log_{10} copies/mL; difference in least-squares mean (LSM): −0.06 log_{10} copies/mL, 95% CI: −0.32 to 0.20 log_{10} copies/mL.

The mean (SD) increases from baseline in CD4+ cell counts were similar between the 2 treatment groups through Week 48 using the FAS, as follows: BIC+F/TAF 258 (221.7) cells/μL; DTG+F/TAF 192 (242.0) cells/μL; difference in LSM: 72 cells/μL, 95% CI: −30 to 174 cells/μL.
### Table 1-5. GS-US-141-1475: Virologic Outcome at Week 48 Using the US FDA-Defined Snapshot Algorithm and HIV-1 RNA < 50 copies/mL (FAS)

<table>
<thead>
<tr>
<th></th>
<th>BIC+F/TAF (N = 65)</th>
<th>DTG+F/TAF (N = 33)</th>
<th>BIC+F/TAF vs DTG+F/TAF</th>
<th>Difference in Percentages (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV-1 RNA &lt; 50 copies/mL</td>
<td>63 (96.9%)</td>
<td>30 (90.9%)</td>
<td>p-value&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.17</td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mL</td>
<td>1 (1.5%)</td>
<td>2 (6.1%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mL in Week 48 window</td>
<td>0</td>
<td>1 (3.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued study drug due to lack of efficacy</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA ≥ 50 copies/mL&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1 (1.5%)</td>
<td>1 (3.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No virologic data in Week 48 window</td>
<td>1 (1.5%)</td>
<td>1 (3.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued study drug due to AE/death</td>
<td>1 (1.5%)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mL&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0</td>
<td>1 (3.0%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Week 48 window was between Day 295 and 378 (inclusive).

<sup>a</sup> p-value for the superiority test comparing the percentages of subjects with HIV-1 RNA < 50 copies/mL between treatment groups was from the Cochran-Mantel-Haenszel test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs > 100,000 copies/mL).

<sup>b</sup> Difference in percentages of subjects with HIV-1 RNA < 50 copies/mL between treatment groups and its 95% CI were calculated based on the baseline HIV-1 RNA stratum-adjusted Mantel-Haenszel proportion.

<sup>c</sup> Discontinuation due to other reasons included subjects who prematurely discontinued study drug due to investigator’s discretion, withdrew consent, lost to follow-up, noncompliance with study drug, protocol violation, pregnancy, and study termination by sponsor.

**Interim Virology Resistance Data**

Through Week 48, no emergent drug resistance was detected in the BIC+F/TAF group.

**Safety Results**

**Adverse Events**

Adverse events were reported in 84.6% (55 of 65 subjects) in the BIC+F/TAF group and 66.7% (22 of 33 subjects) in the DTG+F/TAF group. The most commonly reported AEs by treatment group were as follows:

- **BIC+F/TAF group**—diarrhea (12.3%, 8 of 65 subjects); and headache, nausea, and upper respiratory tract infection (each 7.7%, 5 subjects)
- **DTG+F/TAF group**—diarrhea and nausea (each 12.1%, 4 of 33 subjects); and arthralgia, fatigue, flatulence, furuncle, gastroenteritis, costochondritis, hemorrhoids, and pruritus (each 6.1%, 2 subjects)
The majority of AEs were Grade 1 in severity, with similar incidence of Grade 2, 3, or 4 AEs between the 2 treatment groups. Grade 3 AEs were uncommon, with all Grade 3 AEs reported in the BIC+F/TAF group (6.2%, 4 subjects); only 1 Grade 3 AE was considered related to study drug by the investigator (urticaria in a BIC+F/TAF subject). No individual Grade 3 AE was reported for > 1 subject. No Grade 4 AEs were reported.

Serious AEs were uncommon, with all reported SAEs occurring in the BIC+F/TAF group (4.6%, 3 subjects). No SAE was considered related to study drug by the investigator. The SAEs reported were appendicitis, psychotic disorder/suicidal ideation, and diabetic ketoacidosis.

The incidence of AEs considered related to study drug by the investigator was similar between the 2 treatment groups (BIC+F/TAF 20.0%, 13 subjects; DTG+F/TAF 21.2%, 7 subjects). Nearly all study drug-related AEs were Grade 1 in severity, with similar incidence of Grade 2, 3, or 4 study drug-related AEs between the 2 treatment groups (BIC+F/TAF 3.1%, 2 subjects; DTG+F/TAF 3.0%, 1 subject). The only Grade 3 study drug-related AE reported (urticaria in a BIC+F/TAF subject) was also the only AE leading to premature study drug discontinuation; the event began on Day 130 and led to discontinuation of study drug on Day 162.

No deaths or pregnancies were reported in either treatment group.

**Clinical Laboratory Evaluations**

Most subjects in both treatment groups had at least 1 laboratory abnormality (BIC+F/TAF 84.4%, 54 of 64 subjects; DTG+F/TAF 87.5%, 28 of 32 subjects). Most of the reported laboratory abnormalities were Grade 1 or 2 in severity. The incidence of Grade 3 or 4 laboratory abnormalities was similar between the 2 treatment groups (BIC+F/TAF 25.0%, 16 subjects; DTG+F/TAF 21.9%, 7 subjects).

Graded laboratory abnormalities in ALT and aspartate aminotransferase (AST) were reported more frequently and with greater severity in the BIC+F/TAF group than in the DTG+F/TAF group. Graded ALT abnormalities were reported in 23.4% (15 of 64 subjects) in the BIC+F/TAF group and 9.4% (3 of 32 subjects) in the DTG+F/TAF group, and graded AST abnormalities were reported in 20.3% (13 of 64 subjects) in the BIC+F/TAF group and 9.4% (3 of 32 subjects) in the DTG+F/TAF group. Grade 3 ALT elevations occurred in 1 subject in the BIC+F/TAF group and none in the DTG+F/TAF group. Grade 3 AST elevations were seen in 3 subjects in the BIC+F/TAF group (one of whom also had a Grade 3 ALT elevation) and none in the DTG+F/TAF group. Of the 3 subjects who had Grade 3 transaminase elevations, 2 were associated with simultaneous Grade 4 CK elevations, were transient, and resolved rapidly without any associated AEs. One participant had both Grade 3 AST and ALT persistent elevations that were attributed to ongoing alcohol use. No Grade 4 transaminase elevations were observed in either treatment group.

Grade 3 or 4 CK elevations were seen in 9.4% (6 of 64 subjects) in the BIC+F/TAF group and in 3.1% (1 of 32 subjects) in the DTG+F/TAF group. All of the Grade 3 or 4 CK elevations occurred in young men (age range, 24 to 31 years), were transient, and resolved without treatment interruption, and none of these laboratory abnormalities were associated with AEs.
There were similar increases from baseline in median (Q1, Q3) serum creatinine in both treatment groups at Week 48: BIC+F/TAF 0.08 (0.02, 0.15) mg/dL; DTG+F/TAF 0.12 (0.02, 0.20) mg/dL. There were decreases in median (Q1, Q3) eGFR$_{CG}$ at Week 48, which were smaller in the BIC+F/TAF than in the DTG+F/TAF group: BIC+F/TAF $-7.0\ (−18.7,\ 1.6)$ mL/min; DTG+F/TAF $-11.3\ (−24.5,\ −0.8)$ mL/min.

There were no clinically significant changes from baseline or differences between treatment groups in the median values for hematology, chemistry, or metabolic parameters.

**Conclusions**

Key conclusions from Study GS-US-141-1475 at Week 48 include the following:

- The percentages of subjects with HIV-1 RNA < 50 copies/mL at Week 48 were similar between the 2 treatment groups when assessed using the US FDA-defined snapshot algorithm based on the FAS, as follows: BIC+F/TAF 96.9%; DTG+F/TAF 90.9%; difference in percentages: 6.4%, 95% CI: −6.0% to 18.8%. There was a similar increase in the mean (SD) CD4$^+$ cell count between the 2 treatment groups: BIC+F/TAF 258 (221.7) cells/μL; DTG+F/TAF 192 (242.0) cells/μL; difference in LSM: 72 cells/μL, 95% CI: −30 to 174 cells/μL.

- No resistance to any INSTIs, NRTIs, NNRTIs, or PIs was detected through Week 48 in the BIC+F/TAF group.

- Both BIC+F/TAF and DTG+F/TAF were generally well tolerated through 48 weeks of treatment.

  — The most commonly reported AEs were diarrhea (12.3%, 8 of 65 subjects); and headache, nausea, and upper respiratory tract infection (each 7.7%, 5 subjects) in the BIC+F/TAF group, and diarrhea and nausea (each 12.1%, 4 of 33 subjects); and arthralgia, fatigue, flatulence, furuncle, gastroenteritis, costochondritis, hemorrhoids, and pruritus (each 6.1%, 2 subjects) in the DTG+F/TAF group.

  — One subject discontinued study drug due to AE: Grade 3 urticaria beginning on Day 130 in a BIC+F/TAF subject. There were SAEs in 3 subjects, none of which were considered related to study drug by the investigator, or led to study drug discontinuation.

  — The percentage of subjects with at least 1 treatment-emergent laboratory abnormality was similar between treatment groups. The majority of treatment-emergent laboratory abnormalities were Grade 1 or 2 in severity. Graded laboratory abnormalities in ALT and AST were reported more frequently and with greater severity in the BIC+F/TAF group than in the DTG+F/TAF group.

There were similar increases from baseline in serum creatinine in both treatment groups at Week 48. The decrease from baseline in eGFR$_{CG}$ was smaller in the BIC+F/TAF group than in the DTG+F/TAF group.
1.3. Information About Emtricitabine/Tenofovir Alafenamide (Descovy®, F/TAF)

F/TAF is a FDC tablet containing two medications: emtricitabine (FTC) and TAF.

The safety of F/TAF FDC is based on two year-long clinical studies (GS-US-292-0104 and GS-US-292-0111) in which 866 treatment-naïve subjects received elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) FDC. The following adverse drug reactions have been identified for F/TAF:

Very common (more than or equal to 10%): headache, diarrhea, and nausea

Common (≥ 1% and < 10%): vomiting, abdominal pain, dyspepsia, flatulence, rash, and fatigue

Across all Phase 2 and Phase 3 studies in which 2,394 subjects received E/C/F/TAF FDC, eye disorders were uncommon, balanced between treatment groups, and most were considered by the investigator as unrelated to the study drugs. None were definitive for posterior uveitis, and none resulted in permanent discontinuation of study drugs. One subject in Study GS-US-292-0106 had an adverse reaction of intermediate uveitis (inflammation in the middle of the eye) that was considered related to study drug by the investigator but resolved while the subject continued on study drug without interruption.

For further information on F/TAF, refer to the current Prescribing Information for Descovy®™.

1.4. Information about B/F/TAF

Please refer to the B/F/TAF Investigator’s Brochure for further information.

1.4.1. GS-US-141-1233: Relative Bioavailability of BIC, FTC, and TAF between B/F/TAF and BIC+F/TAF

Study GS-US-141-1233 was a Phase 1, open-label, 2-cohort, multiple-period, fixed-sequence, crossover study conducted at a single center in the US to evaluate the relative bioavailability of 2 B/F/TAF FDC tablets (75/200/25 mg and 50/200/25 mg) compared with the BIC tablet (75 mg) and the F/TAF FDC tablet (200/25 mg) administered simultaneously. For more detailed information on study design and key findings of this study refer to the Investigators’ Brochure.

For the 75-mg B/F/TAF FDC, BICAUC_{inf} and C_{max} were approximately 27% and 31% higher, respectively, than those observed for BIC 75 mg + F/TAF. Emtricitabine and TAF exposures were similar between the 75-mg B/F/TAF FDC and BIC 75 mg + F/TAF.

For the 50-mg B/F/TAF FDC, the GLSM ratios and their 90% CIs comparing the primary PK parameters for BIC, FTC, and TAF between the 50-mg B/F/TAF FDC and BIC 75 mg + F/TAF under fasted conditions were within the protocol-defined boundaries of equivalence, with the exception of TAF C_{max}, for which the GLSM ratio (90% CI) was 84.17% (67.59%, 104.81%; equivalence boundary of 70% to 143%). Emtricitabine exposure was comparable with that observed historically {EMTRIVA® 2012}, and TAF exposure was within the wide range of safe and efficacious exposure established in the Phase 3 Genvoya studies (predicted individual
steady-state mean [95% CI, %CV] AUC 206.4 ng•h/mL [55.6 to 526.1 ng•h/mL, 71.8%]. Together, these results demonstrate that the B/F/TAF (50/200/25 mg) FDC will provide therapeutic concentrations of BIC, FTC, and TAF. The variability associated with BIC exposure following administration of the 50-mg B/F/TAF FDC was lower, irrespective of fasted or fed condition, relative to BIC 75 mg + F/TAF administered under fasted conditions.

1.5. Information about Dolutegravir (DTG, Tivicay®)

An ongoing observational study in Botswana identified neural tube defects (NTDs) in infants born to four of 426 women who started DTG prior to pregnancy, and were on it at the time of conception. The incidence rate for NTDs in these infants was 0.9%, while the reported rate of NTDs for HIV-infected women on non-DTG-containing regimen was 0.1%. These preliminary results suggest that women who received DTG at the time of becoming pregnant or early in the first trimester appear to be at higher risk for these embryonic defects.

The following guidance has been issued regarding the use of DTG in women who are pregnant, who become pregnant, or are of child bearing potential.


For more detailed information, refer to the current Prescribing Information and local product labeling for DTG.

1.6. Rationale for this Study

The two tablet regimen of DTG+F/TAF has become a regimen of choice for the initiation of treatment of HIV infected adults, as this combination provides the safety and efficacy of a TAF based regimen with the benefits of an unboosted INSTI that provides a high barrier to resistance. In addition, all patients taking DTG+F/TDF will switch to an F/TAF containing regimen. HIV-infected patients are often diagnosed earlier and initiate therapy earlier, and despite the availability of single tablet regimen (STRs), a need remains for an STR, particularly an INSTI-based STR that combines potent and sustained efficacy, favorable tolerability, minimal long-term toxicity, and practical, convenient dosing that does not require human leukocyte antigen (HLA) or hepatitis B testing prior to initiation.

Total pill burden, dosing frequency, and safety concerns are among the greatest obstacles to achieving adherence {Stone 2002}, {Chesney 2000}. Incomplete adherence to ARV regimens is a critical factor contributing to the development of viral resistance and treatment failure and thus
is a primary barrier to successful long-term treatment. This is supported by studies in which simple, once-daily HAART regimens demonstrate high levels of adherence and treatment satisfaction resulting in durable viral suppression and CD4+ cell recovery \cite{Maggiolo2001, Felizarta2004, Arribas2004, Willig2008}.

Regimen simplification of an established therapy will reduce pill burden and will potentially enhance long-term safety and tolerability. This study will provide clinical data in patients who are virologically suppressed but who are taking a multi-tablet regimen. The goal of this study is to assess whether switching to a single tablet regimen of B/F/TAF from a 2 tablet regimen of DTG plus F/TAF or F/TDF will provide comparable virologic control along with improved safety and tolerability. DTG+F/TAF was selected as the active comparator for this study as it is a recommended INSTI-based, once-daily regimen \cite{Panel2016, Gunthard2016, EACS2016}. Use of DTG+F/TAF as a comparator in this study will therefore allow for a direct comparison of DTG versus BIC, two second generation, unboosted INSTIs.

1.7. Risk/Benefit Assessment for the Study

All patients with HIV-1 infection should receive effective antiretroviral therapy. Potential risks associated with all classes of ARVs include immune reconstitution syndrome, lipodystrophy, and lactic acidosis with steatosis. The risk of class effects is considered to be low. Interim data will also be reviewed by an independent data monitoring committee. Potential benefits may include provision of a new ARV therapy that is not currently available and which may have fewer side effects than alternative therapies. Other potential benefits include provisions of fixed dose combination therapy, and the knowledge that patient participation will contribute to the body of knowledge of HIV therapies. Following a chronic 39 week study in monkeys, animals administered the highest dose of BIC (1000 mg/kg/day) had bile duct hyperplasia (increased cell growth) and hypertrophy (increased cell size), and some increased cell growth and inflammation in nearby liver cells. These effects were not seen in monkeys administered the mid-level dose (200 mg/kg/day), and these animals had plasma BIC exposures that were approximately 5-fold above human exposures when given the B/F/TAF FDC. No adverse drug reactions associated with liver or bile duct problems has been identified in humans treated with BIC. Potential hepatobiliary toxicity is appropriately managed by study inclusion/exclusion criteria, close clinical and laboratory monitoring, as well as specific toxicity management guidance to investigators (Refer to Section 7.5.5).

The overall benefit-risk assessment for B/F/TAF is favorable at this time.

1.8. Rationale for Dose Selection

TAF

Based upon results of the Phase 1 Study GS-US-120-0104, in which various doses of TAF (8 mg, 25 mg, and 40 mg) were administered to HIV-infected subjects in 10 days of monotherapy, the range of exposure achieved with TAF 25 mg was chosen as the reference exposure. In this study, TAF 25 mg resulted in near-maximal antiviral activity and plasma TFV exposure > 90% lower relative to TDF.
The recommended dose of TAF is based on ensuring that patients have a TAF systemic exposure that is within the range of the reference exposure achieved with TAF 25 mg, or with TAF 10 mg when administered with the boosting agent cobicistat as E/C/F/TAF, for which an extensive safety and efficacy database exists. Specifically, TAF 25 mg is recommended with third agents that do not have a clinically relevant effect on TAF exposure. Study GS-US-141-1218 showed that BIC does not have a clinically relevant effect on TAF exposure. Therefore, the dose of TAF 25 mg is appropriate for the B/F/TAF FDC.

F/TAF

Emtricitabine 200 mg is the marketed dose for the treatment of HIV-1 infection in adults. The F/TAF FDC (200/25 mg) is the marketed dose for the treatment of HIV-1 infection in adults in combination with DTG.

BIC

The dose of BIC for Phase 2 was selected based upon data from Study GS-US-141-1219 (Table 1-6), in which HIV-1-infected subjects were administered 5, 25, 50, or 100 mg doses of BIC monotherapy under fasting conditions for 10 days.

**Table 1-6.** GS-US-141-1219: Trough BIC Plasma Concentrations at Steady State Following BIC Administration Under Fasting Conditions and Corresponding Protein-Adjusted IQ\(_{95}\) Values

<table>
<thead>
<tr>
<th>BIC dose</th>
<th>N</th>
<th>Median (range) C(_{\text{tau},\text{SS}}) (ng/mL)</th>
<th>Median (range) paIQ(_{95})a</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 mg</td>
<td>4</td>
<td>206.5 (146.0 – 342.0)</td>
<td>1.3 (0.9 – 2.1)</td>
</tr>
<tr>
<td>25 mg</td>
<td>4</td>
<td>797.5 (714.0 – 1900.0)</td>
<td>4.9 (4.4 – 12)</td>
</tr>
<tr>
<td>50 mg</td>
<td>4</td>
<td>2170.0 (852.0 – 3020.0)</td>
<td>13 (5.3 – 19)</td>
</tr>
<tr>
<td>100 mg</td>
<td>4</td>
<td>4190.0 (3730.0 – 5970.0)</td>
<td>26 (23 – 37)</td>
</tr>
</tbody>
</table>

a The paIQ\(_{95}\) value is estimated based on steady-state C\(_{\text{tau}}\) values and the in vitro paIC\(_{95}\) value for wild-type HIV-1 (162 ng/mL).  
Source: Data on File

Single-agent BIC was well tolerated at all doses administered. The range of BIC plasma exposure at steady state (C\(_{\text{tau},\text{SS}}\)) observed in the 50-mg cohort correlated with protein adjusted 95% inhibitory quotient (paIQ\(_{95}\)) values ranging from 5.3 to 19, while the range of BIC plasma exposure at steady state (C\(_{\text{tau},\text{SS}}\)) observed in the 100-mg cohort correlated with paIQ\(_{95}\) values ranging from 23 to 37 (Table 1-6).

Based on PK/pharmacodynamics analyses, exposure following a 75-mg dose of single-agent BIC is expected to provide near-maximal virologic response, with a predicted paIQ\(_{95}\) of approximately 20, providing considerable coverage above the target concentration of 162 ng/mL (paIC\(_{95}\)). BIC (75 mg) single agent coadministered with F/TAF (200/25 mg) is currently being evaluated in a Phase 2 study, GS-US-141-1475 (BIC +F/TAF vs DTG+F/TAF). The Week 24 data from this study support the safety and efficacy of B/F/TAF exposures obtained with the 75 mg dose of the single agent.
B/F/TAF FDC Dose Selection

A fixed dose formulation of B/F/TAF was developed for use in Phase 3 studies. Preliminary results from the relative bioavailability (rBA) study (GS-US-141-1233) of B/F/TAF (75/200/25 mg) showed that BIC plasma exposure was higher (with $C_{\text{max}}$ and $AUC_{\text{inf}}$ increase of 31% and 27%, respectively) following administration of the FDC as compared with exposure following administration of BIC (75 mg) + F/TAF (200/25 mg) under fasted conditions. The increase in BIC exposures associated with the FDC formulation results in an estimated mean $\text{palQ}_{95}$ of 24.3, compared to an estimated mean $\text{palQ}_{95}$ of 19.2 for the BIC (75 mg) single agent coadministered with F/TAF, in the fasted state.

In order to bridge exposures of BIC in the FDC to the exposure observed with BIC 75 mg administered as a single agent, and to bridge to the safe and effective exposures observed in the Phase 2 study GS-US-141-1475, a lower strength B/F/TAF FDC was developed for use in the Phase 3 studies. Comparability of BIC exposures was confirmed in an rBA study of B/F/TAF (50/200/25 mg) and BIC (75 mg) + F/TAF prior to initiation of dosing in the Phase 3 studies.

1.9. Compliance

This study will be conducted in compliance with this protocol, Good Clinical Practice (GCP), and all applicable regulatory requirements.
2. OBJECTIVES

The primary objective of this study is:

- To evaluate the efficacy of switching from a regimen of either DTG and F/TAF or DTG and F/TDF to a FDC of B/F/TAF versus DTG+F/TAF in virologically suppressed HIV-1 infected subjects with or without ARV resistance as determined by the proportion of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48

The secondary objective of this study is:

- To evaluate the safety and tolerability of the two treatment groups through Week 48
3. STUDY DESIGN

3.1. Endpoints

The primary efficacy endpoint is:

- The proportion of subjects with HIV-1 RNA $\geq 50$ copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm

The secondary endpoints of this study include:

- The proportion of subjects with HIV-1 RNA $< 50$ copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm

- The change from baseline in CD4+ cell count at Week 48

3.2. Study Design

This protocol describes a randomized, double-blind, multicenter, active-controlled study to evaluate the safety and efficacy of switching to a FDC of B/F/TAF versus DTG+F/TAF in HIV-1 infected subjects who are virologically suppressed (HIV-1 RNA $< 50$ copies/mL) for $\geq 6$ months (if there is documented or suspected NRTI resistance), or $\geq 3$ months (if there is no documented or suspected NRTI resistance), on a stable regimen of DTG+F/TAF or DTG+F/TDF.

3.3. Study Treatments

Subjects who provide written consent and meet all eligibility criteria will be randomized in a 1:1 ratio to one of the following 2 treatment groups:

**Treatment Group 1:** FDC of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) + placebo to match of dolutegravir 50 mg + placebo to match FDC of emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) administered orally, once daily, without regard to food (total of 3 tablets) (n=260)

**Treatment Group 2:** Dolutegravir 50 mg + FDC of emtricitabine 200 mg/tenofovir alafenamide 25 mg (F/TAF) + placebo to match FDC of bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (B/F/TAF) administered orally, once daily, without regard to food (total of 3 tablets) (n=260)

Randomization will be stratified as defined in Section 5.1.

3.4. Duration of Treatment

Subjects who meet eligibility criteria will be treated for at least 48 weeks during the blinded treatment phase. The maximum expected duration is approximately 214 weeks (includes the Screening period, blinded treatment period, the open-label extension phase and Follow-up period).
After Week 48, all subjects will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Once the last subject completes the Week 48 visit and Week 48 analysis is completed, all subjects will return to the clinic (preferably within 30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF FDC is demonstrated following review of unblinded data, subjects in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an open-label (OL) extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.

All subjects participating in the OL extension phase, without regard to their blinded treatment regimen, will return for study visits at Week 12 OL and every 12 weeks thereafter for up to 96 weeks.

Subjects who complete the study through the End of Blinded Treatment Visit and do not continue on the OL extension phase, will be required to return to the clinic 30 days after the End of Blinded Treatment Visit for a 30-Day Follow-Up Visit.

Treatment assignments will be provided to the investigators within 30 days of the last subject completing the End of Blinded Treatment Visit.

**Figure 3-1. Study Schema**

<table>
<thead>
<tr>
<th>Day 1*</th>
<th>Week 48* Primary Endpoint</th>
<th>End of Blinded Treatmentbc</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screening ≤ 30 days prior to Day 1</td>
<td><strong>Treatment Group 1:</strong> (N=260) B/F/TAF FDC QD + Placebo to match DTG QD + Placebo to match F/TAF FDC QD</td>
<td>30-Day FU</td>
</tr>
<tr>
<td></td>
<td><strong>Treatment Group 2:</strong> (N=260) DTG + F/TAF FDC QD + Placebo to match B/F/TAF FDC QD</td>
<td>Open-Label Extension</td>
</tr>
</tbody>
</table>

---

a Following the Day 1 visit, subjects will be required to return for study visits at Weeks 4, 8, 12, and then every 12 weeks through the End of Blinded Treatment Visit. The Primary Endpoint will be met when the last enrolled subject completes the Week 48 visit.

b Once the last subject completes the Week 48 visit and Gilead completes the Week 48 analysis, all subjects will return to the clinic (preferably within 30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF FDC is demonstrated following review of unblinded data, subjects in a country where B/F/TAF FDC is not available will be given the option to receive B/F/TAF FDC in an OL extension for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.

c Subjects who complete the study through the End of Blinded Treatment Visit and do not continue on the open-label B/F/TAF FDC extension phase will be required to return to the clinic 30 days after the last dose of study drugs for a 30-Day Follow-Up Visit.
3.5. Biomarker Testing

PPD

3.5.2. Additional Sample Storage

PPD
4. **SUBJECT POPULATION**

4.1. **Number of Subjects and Subject Selection**

Approximately 520 subjects who meet the eligibility criteria will be enrolled. Eligible subjects with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are permitted to enroll.

4.2. **Inclusion Criteria**

Subjects must meet all of the following inclusion criteria to be eligible for participation in this study.

1) The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures

2) Age ≥ 18 years

3) Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:

   a) ≥ 6 months (if there is documented or suspected NRTI resistance prior to the screening visit),
   
   b) ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)

4) Documented plasma HIV-1 RNA < 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the Screening Visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL)

   a) The last two HIV-1 RNA measurements prior to screening must be < 50 copies/mL; however, unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or “blip”) in the past are acceptable.

   b) If the lower limit of detection of the local HIV-1 RNA assay is < 50 copies/mL (eg, < 20 copies/mL), the plasma HIV-1 RNA level cannot exceed 50 copies/mL on two consecutive HIV-1 RNA tests after < 50 copies/mL has been achieved.

5) Plasma HIV-1 RNA levels < 50 copies/mL at Screening Visit

6) Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant)
7) Adequate renal function:
eGFR ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance \{Cockcroft 1976\}:

a) Male: \[ (140 - \text{age in years}) \times (\text{wt in kg}) = \text{CLcr (mL/min)} \]
\[
\frac{72 \times (\text{serum creatinine in mg/dL})}{140 - \text{age in years}} \times (\text{wt in kg}) = \text{CLcr (mL/sec)}
\]

b) Female: \[ (140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85 = \text{CLcr (mL/min)} \]
\[
\frac{72 \times (\text{serum creatinine in umol/L})}{140 - \text{age in years}} \times (\text{wt in kg}) \times 0.85 = \text{CLcr (mL/sec)}
\]

8) No documented resistance to INSTIs or confirmed virologic failure (2 consecutive HIV-1 RNA ≥ 50 copies/mL after achieving < 50 copies/mL while on an INSTI-containing regimen)

9) Eligible subjects with the following historical ARV resistance are permitted to enroll:
   - Any NRTI resistance mutations
   - Any non-nucleoside reverse transcriptase mutations
   - Any protease inhibitor mutations
   - Subjects with resistance to 2 or more classes of antiretrovirals must be reviewed by the Gilead Medical Monitor to confirm eligibility

10) Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)

11) Total bilirubin ≤ 1.5 mg/dL (≤ 26 umol/L), or normal direct bilirubin

12) Adequate hematologic function (absolute neutrophil count ≥ 750/mm\(^3\) (≥ 0.75 GI/L); platelets ≥ 50,000/mm\(^3\) (≥ 50 GI/L); hemoglobin ≥ 8.5 g/dL (≥ 85 g/L))

13) Serum amylase ≤ 5 × ULN (subjects with serum amylase > 5 × ULN will remain eligible if serum lipase is ≤ 5 × ULN)

14) Male subjects who are fertile and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception as described in Appendix 6

15) Male subjects must agree to refrain from sperm donation from first study drug dose and throughout the study period

16) Life expectancy ≥ 1 year
4.3. Exclusion Criteria

Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.

1) An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening (refer to Appendix 5)

2) Subjects experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, or variceal bleeding)

3) Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies)

4) Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance

5) A history of or ongoing malignancy (including untreated carcinoma in-situ) other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Subjects with biopsy-confirmed cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Day 1 and are not anticipated to require systemic therapy during the study

6) Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1

7) Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial

8) Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the dosing requirements

9) Known hypersensitivity to B/F/TAF FDC or DTG+F/TAF FDC tablets, their metabolites, or formulation excipient

10) Females who are pregnant (as confirmed by positive serum pregnancy test)

11) Females who are breastfeeding

12) Subjects receiving ongoing therapy with any of the following medications in the table below, including drugs not to be used with BIC, FTC, TAF, and DTG
### Drug Class

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Agents Disallowed*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiarrhythmic Agent</td>
<td>Dofetilide</td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine</td>
</tr>
<tr>
<td>Antimycobacterials</td>
<td>Rifampin, Rifapentine</td>
</tr>
<tr>
<td>Antiretrovirals</td>
<td>Any antiretroviral drug that is not part of the study regimen</td>
</tr>
<tr>
<td>GI Motility Agents</td>
<td>Cisapride</td>
</tr>
<tr>
<td>Herbal/Natural Supplements</td>
<td>St. John’s Wort, Echinacea</td>
</tr>
</tbody>
</table>

* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the duration of the study.

13) Acute hepatitis in the 30 days prior to randomization

14) Active tuberculosis infection
5. INVESTIGATIONAL MEDICINAL PRODUCTS (IMP)

5.1. Randomization, Blinding and Treatment Codes

Subjects will be assigned a screening number at the time of consent. **Randomization and Day 1 visits cannot occur until subject eligibility has been confirmed.**

Once eligibility has been confirmed and prior to or during the Day 1 visit, the Investigator or designee will randomize the subject using the Interactive Web Response System (IWRS). Once a subject number has been assigned to a subject, it will not be reassigned to any other subject. The subject number assignment and randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been confirmed.

Subjects will be randomized in a 1:1 ratio to Treatment Group 1 or Treatment Group 2.

Randomization will be stratified by NRTI use (F/TAF vs. F/TDF) and documented or suspected history of NRTI resistance. The following NRTI-associated mutations will be considered as having NRTI resistance: M41L, K65R/E/N, D67N, T69 insertions, K70R, L74I/V, Y115F, Q151M, M184I/V, L210W, T215F/Y, K219Q/E/R/N, T69D, K70E/G/M/Q/S/T, V75A/S/M/T. NRTI resistance will be stratified by the following categories:

1. K65R/E/N, or 3 or more thymidine analogue mutations (TAMs) that include M41L or L210W, or T69 insertions, (TAMs are: M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/R/N)
3. None of these mutations/No NRTI resistance

For subjects that qualify for more than one resistance category, stratification will be prioritized by category 1, then 2, then 3 above. The IWRS will assign study drug bottle numbers of blinded B/F/TAF FDC + placebo to match DTG + placebo to match F/TAF FDC, or DTG+F/TAF FDC + placebo to match B/F/TAF FDC, at each study visit for each subject.

5.1.1. Procedures for Breaking Treatment Codes

In the event of a medical emergency where breaking the blind is required to provide medical care to the subject or in the case of pregnancy that occurs while on study drug, the investigator may obtain treatment assignment for that subject. Gilead recommends but does not require that the investigator contact the Gilead medical monitor before breaking the blind. Treatment assignment should remain blinded unless that knowledge is necessary to determine subject emergency medical care or in the event of a pregnancy that occurs while on study drug. The rationale for unblinding must be clearly explained in source documentation and on the electronic case report form (eCRF), along with the date on which the treatment assignment was obtained. The investigator is requested to contact the Gilead medical monitor promptly in case of any treatment unblinding.
Blinding of study treatment is critical to the integrity of this clinical trial and therefore, if a subject’s treatment assignment is disclosed to the investigator, the subject will have study treatment discontinued. All subjects will be followed until study completion unless consent to do so is specifically withdrawn by the subject.

Gilead Pharmacovigilance and Epidemiology (PVE) (formerly referred to as Drug Safety and Public Health) may independently unblind cases for expedited reporting of suspected unexpected serious adverse reactions (SUSARs).

5.2. Description and Handling

5.2.1. Formulation

5.2.1.1. B/F/TAF (50/200/25 mg) and PTM Tablets

The B/F/TAF (50/200/25 mg) tablets are capsule-shaped, film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side of the tablet. Each tablet core contains 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the B/F/TAF tablets contain croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

The PTM B/F/TAF tablets are capsule-shaped, film-coated purplish-brown, debossed with "GSI" on one side of the tablet and "9883" on the other side and are identical in physical appearance to B/F/TAF tablets. The placebo tablets contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The tablet cores are film-coated with iron oxide red, iron oxide black, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

5.2.1.2. DTG (50 mg) and PTM Tablets

Dolutegravir 50-mg tablets are round, film-coated yellow, debossed with “50” on one side and debossed with “SV 572” on the other side. Each tablet core contains 50 mg of dolutegravir. In addition to the active ingredient, DTG tablets contain D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate and sodium stearyl fumarate. The tablet cores are film-coated with iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

The PTM DTG tablets are round, film coated yellow, debossed with “50” on one side and debossed with “SV 572” on the other side. PTM DTG tablets are identical in physical appearance to DTG 50-mg tablets. The placebo tablet cores contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The tablet cores are film-coated with iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.
5.2.1.3. F/TAF (200/25 mg) and PTM Tablets

The F/TAF (200/25 mg) tablets are rectangular-shaped, film-coated blue, debossed with "GSI" on one side of the tablet and "225" on the other side of the tablet. Each tablet core contains 200 mg of emtricitabine and 25 mg of tenofovir alafenamide. In addition to the active ingredients, the F/TAF tablets contain croscarmellose sodium, magnesium stearate and microcrystalline cellulose. The tablet cores are film-coated with FD&C blue #2/indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

The PTM F/TAF tablets are rectangular-shaped, film-coated blue, debossed with "GSI" on one side of the tablet and "225" on the other side of the tablet. PTM F/TAF tablets are identical in physical appearance to F/TAF (200/25 mg) tablets. The placebo tablet cores contain microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. The tablet cores are film-coated with FD&C blue #2/indigo carmine aluminum lake, polyethylene glycol, polyvinyl alcohol, talc and titanium dioxide.

5.2.2. Packaging and Labeling

5.2.2.1. B/F/TAF (50/200/25 mg) and PTM Tablets

B/F/TAF tablets and PTM B/F/TAF tablets are packaged in white, high density polyethylene (HDPE) bottles. Each bottle contains 30 tablets, silica gel desiccant and polyester packing material. Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an induction-sealed and aluminum-faced liner.

Study drug(s) to be distributed to centers in the US and other participating countries shall be labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.

5.2.2.2. DTG (50 mg) and PTM Tablets

DTG 50-mg tablets and PTM tablets are packaged in white, HDPE bottles. Each bottle contains 30 tablets. Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an induction-sealed and aluminum-faced liner.

Study drug(s) to be distributed to centers in the US and other participating countries shall be labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.

5.2.2.3. F/TAF (200/25 mg) and PTM Tablets

F/TAF (200/25 mg) and PTM tablets are packaged in white, HDPE bottles. Each bottle contains 30 tablets, silica gel desiccant, and polyester packing material. Each bottle is enclosed with a white, continuous thread, child-resistant polypropylene screw cap with an induction-sealed and aluminum-faced liner.
Study drug(s) to be distributed to centers in the US and other participating countries shall be labeled to meet applicable requirements of the US FDA, EU Guideline to Good Manufacturing Practice - Annex 13 (Investigational Medicinal Products), and/or other local regulations.

5.2.3. Storage and Handling

Study drugs should be stored at controlled room temperature of 25°C (77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F). Storage conditions are specified on the label. Until dispensed to the subjects, all bottles of study drugs should be stored in a securely locked area, accessible only to authorized site personnel.

To ensure the stability and proper identification, study drug(s) should not be stored in a container other than the container in which they were supplied. Keep the bottle tightly closed to protect from moisture.

Consideration should be given to handling, preparation, and disposal through measures that minimize drug contact with the body. Appropriate precautions should be followed to avoid direct eye contact or exposure through inhalation when handling.

5.3. Dosage and Administration of B/F/TAF and DTG+F/TAF

Study drug B/F/TAF FDC, DTG, F/TAF FDC, and PTM tablets will be provided by Gilead.

Treatment Group 1: FDC B/F/TAF (50/200/25 mg) + PTM of DTG (50 mg) + PTM FDC of F/TAF (200/25 mg) administered orally, once daily, without regard to food (total of 3 tablets)

Treatment Group 2: DTG (50 mg) + FDC of F/TAF (200/25 mg) + PTM FDC B/F/TAF (50/200/25 mg) administered orally, once daily, without regard to food (total of 3 tablets)

After the End of Blinded Treatment Visit, all subjects who choose to participate in the open label extension will receive B/F/TAF FDC once daily for up to 96 weeks.

5.4. Prior and Concomitant Medications

- The use of medications for the treatment of HIV, other than study drug, is prohibited.

- Medications listed in the following table and use of herbal/natural supplements are excluded or should be used with caution while subjects are participating in the study. Subjects will refrain from consumption of grapefruit juice and Seville orange juice throughout participation in the study.
### Table 5-1. Prior and Concomitant Medications

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Agents Disallowed*</th>
<th>Use Discouraged and To Be Used With Caution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acid Reducing Agents</td>
<td></td>
<td>Concentration of study drug may decrease with antacids. Subjects may not take antacids (e.g., Tums or Rolaids); the ulcer medication sucralfate (Carafate); or vitamin or mineral supplements that contain calcium, iron or zinc for a minimum of 6 hours before and 2 hours after any dose of study drug.</td>
</tr>
<tr>
<td>Antacids</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buffered medications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antiarrhythmic Agent</td>
<td>Dofetilide</td>
<td></td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td>Phenobarbital, Phenytoin, Carbamazepine, Oxcarbazepine</td>
<td></td>
</tr>
<tr>
<td>Antimycobacterials</td>
<td>Rifampin, Rifapentine</td>
<td></td>
</tr>
<tr>
<td>Antiretrovirals</td>
<td>Any antiretroviral drug that is not part of the study regimen</td>
<td></td>
</tr>
<tr>
<td>GI Motility Agents</td>
<td>Cisapride</td>
<td></td>
</tr>
<tr>
<td>Herbal/Natural Supplements</td>
<td>St. John’s Wort, Echinacea</td>
<td></td>
</tr>
<tr>
<td>Oral Hypoglycemic Agent</td>
<td></td>
<td>Metformin: close monitoring is recommended. A dose adjustment of Metformin may be necessary. Limit total daily doses of Metformin to 1000mg when initiating study medication or if initiating metformin while on study drug.</td>
</tr>
</tbody>
</table>

* Administration of any of the above medications must be discontinued at least 30 days prior to the Day 1 visit and for the duration of the study.

Should subjects have a need to initiate treatment with any excluded concomitant medication, the Gilead Medical Monitor must be consulted prior to initiation of the new medication. In instances where an excluded medication is initiated prior to discussion with the Sponsor, the Investigator must notify Gilead as soon as he/she is aware of the use of the excluded medication.

### 5.5. Accountability for IMP

Subjects will be instructed to bring all study medication in the original container at each clinic visit for drug accountability. The Investigator will be responsible for maintaining accurate records for all study drug bottles dispensed and tablets returned. The inventory and dispensing logs must be available for inspection by the study monitor. Study medication supplies, including partially used or empty bottles, must be accounted for by the study monitor prior to destruction or return.

The investigator is responsible for ensuring adequate accountability of all used and unused IMP. This includes acknowledgement of receipt of each shipment of IMP (quantity and condition). All used and unused IMP dispensed to subjects must be returned to the site.
Study Drug accountability records will be provided to each study site to:

- Record the date received and quantity of IMP kits
- Record the date, subject number, subject initials, the IMP kit number dispensed
- Record the date, quantity of used and unused IMP returned, along with the initials of the person recording the information

5.5.1. IMP Return or Disposal

Study drug return and disposal will be performed as outlined in Section 9.1.7.
6. STUDY PROCEDURES

The study procedures to be conducted for each subject enrolled in the study are presented in tabular form in Appendix 2 and described in the text that follows.

The investigator must document any deviation from protocol procedures and notify the sponsor or contract research organization (CRO).

6.1. Subject Enrollment and Treatment Assignment

It is the responsibility of the Investigator to ensure that subjects are eligible for study prior to enrollment. Please refer to Section 6.2.2 for details about randomization and treatment assignment.

6.2. Pretreatment Assessments

6.2.1. Screening Visit

Subjects will be screened within 30 days before Day 1 to determine eligibility for participation in the study. The following will be performed and documented at screening:

- Obtain written informed consent(s)
- Obtain medical history including history of HIV-1 disease-related events, and prior medications within 30 days of the screening visit
- If available, obtain documentation of historical genotype(s) (not required for entry to study)
- Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)
- 12-lead ECG performed supine
- Height
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2
- Review concomitant medications
- Record any SAEs and all AEs related to protocol mandated procedures occurring after signing of the consent form
Subjects meeting all of the inclusion criteria, and none of the exclusion criteria, will return to the clinic within 30 days after screening for the Day 1 Visit into the study. Subjects must continue to take their prior treatment regimen up until their scheduled Day 1 visit.

From the time of obtaining informed consent through the first administration of study drug, record all SAEs, as well as any AEs related to protocol-mandated procedures on the adverse events eCRF. All other untoward medical occurrences observed during the screening period, including exacerbation or changes in medical history are to be captured on the medical history eCRF. See Section 7 Adverse Events and Toxicity Management for additional details.

### 6.2.2. Day 1 Assessments

The following evaluations are to be completed at the Day 1 Visit. **The Investigator must have confirmed eligibility before proceeding with the Day 1 visit.** The subject must complete all study procedures before being administered the study drug:

- Short Form 36 Health Survey (SF-36), HIV Symptoms Distress Module, Work Productivity and Activity Impairment Questionnaire (WPAI) and Pittsburgh Sleep Quality Index (PSQI) to be completed by the subject. Subject is to read questionnaire by himself/herself and write/mark answers directly onto questionnaires.

- Review of AEs and changes in concomitant medications

- Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)

- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight

- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2.

- Dispense study drug

- Observed first dose administration of the assigned study drugs as described in Section 5.3

- Subjects should be instructed to take study drugs without regard to food. The subject should be counseled regarding the importance of adherence and taking their study medications at approximately the same time each day as directed by the Investigator.

### 6.3. Randomization

Once eligibility has been confirmed, prior to or during the Day 1 visit, the Investigator or designee will randomize the subject using IWRS. Once a subject number has been assigned to a subject, it will not be reassigned to any other subject. The subject number assignment and randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed, and subject eligibility has been confirmed.
6.4. Treatment Assessments (Week 4 - 48)

The following evaluations are to be completed at Weeks 4, 8, 12, 24, 36, and 48 unless otherwise specified.

Study visits are to be completed within ± 2 days of the protocol specified visit date (based on the Day 1 visit) through Week 12, and completed within ± 6 days of the protocol specified visit date through Week 36, unless otherwise specified. The visit window at Week 48 will be ± 6 weeks of the protocol specified visit date, and this clinical visit window coincides with the Week 48 statistical analysis window for HIV-1 RNA.

Regularly scheduled evaluations will be made on all subjects whether or not they continue to receive study drug.

- SF-36, HIV Symptoms Distress Module, WPAI and PSQI to be completed by the subject at Weeks 4, 12 and 48. Subject is to read questionnaire by himself/herself and write/mark answers directly onto questionnaires

- Review of AEs and changes in concomitant medications

- Complete physical examination (Weeks 24 and 48) (urogenital/anorectal exams will be performed at the discretion of the Investigator) or symptom-directed physical examination, as needed

- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight

- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2

- Document study drug dispensation and accountability for all study drugs dispensed.

- Subjects who meet the criteria for virologic failure will be managed according to the Management of Virologic Rebound Section 6.11.1 and 6.11.2
6.5. **Treatment Assessments (Post Week 48 until the End of Blinded Treatment Visit)**

6.5.1. **Post Week 48 Assessments**

After Week 48, all subjects will continue to take their blinded study drugs and attend visits every 12 weeks until the End of Blinded Treatment Visit. Once the last subject completes the Week 48 visit, and Gilead completes the Week 48 analysis, all subjects will return to the clinic (preferably within 30 days) for the End of Blinded Treatment Visit. Study visits are to be completed within ±6 days of the protocol specified visit date, unless otherwise specified.

- Review of AEs and changes in concomitant medications
- Complete physical examination (**Every 48 weeks**) (urogenital/anorectal exams will be performed at the discretion of the Investigator) or symptom-directed physical examination as needed
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2
- Document study drug dispensation and accountability for all study drugs dispensed
- Subjects who meet the criteria for virologic failure will be managed according to the Management of Virologic Rebound Section 6.11.1 and 6.11.2

6.5.2. **End of Blinded Treatment Visit Assessments**

Once the last subject completes the Week 48 visit, and Gilead completes the Week 48 analysis, all subjects will return to the clinic (preferably within 30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF FDC is demonstrated, following review of unblinded data, subjects in a country where B/F/TAF FDC is not available, will be given the option to receive B/F/TAF FDC in an OL extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first.

Subjects who receive the OL B/F/TAF FDC will return for study visits every 12 weeks.

Subjects who choose to not receive the OL B/F/TAF FDC will be required to return to the clinic for a 30-Day Follow-up visit following the End of Blinded Treatment Visit. Subjects who have discontinued study drug prior to the End of Blinded Treatment Visit will not be eligible for the OL extension. However, these subjects will be asked to continue attending the scheduled study visits through to the End of Blinded Treatment Visit, and then discontinue from the study after the End of Blinded Treatment Visit.
Treatment assignments will be provided to the investigators within 30 days of the last subject completing the End of Blinded Treatment Visit.

The following will be performed at the End of Blinded Treatment Visit:

- Review of AEs and changes in concomitant medications
- Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2
- Document study drug dispensation, if applicable, and accountability for all blinded study drugs dispensed
- Subjects who wish to continue in the OL Extension study will receive OL B/F/TAF

6.5.3. OL Extension Assessments

For purposes of study visit identification during the OL extension, study visits will be identified by the number of weeks that have elapsed between the End of Blinded Treatment Visit and the corresponding OL study visit, and labeled with “OL” (eg, Week 12 OL, Week 24 OL, etc.).

All subjects participating in the OL extension phase, without regard to their blinded treatment regimen, will return for study visits at Week 12 OL, and every 12 weeks thereafter for up to 96 weeks.

Study visits are to be completed within ± 6 days of the protocol specified visit date (based on the End of Blinded Treatment Visit date) unless otherwise specified.

The following will be performed at the OL Extension Visits:

- Review of AEs and changes in concomitant medications
- Complete physical examination (Weeks 48 and 96 OL) (urogenital/anorectal exams will be performed at the discretion of the Investigator) or symptom-directed physical examination, as needed
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2
• Document study drug dispensation and accountability for all study drugs dispensed

• Subjects who meet the criteria for virologic failure will be managed according to the Management of Virologic Rebound Section 6.11.1 and 6.11.2

6.6. Post-treatment Assessments

6.6.1. Early Study Drug Discontinuation Assessments

If the subject discontinues study drug prior to the End of Blinded Treatment Visit, the subject will be asked to return to the clinic within 72 hours of stopping study drug for the Early Study Drug Discontinuation Visit. Prior to the End of Blinded Treatment Visit, if a subject discontinues study dosing (for example, as a result of an AE), every attempt should be made to keep the subject in the study and continue to perform the required study-related follow-up and procedures through to the End of Blinded Treatment Visit (see Section 6.7, Criteria for Discontinuation of Study Treatment). If this is not possible or acceptable to the subject or investigator, the subject may be withdrawn from the study.

If the subject discontinues study drug during the OL extension, the subject will be asked to return to the clinic within 72 hours of stopping the study drug for the Early Study Drug Discontinuation Visit, and will be discontinued from both study drug and study.

At the Early Study Drug Discontinuation Visit, any evaluations showing abnormal results indicating that there is a possible or probable causal relationship with the study drug, will be repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to baseline (Day 1) value, or is otherwise explained.

The following evaluations are to be completed at the Early Study Drug Discontinuation Visit:

• Review of AEs and changes in concomitant medications

• Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator)

• Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight

• Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2

• Document study drug accountability for all study drugs dispensed
6.6.2. 30-Day Follow-Up Visit

Subjects who prematurely discontinue study drug during the blinded phase, and refuse to continue in the study through the End of Blinded Treatment Visit will be asked to return to the clinic 30 days after the completion of the Early Study Drug Discontinuation Visit, for the 30-Day Follow-Up Visit.

Subjects who complete the study drug through the End of Blinded Treatment Visit, and who do not wish to participate in the open-label extension, will be required to return to the clinic 30 days after the last dose of study drug, for the 30-Day Follow-Up Visit.

Those subjects who prematurely discontinue study drug during the blinded phase and continue in the study through at least one subsequent visit after the Early Study Drug Discontinuation Visit will not be required to complete the 30-Day Follow-Up Visit.

Subjects who prematurely discontinue study drug during the OL extension will be asked to return to the clinic 30 days after the completion of the Early Study Drug Discontinuation Visit, for the 30-day Follow-Up Visit. The subject will not continue attending the scheduled OL study visits.

Subjects who complete the OL extension phase will be asked to return to the clinic 30 days after the completion of study drug for the 30-day Follow-Up Visit.

For the purpose of scheduling a 30-Day Follow-Up Visit, a ± 6 days window may be used. The following evaluations are to be completed at the 30-Day Follow-Up Visit:

- Review of AEs and changes in concomitant medications
- Symptom-directed physical examination
- Vital signs measurement (blood pressure, pulse, respiration rate, and temperature), including weight
- Obtain blood and urine samples as described in Sections 6.10.1 and 6.10.2

At the 30-Day Follow-Up Visit, any evaluations showing abnormal results believed to be a reasonable possibility of a causal relationship with the study drugs will be repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to baseline (Day 1) value, or is otherwise explained.

6.7. Criteria for Discontinuation of Study Treatment

Study medication will be discontinued in the following instances:

- Unacceptable toxicity, or toxicity that, in the judgment of the investigator, compromises the ability to continue study-specific procedures or is considered to not be in the subject’s best interest


- Subject request to discontinue for any reason

- Pregnancy during the study; refer to Appendix 6
  Note: Female subjects who become pregnant during the study will be discontinued from the study and their study treatment assignment will be unblinded by the investigator and shared with the subject.

- Development of active tuberculosis infection

- Discontinuation of the study at the request of Gilead, a regulatory agency or an institutional review board or independent ethics committee (IRB/IEC)

Study medication may be discontinued in the following instances:

- Intercurrent illness that would, in the judgment of the investigator, affect assessments of clinical status to a significant degree. Following resolution of intercurrent illness, the subject may resume study dosing at the discretion of the investigator.

- Lack of efficacy

- Subject noncompliance

6.8. End of Study

The end of study will be the last patient’s last observation (or visit).

6.9. Post Study Care

After a subject has completed/terminated their participation in the study, long-term care for the subject will remain the responsibility of their primary treating physician.

6.10. Clinical Laboratory Assessments

Blood and urine samples will be collected throughout the study as outlined below, within Section 6, and in Appendix 2 Study Procedures Table.

6.10.1. Blood Samples

- Blood sample collection for the following laboratory analyses:
  
  — Serum pregnancy test (females of childbearing potential only). If the test is positive, the subject will not be enrolled

  — Chemistry profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect bilirubin, total protein, albumin, CPK, bicarbonate, blood urea nitrogen (BUN), chloride, creatinine, glucose, potassium, sodium, amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 × ULN)

  ■ Calcium, phosphorus, magnesium (**Screening and Day 1**)
— Metabolic assessments: Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, and triglycerides) collected at Day 1, Weeks 12, 24, and 48, and every 24 weeks thereafter, End of Blinded Treatment Visit, and every 24 weeks in the OL extension phase

■ If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments

— eGFR according to the Cockcroft-Gault formula:

Male: \[
\frac{(140 - \text{age in years}) \times (\text{wt in kg})}{72 \times (\text{serum creatinine in mg/dL})} = \text{creatinine clearance (CLcr) (mL/min)}
\]

\[
\frac{(140 - \text{age in years}) \times (\text{wt in kg})}{72 \times (\text{serum creatinine in umol/L}) \times 0.6786} = \text{CLcr (mL/sec)}
\]

Female: \[
\frac{(140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85}{72 \times (\text{serum creatinine in mg/dL})} = \text{CLcr (mL/min)}
\]

\[
\frac{(140 - \text{age in years}) \times (\text{wt in kg}) \times 0.85}{72 \times (\text{serum creatinine in umol/L}) \times 0.6786} = \text{CLcr (mL/sec)}
\]

— Hematology profile: complete blood count (CBC) with differential and platelet count

— CD4+ cell count and percentage

— Plasma HIV-1 RNA

— HBV blood panel (Screening, Week 48, every 48 weeks through End of Blinded Treatment Visit, and Weeks 48OL, 96OL): Hepatitis B virus surface antigen (HBsAg), Hepatitis B virus surface antibody (HBsAb) and Hepatitis B virus core antibody (HBcAb)

The following tests will be conducted by the central laboratory if the following criteria are met:

■ If positive HBsAg: reflex testing for plasma HBV DNA, Hepatitis B virus e-antigen (HBeAg) (if negative, reflex Hepatitis B virus e-Antibody [HBeAb]), and quantitative HBsAg

■ If positive HBcAb with negative HBsAg and negative HBsAb: reflex testing for plasma HBV DNA (if positive, reflex HBeAg). If HBeAg is performed and found to be negative, reflex HBeAb

— Plasma HBV DNA for patients who are HBV co-infected
HCV antibody (Ab) serology. Subjects who are HCVAb positive will have a HCV RNA test performed (Screening, Week 48, every 48 weeks through End of Blinded Treatment Visit, and Weeks 48OL, 96OL).

6.10.2. Urine Samples

Urine samples will be collected for the following laboratory analyses:

- Urinalysis
- Urine pregnancy testing (Not collected at Screening and 30-day Follow-up Visits)

6.11. Virologic Failure

Virologic failure is defined as virologic rebound or having HIV-1 RNA ≥ 50 copies/mL at study drug discontinuation, or Week 48.

6.11.1. Management of Virologic Rebound

Subjects who meet the criteria listed below will be considered to have virologic rebound:

- At any post Day 1 visit, a rebound in HIV-1 RNA ≥ 50 copies/mL, which is subsequently confirmed at the following scheduled or unscheduled visit; OR
- Any subject with HIV RNA ≥ 50 copies/mL at study drug discontinuation

Following the unconfirmed virologic rebound, subjects will be asked to return to the clinic for a scheduled or unscheduled blood draw (2 to 3 weeks after the date of the original test that resulted in HIV-1 RNA virologic rebound) for confirmation of virologic rebound. If virologic rebound is confirmed at the scheduled or unscheduled visit and the HIV-1 RNA is ≥ 200 copies/mL, the blood sample from the confirmation visit will be the primary sample used for HIV-1 genotypic
and phenotypic testing. After a subject’s first post-baseline resistance test, additional testing will be conducted on a case-by-case basis. Any subject may be discontinued at Investigator’s discretion or per local treatment guidelines.

If no resistance is detected from the genotype or phenotype, the subject may remain on study drugs and HIV-1 RNA test should be repeated (2 to 3 weeks after date of test with HIV-1 RNA \( \geq 50 \) copies/mL). Investigators should carefully evaluate the benefits and risks of remaining on study drug for each individual subject and document this assessment in the on-site medical record.

Subjects who are noncompliant on an ongoing basis will be considered for discontinuation per the Investigator’s discretion or local treatment guidelines. Investigators who opt to discontinue study drugs for an individual subject must discuss with the Medical Monitor prior to study drug discontinuation.

For subjects who are off study drug but remain on study, it will be the Investigator’s discretion to manage virologic rebound.

Please refer to Figure 6-1 for the management of subjects who meet the criteria for virologic rebound.

**Figure 6-1. Virologic Rebound Schema**

<table>
<thead>
<tr>
<th>Screening</th>
<th>Treatment Period</th>
<th>30-Day Follow-up</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>At any post Day 1 visit, a rebound in HIV-1 RNA to ( \geq 50 ) copies/mL</td>
<td>Return for scheduled/unscheduled HIV-1 RNA and potential genotype/phenotype (2-3 weeks later)</td>
<td></td>
</tr>
<tr>
<td><strong>Unconfirmed</strong> virologic rebound: remain on current regimen(^a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Confirmed</strong> virologic rebound(^b)</td>
<td>Remain on study</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HIV-1 genotype/phenotype(^c)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If no new reverse transcriptase or integrase resistance mutations detected, continue on study drugs(^d)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>If new reverse transcriptase or integrase resistance mutations detected, discontinue study drugs and construct a new ARV regimen(^e)</td>
</tr>
</tbody>
</table>

\( a \). If virologic rebound is not confirmed, the subject will remain on their current regimen.
\( b \). If virologic rebound is confirmed and the HIV-1 RNA is \( \geq 200 \) copies/mL, the HIV-1 genotype and phenotype (reverse transcriptase, protease, and integrase) will be analyzed.
\( c \). Based on the results of the genotypic and phenotypic assays, the subject will remain on study drugs or study drugs will be discontinued. If genotyping or phenotyping fails, a new ARV regimen may be configured at the discretion of the Investigator.
\( d \). If no new resistance is detected, HIV-1 RNA will be repeated (2-3 weeks later). Investigator reviews study drug continuation/discontinuation options and discusses with the Medical Monitor prior to study drug discontinuation.
\( e \). A new ARV regimen will be configured, at the Investigator’s discretion, and the subject will remain in the study.
6.11.2. **Subjects with HIV-1 RNA ≥ 50 copies/mL at Study Drug Discontinuation, or Week 48**

Subjects with HIV-1 RNA ≥ 50 copies/mL at study drug discontinuation, or last visit, or Week 48 will be considered virologic failures. Subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48, will be asked to return for an unscheduled visit within the visit window for a retest.

Subjects with HIV-1 RNA ≥ 200 copies/mL at study drug discontinuation, last visit, or Week 48, will also have resistance testing conducted.
7. ADVERSE EVENTS AND TOXICITY MANAGEMENT

7.1. Definitions of Adverse Events, Adverse Reactions, and Serious Adverse Events

7.1.1. Adverse Events

An adverse event is any untoward medical occurrence in a clinical study subject administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs may also include pre- or post-treatment complications that occur as a result of protocol specified procedures, lack of efficacy, overdose, drug abuse/misuse reports, or occupational exposure. Preexisting events that increase in severity or change in nature during or as a consequence of participation in the clinical study will also be considered AEs.

An AE does not include the following:

- Medical or surgical procedures such as surgery, endoscopy, tooth extraction, and transfusion. The condition that led to the procedure may be an adverse event and must be reported.
- Pre-existing diseases, conditions, or laboratory abnormalities present or detected before the screening visit that do not worsen
- Situations where an untoward medical occurrence has not occurred (eg, hospitalization for elective surgery, social and/or convenience admissions)
- Overdose without clinical sequelae (see Section 7.6.1)
- Any medical condition or clinically significant laboratory abnormality with an onset date before the consent form is signed and not related to a protocol-associated procedure is not an AE. It is considered to be pre-existing and should be documented on the medical history eCRF.

7.1.2. Serious Adverse Events

A serious adverse event is defined as an event that, at any dose, results in the following:

- Death
- Life-threatening (Note: The term “life-threatening” in the definition of “serious” refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.)
- In-patient hospitalization or prolongation of existing hospitalization
• Persistent or significant disability/incapacity

• A congenital anomaly/birth defect

• A medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. Medical and scientific judgment must be exercised to determine whether such an event is a reportable under expedited reporting rules. Examples of medically important events include intensive treatment in an emergency room or at home for allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; and development of drug dependency or drug abuse. For the avoidance of doubt, infections resulting from contaminated medicinal product will be considered a medically important event and subject to expedited reporting requirements.

7.1.3. Clinical Laboratory Abnormalities and Other Abnormal Assessments as Adverse Events or Serious Adverse Events

Laboratory abnormalities without clinical significance are not recorded as AEs or SAEs. However, laboratory abnormalities (eg, clinical chemistry, hematology, and urinalysis) that require medical or surgical intervention or lead to IMP interruption, modification, or discontinuation must be recorded as an AE, as well as an SAE, if applicable. In addition, laboratory or other abnormal assessments (eg, electrocardiogram, x-rays, vital signs) that are associated with signs and/or symptoms must be recorded as an AE or SAE if they meet the definition of an AE or SAE as described in Sections 7.1.1 and 7.1.2. If the laboratory abnormality is part of a syndrome, record the syndrome or diagnosis (eg, anemia), not the laboratory result (ie, decreased hemoglobin).

For specific information on handling of clinical laboratory abnormalities in this study, please refer to Section 7.5.

7.2. Assessment of Adverse Events and Serious Adverse Events

The investigator or qualified subinvestigator is responsible for assessing AEs and SAEs for causality and severity, and for final review and confirmation of accuracy of event information and assessments.

7.2.1. Assessment of Causality for Study Drugs and Procedures

The investigator or qualified subinvestigator is responsible for assessing the relationship to IMP therapy using clinical judgment and the following considerations:

• **No:** Evidence exists that the adverse event has an etiology other than the IMP. For SAEs, an alternative causality must be provided (eg, pre-existing condition, underlying disease, intercurrent illness, or concomitant medication).

• **Yes:** There is reasonable possibility that the event may have been caused by the investigational medicinal product.
It should be emphasized that ineffective treatment should not be considered as causally related in the context of adverse event reporting.

The relationship to study procedures (eg, invasive procedures such as venipuncture or biopsy) should be assessed using the following considerations:

- **No**: Evidence exists that the adverse event has an etiology other than the study procedure.
- **Yes**: The adverse event occurred as a result of protocol procedures, (eg, venipuncture)

### 7.2.2. Assessment of Severity

AE severity should be recorded and graded according to the Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities (Appendix 4). For adverse events associated with laboratory abnormalities, the event should be graded on the basis of the clinical severity in the context of the underlying conditions; this may or may not be in agreement with the grading of the laboratory abnormality.

The distinction between the seriousness and the severity of an adverse event should be noted. Severe is a measure of intensity; thus, a severe reaction is not necessarily a serious reaction. For example, a headache may be severe in intensity, but would not be classified as serious unless it met one of the criteria for serious events.

For AEs associated with laboratory abnormalities, the event should be graded on the basis of the clinical severity in the context of the underlying conditions; this may or may not be in agreement with the grading of the laboratory abnormality.

### 7.3. Investigator Requirements and Instructions for Reporting Adverse Events and Serious Adverse Events to Gilead

Requirements for collection prior to study drug initiation:

After informed consent, but prior to initiation of study medication, the following types of events should be reported on the eCRF:

- all SAEs and adverse events related to protocol-mandated procedures.

#### 7.3.1. Adverse Events

Following initiation of study medication, collect all AEs, regardless of cause or relationship, until 30-days after last administration of study IMP must be reported to the eCRF database as instructed.

All AEs should be followed up until resolution or until the adverse event is stable, if possible. Gilead may request that certain AEs be followed beyond the protocol defined follow up period.
7.3.2. Serious Adverse Events

All SAEs, regardless of cause or relationship, that occurs after the subject first consents to participate in the study (ie, signing the informed consent) and throughout the duration of the study, including the protocol-required post treatment follow-up period, must be reported to the eCRF database and Gilead PVE as instructed. This also includes any SAEs resulting from protocol-associated procedures performed after informed consent is signed.

Any SAEs and deaths that occur after the post treatment follow-up visit but within 30-days of the last dose of study IMP, regardless of causality, should also be reported.

Investigators are not obligated to actively seek SAEs after the protocol defined follow up period; however, if the investigator learns of any SAEs that occur after study participation has concluded and the event is deemed relevant to the use of IMP, he/she should promptly document and report the event to Gilead PVE.

Electronic Serious Adverse Event Reporting Process

- Site personnel record all SAE data in the eCRF database and from there transmit the SAE information to Gilead PVE within 24 hours of the investigator’s knowledge of the event. Detailed instructions can be found in the eCRF completion guidelines.

- If it is not possible to record and submit the SAE information electronically, because the eCRF database cannot be accessed or is not available (including at study start), record the SAE on the paper serious adverse event report form and submit by e-mail or fax within 24 hours of the investigator’s knowledge of the event to:

  Gilead PVE contact information:  
  Email: PPD 
  Fax: PPD

- As soon as it is possible to do so, any SAE reported via paper must be transcribed into the eCRF Database according to instructions in the eCRF completion guidelines.

- If an SAE has been reported via a paper form because the eCRF database has been locked, no further action is necessary.

- All AEs and SAEs will be recorded in the eCRF database within the timelines outlined in the eCRF completion guideline.

- Additional information may be requested to ensure the timely completion of accurate safety reports.

- Any medications necessary for treatment of the SAE must be recorded onto the concomitant medication section of the subject’s eCRF and the event description section of the SAE form.
• For fatal or life-threatening events, copies of hospital case reports, autopsy reports, and other documents are also to be submitted by e-mail or fax only when requested and applicable. Transmission of such documents should occur without personal subject identification, maintaining the traceability of a document to the subject identifiers.

7.4. **Gilead Reporting Requirements**

Depending on relevant local legislation or regulations, including the applicable US FDA Code of Federal Regulations, the EU Clinical Trials Directive (2001/20/EC) and relevant updates, and other country-specific legislation or regulations, Gilead may be required to expedite to worldwide regulatory agencies reports of SAEs, serious adverse drug reactions (SADRs), or SUSARs. In accordance with the EU Clinical Trials Directive (2001/20/EC), Gilead or a specified designee will notify worldwide regulatory agencies and the relevant IEC in concerned Member States of applicable SUSARs as outlined in current regulations.

Assessment of expectedness for SAEs will be determined by Gilead using reference safety information specified in the investigator’s brochure, EU Summary of Product Characteristics (SmPC), or relevant local label as applicable.

All investigators will receive a safety letter notifying them of relevant SUSAR reports associated with any study IMP. The investigator should notify the IRB or IEC of SUSAR reports as soon as is practical, where this is required by local regulatory agencies, and in accordance with the local institutional policy.

7.5. **Toxicity Management**

All clinical and clinically significant laboratory toxicities will be managed according to uniform guidelines detailed in Appendix 4 as outlined below.

• Clinical events and clinically significant laboratory abnormalities will be graded according to the Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities (Appendix 5).

• Grade 3 and 4 clinically significant laboratory abnormalities should be confirmed by repeat testing within 3 calendar days of receipt of results and before study drug discontinuation, unless such a delay is not consistent with good medical practice.

Any questions regarding toxicity management should be directed to the Gilead Medical Monitor.

7.5.1. **Grades 1 and 2 Laboratory Abnormality or Clinical Event**

Continue study drug at the discretion of the Investigator.

7.5.2. **Grade 3 Laboratory Abnormality or Clinical Event**

• For Grade 3 clinically significant laboratory abnormality or clinical event, study drug may be continued if the event is considered to be unrelated to study drug.
For a Grade 3 clinical event, or clinically significant laboratory abnormality confirmed by repeat testing, that is considered to be related to study drug, study drug will be withheld until the toxicity returns to ≤ Grade 2. When restarting study drug following resolution of the adverse event, the study drug should be restarted at full dose upon discussion with the Gilead Medical Monitor.

If a laboratory abnormality recurs to ≥ Grade 3 following rechallenge with study drug and is considered related to study drug, then study drug will be permanently discontinued and the subject managed according to local practice. Recurrence of laboratory abnormalities considered unrelated to study drug may not require permanent discontinuation but requires discussion with the Gilead Medical Monitor.

7.5.3. Grade 4 Laboratory Abnormality or Clinical Event

For a Grade 4 clinical event or clinically significant Grade 4 laboratory abnormality confirmed by repeat testing that is considered related to study drug, study drug will be permanently discontinued and the subject managed according to local practice. The subject should be followed as clinically indicated until the laboratory abnormality returns to baseline or is otherwise explained, whichever occurs first. A clinically significant Grade 4 laboratory abnormality that is not confirmed by repeat testing should be managed according to the algorithm for the new toxicity grade.

Study drug may be continued without dose interruption for a clinically non-significant Grade 4 laboratory abnormality (e.g., Grade 4 CK after strenuous exercise, or triglyceride elevation that is nonfasting or that can be medically managed) or a clinical event considered unrelated to study drug requires discussion with the Gilead Medical Monitor.

7.5.4. On-Treatment ALT Flare

An On-Treatment ALT Flare is defined as:

- Confirmed (within 3 days of receipt of initial laboratory results) serum ALT > 2 × Day 1 value and > 10 × ULN, with or without associated symptoms.

7.5.4.1. Management of ALT Flare in Subjects Receiving Study Medication

If laboratory results indicate elevation of ALT > 2 × Day 1 value and > 10 × ULN, the following is recommended:

- Schedule the subject to return to the clinic as soon as possible (ideally within 3 days after initial laboratory results were drawn). During the visit, a clinical assessment of the subject will be performed. The assessment should include a physical examination and evaluation of the subject’s mental status.

- If the ALT elevation is confirmed, request the central clinical laboratory to conduct reflex testing for plasma HBV DNA, HBV serology (HBsAg and HBsAb), HDV, HAV IgM, and HCV serology
Check the following laboratory parameters: serum ALT and AST, total bilirubin, and serum albumin. Based on the results of the confirmatory tests, the following treatment modifications are recommended:

**Elevated Liver Enzymes, Normal or Stable relative to Day 1 Liver Function Tests**

If ALT levels are elevated (ie, $> 2 \times \text{Day 1}$ and $> 10 \times \text{ULN}$) with normal or stable total bilirubin, the subject may remain on study medication and should be monitored weekly as long as ALT levels return to normal or Day 1 level. During monitoring, if the ALT values remain persistently elevated, the Investigator should discuss with the Gilead Medical Monitor whether the study drug should be discontinued.

**Elevated Liver Enzymes, Elevated Liver Function Tests**

If ALT values are elevated (ie, $> 2 \times \text{Day 1}$ and $> 10 \times \text{ULN}$), and total bilirubin is confirmed to be $2 \times \text{Day 1}$ value, provided both are $> \text{ULN}$, the investigator should consider discontinuing study medication (upon discussion with the Gilead Medical Monitor, unless the safety of the patient is of immediate concern). The subject should be monitored weekly as long as ALT, and total bilirubin remain elevated or above Day 1 values.

During monitoring, if the ALT values and the liver function tests remain persistently elevated, the Investigator should discuss with the Gilead Medical Monitor whether the study drug should be discontinued.

**7.5.5. Management of Potential Hepatobiliary Toxicity**

Monkeys given a high dose (1000 mg/kg/day) for 39 weeks had evidence of biliary hyperplasia and hepatocyte hypertrophy on histopathologic examination. The risk to humans given the clinical dose of BIC (50 mg/day) is unknown. Investigators should be aware of this potential toxicity. Any study subject exhibiting signs/symptoms or laboratory abnormalities suggestive of possible hepatobiliary toxicity should undergo thorough examination and clinical workup as deemed appropriate by the Investigator, and the Investigator must communicate promptly with the Gilead Medical Monitor. Consideration should be given to appropriate imaging studies (for example, ultrasound of the liver and biliary tree) and potential consultation with a gastroenterologist with specialty training in hepatobiliary diseases. Management of graded laboratory and clinical abnormalities will be managed as outlined in Section 7.5.

**7.5.6. On-Treatment Hepatitis C Management**

If a subject tests positive for HCV RNA at screening or develops signs or symptoms of active Hepatitis C virus Gilead recommends that local medical practice is followed at the discretion of the Investigator. Study drug may be continued without dose interruption. Should the Investigator decide to initiate Hepatitis C treatment the Investigator must contact the Gilead Medical Monitor to confirm that no drug-drug interactions are expected. Subjects should return to the clinic for scheduled or unscheduled follow up visit(s) according to local medical practice for laboratory evaluations. If Hepatitis C treatment is initiated, Investigators should use the Gilead provided retest laboratory kits to manage the active Hepatitis C.
7.6. Special Situations Reports

7.6.1. Definitions of Special Situations

Special situation reports include all reports of medication error, abuse, misuse, overdose, reports of adverse events associated with product complaints, reports of adverse reactions in infants following exposure from breastfeeding, occupational exposure with an adverse event, and pregnancy reports regardless of an associated AE.

Medication error is any unintentional error in the prescribing, dispensing, or administration of a medicinal product while in the control of the health care provider, subject, or consumer.

Abuse is defined as persistent or sporadic intentional excessive use of a medicinal product by a subject.

Misuse is defined as any intentional and inappropriate use of a medicinal product that is not in accordance with the protocol instructions or the local prescribing information.

An overdose is defined as an accidental or intentional administration of a quantity of a medicinal product given per administration or cumulatively which is above the maximum recommended dose as per protocol or in the product labelling (as it applies to the daily dose of the subject in question). In cases of a discrepancy in drug accountability, overdose will be established only when it is clear that the subject has taken the excess dose(s). Overdose cannot be established when the subject cannot account for the discrepancy except in cases in which the investigator has reason to suspect that the subject has taken the additional dose(s).

Product complaint is defined as complaints arising from potential deviations in the manufacture, packaging, or distribution of the medicinal product.

Occupational exposure is defined as exposure to a medicinal product as a result of one’s professional or non-professional occupation.

7.6.2. Instructions for Reporting Special Situations

7.6.2.1. Instructions for Reporting Pregnancies

The investigator should report pregnancies in female study subjects that are identified after initiation of study medication and throughout the study, including the post study drug follow-up period, to Gilead PVE using the pregnancy report form within 24 hours of becoming aware of the pregnancy.

The subject’s treatment assignment will be unblinded by the Investigator as described in Protocol Section 5.1.1.

Refer to below and the eCRF completion guidelines for full instructions on the mechanism of pregnancy reporting.
The pregnancy itself is not considered an AE nor is an induced elective abortion to terminate a pregnancy without medical reasons.

Any premature termination of pregnancy (e.g., a spontaneous abortion, an induced therapeutic abortion due to complications or other medical reasons) must be reported within 24 hours as an SAE. The underlying medical reason for this procedure should be recorded as the AE term.

A spontaneous abortion is always considered to be an SAE and will be reported as described in Section 7.3. Furthermore, any SAE occurring as an adverse pregnancy outcome post study must be reported to Gilead PVE.

The subject should receive appropriate monitoring and care until the conclusion of the pregnancy. Any complications during pregnancy and the outcome should be reported to Gilead PVE using the pregnancy outcome report form. If the end of the pregnancy occurs after the study has been completed, the outcome should be reported directly to Gilead PVE. Gilead PVE contact information is as follows:

Email: PPD or Fax: PPD

Refer to Appendix 6 for Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements.

7.6.2.2. Reporting Other Special Situations

All other special situation reports must be reported on the special situations report form and forwarded to Gilead PVE within 24 hours of the investigator becoming aware of the situation. These reports must consist of situations that involve study IMP and/or Gilead concomitant medications, but do not apply to non-Gilead concomitant medications.

Special situations involving non-Gilead concomitant medications does not need to be reported on the special situations report form; however, for special situations that result in AEs due to a non-Gilead concomitant medication, the AE should be reported on the AE form.

Any inappropriate use of concomitant medications prohibited by this protocol should not be reported as “misuse,” but may be more appropriately documented as a protocol deviation.

Refer to Section 7.3 and the eCRF completion guidelines for full instructions on the mechanism of special situations reporting.

All clinical sequelae in relation to these special situation reports will be reported as AEs or SAEs at the same time using the AE eCRF and/or the SAE report form. Details of the symptoms and signs, clinical management, and outcome will be reported, when available.
8. STATISTICAL CONSIDERATIONS

8.1. Analysis Objectives and Endpoints

8.1.1. Analysis Objectives

The primary objective of this study is:

- To evaluate the efficacy of switching from a regimen of either DTG and F/TAF or DTG and F/TDF to a FDC of B/F/TAF versus DTG+F/TAF in virologically suppressed HIV-1 infected subjects with or without ARV resistance as determined by the proportion of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48

The secondary objective of this study is:

- To evaluate the safety and tolerability of the two treatment groups through Week 48

8.1.2. Primary Endpoint

The proportion of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm.

8.1.3. Secondary Endpoint

Secondary endpoints include:

- The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm
- The change from baseline in CD4+ cell count at Week 48

8.2. Analysis Conventions

8.2.1. Analysis Sets

8.2.1.1. All Randomized

The randomized analysis set includes all subjects who are randomized into the study. This is the primary analysis set for by-subject listings.
8.2.1.2. Efficacy

8.2.1.2.1. Full Analysis Set

The primary analysis set for efficacy analyses is defined as FAS, which will include all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study drug. Subjects will be grouped according to the treatment to which they were randomized.

8.2.1.2.2. Per-Protocol (PP) Analysis Set

The secondary analysis set for efficacy analyses is defined as PP analysis set, which will include all subjects who (1) are randomized into the study, (2) have received at least 1 dose of study drug, and (3) have not committed any major protocol violation, including the violation of key entry criteria. Subjects will be grouped according to the treatment they actually received.

Subjects meeting any of the following criteria will be excluded from the Week 48 PP analysis set:

- Subjects who do not have on-treatment HIV-1 RNA in the Week 48 analysis window, except when missing, due to discontinuation of study drug for lack of efficacy.
- Subjects who meet the exclusion criterion for receiving ongoing therapy with any of the medications listed in the table in protocol Section 4.3 including drugs not to be used with BIC, FTC, TAF, and DTG.
- Nonadherence to study drug: subjects with adherence rate for active study drug up to the Week 48 Visit below the 2.5\textsuperscript{th} percentile

8.2.1.3. Safety

The primary analysis set for safety analyses is defined as safety analysis set, which will include all subjects who (1) are randomized into the study and (2) have received at least 1 dose of study drug. All the data collected up to 30 days after subjects permanently discontinue their study drug will be included in the safety summaries, unless specified otherwise. Subjects will be grouped according to the treatment they actually received.

8.3. Data Handling Conventions

HIV-1 RNA results of ‘No HIV-1 RNA detected’ and “<20 cp/mL HIV-1 RNA Detected” will be imputed as 19 copies/mL for analysis purpose.

Laboratory data that are continuous in nature, but are less than the lower limit of quantitation or above the upper limit of quantitation, will be imputed to the value of the lower or upper limit plus or minus one significant digit, respectively (eg, if the result of a continuous laboratory test is < 20, a value of 19 will be assigned).
Missing data can have an impact upon the interpretation of the trial data. In general, values for missing data will not be imputed. However, a missing pre-treatment laboratory result would be treated as normal (ie, no toxicity grade) for the laboratory abnormality summary.

All available data for subjects that do not complete the study will be included in data listings.

8.4. Demographic Data and Baseline Characteristics

Demographic and baseline characteristics will be summarized using standard descriptive methods, including sample size, mean, SD, median, Q1, Q3, minimum, and maximum for continuous variables, and frequency and percentages for categorical variables.

Demographic data will include sex, race, ethnicity, and age.

Baseline characteristics will include body weight, height, eGFR, HIV-1 infection, and enrollment distribution will be summarized.

For categorical demographic and baseline characteristics, the Cochran–Mantel–Haenszel test will be used to compare treatment groups. For continuous demographic and baseline characteristics, the Wilcoxon rank sum test will be used to compare treatment groups.

8.5. Efficacy Analysis

8.5.1. Primary Analysis

The primary analysis will consist of a non-inferiority test of switching to FDC B/F/TAF versus DTG+F/TAF, with respect to the proportion of subjects with HIV 1 RNA ≥ 50 copies/mL at Week 48, as defined by the US FDA-defined snapshot algorithm. The primary analysis of the efficacy endpoint will be based on the FAS.

8.5.1.1. US FDA-defined Snapshot Algorithm

The analysis window at Week 48 is defined as from Study Day 295 to Study Day 378, inclusive. All HIV-1 RNA data collected on-treatment (ie, including data collected up to 1 day after the last dose date of study drug) will be used in the snapshot algorithm. Virologic outcome will be defined as the following categories:

- **HIV-1 RNA < 50 copies/mL**: this includes subjects who have the last available on-treatment HIV-1 RNA < 50 copies/mL in the Week 48 analysis window

- **HIV-1 RNA ≥ 50 copies/mL**: this includes subjects

  a) Who have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 48 analysis window, or
b) Who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window and

1. Who discontinue study drug prior to or in the Week 48 analysis window due to lack of efficacy, or

2. Who discontinue study drug prior to or in the Week 48 analysis window due to reason other than lack of efficacy and have the last available on-treatment HIV-1 RNA ≥ 50 copies/mL

- **No Virologic Data in the Week 48 Analysis Window**: this includes subjects who do not have on-treatment HIV-1 RNA data in the Week 48 analysis window because of the following:

  a) Discontinuation of study drug prior to or in the Week 48 analysis window due to reasons other than lack of efficacy and the last available on-treatment HIV-1 RNA < 50 copies/mL, or

  b) Missing data during the window but on study drug

8.5.1.2. Analysis of Primary Efficacy Endpoint

The null hypothesis is that the proportion of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 in the B/F/TAF group is at least 4% higher than that in the DTG+F/TAF group; the alternative hypothesis is that the proportion of subjects with HIV-1 RNA ≥ 50 copies/mL in the B/F/TAF group is less than 4% higher than that in the DTG+F/TAF group.

Non-inferiority will be assessed using the conventional CI approach. The point estimate of treatment difference (B/F/TAF group – DTG+F/TAF group) and the associated 2-sided 95% CI will be constructed based on the exact method.

It will be concluded that B/F/TAF FDC is non-inferior to DTG+F/TAF if the upper bound of the 2-sided 95% CI of the difference between treatment groups (B/F/TAF group – DTG+F/TAF group) in the percentage of subjects with HIV-1 RNA ≥ 50 copies/mL is less than 4% (ie, a margin of 4% is applied to non-inferiority assessment). The 2-sided 95% CIs will be constructed based on the exact method.

8.5.2. Secondary Analyses

The proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48 as defined by the US FDA-defined snapshot algorithm will also be summarized. The 95% CIs will be constructed in the same manner as described for the primary efficacy endpoint. However, non-inferiority will be assessed using a margin of 10%. It will be concluded that B/F/TAF FDC is noninferior to DTG+F/TAF if the lower bound of the 2-sided 95% CI of the difference between treatment groups (B/F/TAF group – DTG+F/TAF group) in the response rate is greater than -10%.
The change from baseline in CD4+ cell count at Week 48 will be summarized by treatment using descriptive statistics. The differences and the associated 95% CIs will be constructed using an Analysis of Variance (ANOVA) model, including treatment (B/F/TAF group vs. DTG+F/TAF group), prior NRTI use (F/TAF vs. F/TDF) and history of NRTI resistance as fixed effects in the model.

8.6. Safety Analysis

All safety analyses will be performed using the safety analysis set.

All safety data collected on or after the date that the study drug was first administered up to the date of the last dose of study drug plus 30 days, unless specified otherwise, will be summarized for subjects in the safety analysis set according to the study drug received.

Data for the pretreatment period, and the period post the date of last dose of study drug plus 30 days, will be included in data listings for all enrolled subjects.

8.6.1. Extent of Exposure

A subject’s extent of exposure to study drug will be generated from the study drug administration page in eCRF. Exposure data will be summarized by treatment group.

Duration of exposure to study drug will be expressed as the number of weeks between the first and last dose of the study drug, inclusive, regardless of temporary interruptions in study drug administration and summarized by treatment.

Dosing information for individual subjects will be listed.

8.6.2. Adverse Events

Clinical and laboratory adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). System Organ Class (SOC), High-Level Group Term (HLGT), High-Level Term (HLT), Preferred Term (PT), and Lower-Level Term (LLT) will be attached to the clinical database.

Events will be summarized on the basis of the date of onset for the event. A treatment-emergent adverse event will be defined as any adverse event with onset date on or after the study drug start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.

Summaries (number and percentage of subjects) of treatment-emergent adverse events (by SOC, HLT [if applicable], and PT) will be provided by treatment. Additional summaries will include summaries for adverse events by grade, Investigator’s assessment of relationship to study drug, and effect on study drug dosing.
On an ongoing basis adverse events will be reviewed for events that might meet the definition of Stage 3 Opportunistic Illnesses in HIV are indicative of an AIDS-Defining Diagnoses. The Gilead medical personnel will review the possible Stage 3 events and approve the events that meet the definition. Those events that do meet the Stage 3 Opportunistic Illness definition of an AIDS-Defining Diagnosis will be listed.

A listing of Stage 3 Opportunistic Illnesses in HIV can be found in Appendix 5.

8.6.3. Laboratory Evaluations

Selected laboratory data (using conventional units) will be summarized using only observed data. Absolute values and changes from baseline at all scheduled visits will be summarized.

Graded laboratory abnormalities will be defined using the grading scheme defined in Grading of laboratory abnormalities attached in Appendix 4.

Incidence of treatment-emergent laboratory abnormalities, defined as values that increase at least 1 toxicity grade from baseline at any time post baseline up to, and including, the date of last dose of study drug plus 30 days, will be summarized by treatment. If baseline data are missing, then any graded abnormality (ie, at least a Grade 1) will be considered treatment emergent. The maximum postbaseline toxicity grade will be summarized by laboratory parameter.

Laboratory abnormalities that occur before the first dose of study drug or after the last dose of study drug plus 30 days will be included in a data listing.

8.6.4. Other Safety Evaluations

Vital signs will be summarized as appropriate.

8.7. Patient Reported Outcomes (PRO)

The PRO measures based on questionnaires may be summarized by treatment and visit using descriptive statistics.

8.8. Sample Size

A total of approximately 520 HIV-1 infected subjects, randomized in a 1:1 ratio to 2 treatment groups (260 subjects per treatment group), achieves at least 90% power to detect a non-inferiority margin of 4% in difference in percentage of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 between the 2 treatment groups.

For sample size and power computation, it is assumed that both treatment groups have 2% of subjects with HIV-1 RNA ≥ 50 copies/mL at Week 48 (based on the historical Gilead Genvoya® and Stribild® studies), that a non-inferiority margin is 4%, and that the significance level of the test is at a one-sided 0.025 level. Sample size and power calculations were made using the statistical software package nQuery Advisor (Version 6.0).
8.9. Data Monitoring Committee

An external Independent Data Monitoring Committee (IDMC) will review the progress, efficacy, and safety data of this study while the study is ongoing. The committee will convene after all subjects have completed their Week 12 Visit or prematurely discontinued from the study drug. However, Gilead will defer to the IDMC for any decision to convene earlier or more frequently. The IDMC will examine the safety results of the trial and also focus on logistical issues such as accrual, retention, quality of clinical and laboratory data, and implications of results of external studies. Blinding will be preserved during the conduct of the study and access to unblinded data will be limited to designated parties.

No formal stopping rules will be used by the IDMC for safety outcomes. Rather, a clinical assessment will be made to determine if the nature, frequency, and severity of adverse events associated with a study regimen warrant the early termination of the study in the best interest of the participants.

For each IDMC analysis performed prior to the analysis of the primary efficacy endpoint, an alpha penalty of 0.00001 will be applied for the analysis of the primary endpoint.

8.10. Analysis Schedule

The Week 48 analysis will be conducted after all subjects either complete their Week 48 visit or prematurely discontinue from the study drug, respectively. Final analysis will be performed after all subjects complete the study or prematurely discontinue from the study.
9. RESPONSIBILITIES

9.1. Investigator Responsibilities

9.1.1. Good Clinical Practice

The investigator will ensure that this study is conducted in accordance with the principles of the Declaration of Helsinki (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and regulations of the country in which the research is conducted, whichever affords the greater protection to the study subject. These standards are consistent with the European Union Clinical Trials Directive 2001/20/EC and Good Clinical Practice Directive 2005/28/EC.


The investigator and all applicable subinvestigators will comply with 21 CFR, Part 54, 1998, providing documentation of their financial interest or arrangements with Gilead, or proprietary interests in the study drug under study. This documentation must be provided prior to the investigator’s (and any subinvestigator’s) participation in the study. The investigator and subinvestigator agree to notify Gilead of any change in reportable interests during the study and for 1 year following completion of the study. Study completion is defined as the date when the last subject completes the protocol-defined activities.

9.1.2. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) Review and Approval

The investigator (or sponsor as appropriate according to local regulations) will submit this protocol, informed consent form, and any accompanying material to be provided to the subject (such as advertisements, subject information sheets, or descriptions of the study used to obtain informed consent) to an IRB/IEC. The investigator will not begin any study subject activities until approval from the IRB/IEC has been documented and provided as a letter to the investigator.

Before implementation, the investigator will submit to and receive documented approval from the IRB/IEC any modifications made to the protocol or any accompanying material to be provided to the subject after initial IRB/IEC approval, with the exception of those necessary to reduce immediate risk to study subjects.

9.1.3. Informed Consent

The investigator is responsible for obtaining written informed consent from each individual participating in this study after adequate explanation of the aims, methods, objectives, and potential hazards of the study and before undertaking any study-related procedures. The
investigator must use the most current IRB/IEC-approved consent form for documenting written informed consent. Each informed consent (or assent as applicable) will be appropriately signed and dated by the subject or the subject’s legally authorized representative and the person conducting the consent discussion, and also by an impartial witness if required by IRB or IEC or local requirements. The consent form will inform subjects about pharmacogenomic testing and sample retention, and their right to receive clinically relevant pharmacogenomic analysis results.

9.1.4. Confidentiality

The investigator must assure that subjects’ anonymity will be strictly maintained and that their identities are protected from unauthorized parties. Only subject initials, year of birth, another unique identifier (as allowed by local law) and an identification code will be recorded on any form or biological sample submitted to the Sponsor, or laboratory. Laboratory specimens must be labeled in such a way as to protect subject identity while allowing the results to be recorded to the proper subject. Refer to specific laboratory instructions. NOTE: The investigator must keep a screening log showing codes, names, and addresses for all subjects screened and for all subjects enrolled in the trial. Subject data will be processed in accordance with all applicable regulations.

The investigator agrees that all information received from Gilead, including but not limited to the investigator brochure, this protocol, eCRF, the IMP, and any other study information, remain the sole and exclusive property of Gilead during the conduct of the study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior written consent from Gilead. The investigator further agrees to take all reasonable precautions to prevent the disclosure by any employee or agent of the study site to any third party or otherwise into the public domain.

9.1.5. Study Files and Retention of Records

The investigator must maintain adequate and accurate records to enable the conduct of the study to be fully documented and the study data to be subsequently verified. These documents should be classified into at least the following two categories: (1) investigator’s study file, and (2) subject clinical source documents.

The investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB or IEC and governmental approval with correspondence, informed consent, drug records, staff curriculum vitae and authorization forms, and other appropriate documents and correspondence.

The required source data should include sequential notes containing at least the following information for each subject:

- Subject identification (name, date of birth, gender);

- Documentation that subject meets eligibility criteria, (ie, history, physical examination, and confirmation of diagnosis), to support inclusion and exclusion criteria;
• Documentation of the reason(s) a consented subject is not enrolled

• Participation in study (including study number);

• Study discussed and date of informed consent;

• Dates of all visits;

• Documentation that protocol specific procedures were performed;

• Results of efficacy parameters, as required by the protocol;

• Start and end date (including dose regimen) of IMP, including dates of dispensing and return;

• Record of all adverse events and other safety parameters (start and end date, and including causality and severity);

• Concomitant medication (including start and end date, dose if relevant; dose changes);

• Date of study completion and reason for early discontinuation, if it occurs.

All clinical study documents must be retained by the investigator until at least 2 years or according to local laws, whichever is longer, after the last approval of a marketing application in an ICH region (ie, United States, Europe, or Japan) and until there are no pending or planned marketing applications in an ICH region; or, if no application is filed or if the application is not approved for such indication, until 2 years after the investigation is discontinued and regulatory authorities have been notified. Investigators may be required to retain documents longer if specified by regulatory requirements, by local regulations, or by an agreement with Gilead. The investigator must notify Gilead before destroying any clinical study records.

Should the investigator wish to assign the study records to another party or move them to another location, Gilead must be notified in advance.

If the investigator cannot provide for this archiving requirement at the study site for any or all of the documents, special arrangements must be made between the investigator and Gilead to store these records securely away from the site so that they can be returned sealed to the investigator in case of an inspection. When source documents are required for the continued care of the subject, appropriate copies should be made for storage away from the site.

9.1.6. Case Report Forms

For each subject consented, an eCRF casebook will be completed by an authorized study staff member whose training for this function is completed in EDC. The eCRF casebook will only capture the data required per the protocol schedule of events and procedures. The Inclusion/Exclusion Criteria and Enrollment eCRFs should be completed only after all data related to eligibility have been received. Subsequent to data entry, a study monitor will perform
source data verification within the EDC system. System-generated or manual queries will be issued to the investigative site staff as data discrepancies are identified by the monitor or internal Gilead staff, who routinely review the data for completeness, correctness, and consistency. The site coordinator is responsible for responding to the queries in a timely manner, within the system, either by confirming the data as correct or updating the original entry, and providing the reason for the update (e.g., data entry error). Original entries as well as any changes to data fields will be stored in the audit trail of the system. Prior to any interim time points or database lock (as instructed by Gilead), the investigator will use his/her log in credentials to confirm that the forms have been reviewed, and that the entries accurately reflect the information in the source documents. At the conclusion of the trial, Gilead will provide the site with a read-only archive copy of the data entered by that site. This archive must be stored in accordance with the records retention requirements outlined in Section 9.1.5.

9.1.7. Investigational Medicinal Product Accountability and Return

Gilead recommends that used and unused study drug supplies be returned to the shipping facility from which it came for eventual destruction. The study monitor will provide instructions for return. If return is not possible, the study monitor will evaluate each study center’s study drug disposal procedures and provide appropriate instruction for destruction of unused study drug supplies. If the site has an appropriate standard operating procedure (SOP) for drug destruction as determined by Gilead QA, the site may destroy used (empty or partially empty) and unused IMP supplies in accordance with that site’s approved SOP. A copy of the site’s approved SOP will be obtained for central files.

If study drug is destroyed on site, the investigator must maintain accurate records for all study drug destroyed. Records must show the identification and quantity of each unit destroyed, the method of destruction, and the person who disposed of the study drug. Upon study completion, copies of the study drug accountability records must be filed at the site. Another copy will be returned to Gilead.

The study monitor will review study drug supplies and associated records at periodic intervals.

9.1.8. Inspections

The investigator will make available all source documents and other records for this trial to Gilead’s appointed study monitors, to IRBs/IECs, or to regulatory authority or health authority inspectors.

9.1.9. Protocol Compliance

The investigator is responsible for ensuring the study is conducted in accordance with the procedures and evaluations described in this protocol.
9.2. Sponsor Responsibilities

9.2.1. Protocol Modifications

Protocol modifications, except those intended to reduce immediate risk to study subjects, may be made only by Gilead. The investigator must submit all protocol modifications to the IRB or IEC in accordance with local requirements and receive documented IRB or IEC approval before modifications can be implemented.

9.2.2. Study Report and Publications

A clinical study report (CSR) will be prepared and provided to the regulatory agency(ies). Gilead will ensure that the report meets the standards set out in the ICH Guideline for Structure and Content of Clinical Study Reports (ICH E3). Note that an abbreviated report may be prepared in certain cases.

Investigators in this study may communicate, orally present, or publish in scientific journals or other scholarly media only after the following conditions have been met:

The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form or the study has been completed at all study sites for at least 2 years.

The investigator will submit to Gilead any proposed publication or presentation along with the respective scientific journal or presentation forum at least 30 days before submission of the publication or presentation.

No such communication, presentation, or publication will include Gilead’s confidential information (see Section 9.1.4).

The investigator will comply with Gilead’s request to delete references to its confidential information (other than the study results) in any paper or presentation and agrees to withhold publication or presentation for an additional 60 days in order to obtain patent protection if deemed necessary.

9.3. Joint Investigator/Sponsor Responsibilities

9.3.1. Payment Reporting

Investigators and their study staff may be asked to provide services performed under this protocol, eg attendance at Investigator's Meetings. If required under the applicable statutory and regulatory requirements, Gilead will capture and disclose to Federal and State agencies any expenses paid or reimbursed for such services, including any clinical trial payments, meal, travel expenses or reimbursements, consulting fees, and any other transfer of value.
9.3.2. Access to Information for Monitoring

In accordance with regulations and guidelines, the study monitor must have direct access to the investigator’s source documentation in order to verify the accuracy of the data recorded in the eCRF.

The monitor is responsible for routine review of the eCRF at regular intervals throughout the study to verify adherence to the protocol and the completeness, consistency, and accuracy of the data being entered on them. The monitor should have access to any subject records needed to verify the entries on the eCRF. The investigator agrees to cooperate with the monitor to ensure that any problems detected through any type of monitoring (central, on site) are resolved.

9.3.3. Access to Information for Auditing or Inspections

Representatives of regulatory authorities or of Gilead may conduct inspections or audits of the clinical study. If the investigator is notified of an inspection by a regulatory authority the investigator agrees to notify the Gilead Medical Monitor immediately. The investigator agrees to provide to representatives of a regulatory agency or Gilead access to records, facilities, and personnel for the effective conduct of any inspection or audit.

9.3.4. Study Discontinuation

Both the sponsor and the investigator reserve the right to terminate the study at any time. Should this be necessary, both parties will arrange discontinuation procedures and notify the appropriate regulatory authority(ies), IRBs, and IECs. In terminating the study, Gilead and the investigator will assure that adequate consideration is given to the protection of the subjects’ interests.
10. REFERENCES


EMTRIVA®, Gilead Sciences Inc. EMTRIVA® (emtricitabine) capsule, for oral use. EMTRIVA® (emtricitabine) oral solution. US Prescribing Information. Foster City, CA. Revised November. 2012:


11. APPENDICES

Appendix 1. Investigator Signature Page
Appendix 2. Study Procedures Table
Appendix 3. Management of Clinical and Laboratory Adverse Events
Appendix 4. Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching from a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects who are Virologically Suppressed

GS-US-380-4030 Protocol Amendment 2, 28 June 2018

This protocol has been approved by Gilead Sciences, Inc. The following signature documents this approval.

INVESTIGATOR STATEMENT

I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.

I will provide all study personnel under my supervision copies of the protocol and access to all information provided by Gilead Sciences, Inc. I will discuss this material with them to ensure that they are fully informed about the drugs and the study.

Principal Investigator Name (Printed)                                    Signature

Date                                                                 Site Number

28 June 2018
### Appendix 2. Study Procedures Table

<table>
<thead>
<tr>
<th>Study Procedures</th>
<th>Screening&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Day 1</th>
<th>4</th>
<th>8</th>
<th>12</th>
<th>24</th>
<th>36</th>
<th>48</th>
<th>Post-Week 48</th>
<th>Every 12 Weeks&lt;sup&gt;c,d&lt;/sup&gt;</th>
<th>End of Blinded Treatment Visit&lt;sup&gt;e&lt;/sup&gt;</th>
<th>Open Label Extension (OL) Weeks&lt;sup&gt;f&lt;/sup&gt;</th>
<th>30 Day Follow up&lt;sup&gt;g&lt;/sup&gt;</th>
<th>ESDD&lt;sup&gt;h&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Questionnaires&lt;sup&gt;i&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Complete/ Symptom-Directed&lt;sup&gt;k&lt;/sup&gt; Physical Exam</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>12-Lead ECG (performed supine)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vital signs&lt;sup&gt;m&lt;/sup&gt; and Weight</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Urinalysis</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Serum Pregnancy Test&lt;sup&gt;o&lt;/sup&gt;</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine Pregnancy Test&lt;sup&gt;o&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>PPD</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chemistry Profile&lt;sup&gt;a&lt;/sup&gt;</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>eGFR</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

<sup>a</sup> Indicates the specific day on which the procedure was conducted.

<sup>b</sup> Indicates the week during which the procedure was conducted.

<sup>c</sup> Indicates the week of the post-treatment visit during which the procedure was conducted.

<sup>d</sup> Indicates the every 12 weeks during which the procedure was conducted.

<sup>e</sup> Indicates the end of blinded treatment visit during which the procedure was conducted.

<sup>f</sup> Indicates the open label extension (OL) weeks during which the procedure was conducted.

<sup>g</sup> Indicates the 30 day follow-up period during which the procedure was conducted.

<sup>h</sup> Indicates the ESDD period during which the procedure was conducted.

<sup>i</sup> Questionnaires are conducted at the beginning of the study and every 12 weeks thereafter.

<sup>j</sup> Indicates the specific week on which the procedure was conducted.

<sup>k</sup> Complete/Symptom-Directed Physical Exam is conducted at the beginning of the study and every 12 weeks thereafter.

<sup>l</sup> Height and weight are measured at the beginning of the study and every 12 weeks thereafter.

<sup>m</sup> Vital signs and weight are measured at the beginning of the study and every 12 weeks thereafter.

<sup>n</sup> Pregnancy tests are conducted at the beginning of the study and every 12 weeks thereafter.

<sup;o</sup> Chemistry profile and eGFR are measured at the beginning of the study and every 12 weeks thereafter.
Study Procedures | Screening\(^a\) | Day 1 | Week\(^b,c\) | Post-Week 48 | End of Blinded Treatment Visit\(^e\) | Open Label Extension (OL) Weeks\(^c,f\) | 30 Day Follow up\(^g\) | ESDD\(^h\)
--- | --- | --- | --- | --- | --- | --- | --- | ---
Hematology Profile\(^p\) | X | X | X | X | X | X | X | X | X
Metabolic Assessments\(^q\) | X | X | X | X | X | X | X | X | X
Plasma HIV-1 RNA | X | X | X | X | X | X | X | X | X

| Study Procedures | Screening\(^a\) | Day 1 | Week\(^b,c\) | Post-Week 48 | End of Blinded Treatment Visit\(^e\) | Open Label Extension (OL) Weeks\(^c,f\) | 30 Day Follow up\(^g\) | ESDD\(^h\)
--- | --- | --- | --- | --- | --- | --- | --- | ---
CD4\(^+\) Cell Count and Percentage | X | X | X | X | X | X | X | X | X
HCV Serology\(^s\) | X | X | X | X | X | X | X | X | X
HBV blood panel\(^t\) | X | X | X | X | X | X | X | X | X
Plasma HBV DNA\(^v\) | X | X | X | X | X | X | X | X | X
Randomization\(^w\) | X | X | X | X | X | X | X | X | X
Study Drug Dispensation | X | X | X | X | X | X | X | X | X
Study Drug Accountability | X | X | X | X | X | X | X | X | X
HIV-1 Genotype/Phenotype\(^c\) | X | X | X | X | X | X | X | X | X

PPD

PPD

CD4\(^+\) Cell Count and Percentage | X | X | X | X | X | X | X | X | X
HCV Serology\(^s\) | X | X | X | X | X | X | X | X | X
HBV blood panel\(^t\) | X | X | X | X | X | X | X | X | X
Plasma HBV DNA\(^v\) | X | X | X | X | X | X | X | X | X
Randomization\(^w\) | X | X | X | X | X | X | X | X | X
Study Drug Dispensation | X | X | X | X | X | X | X | X | X
Study Drug Accountability | X | X | X | X | X | X | X | X | X
HIV-1 Genotype/Phenotype\(^c\) | X | X | X | X | X | X | X | X | X

PPD

PPD
a. Evaluations to be completed within 30 days prior to Day 1.
b. Study visits are to be completed within ± 2 days of the protocol specified visit date (based on the Day 1) through Week 12 and within ± 6 days through to Week 36, unless otherwise specified. The visit window for Week 48 will be ± 6 weeks of the protocol specified visit date.
c. HIV-1 genotype and phenotype testing for subjects with confirmed virologic failure and HIV-1 RNA > 200 copies/mL. Following virologic rebound, subjects will be asked to return to the clinic (2-3 weeks later) prior to the next scheduled visit or at the next scheduled study visit for a HIV-1 RNA and HIV-1 resistance analysis (reverse transcriptase, protease, and integrase genotype and phenotype) blood draw. Based on the results of this testing, subjects should be managed according to the Virologic Rebound Schema (Section 6.11).
d. After Week 48, all subjects will continue to take their blinded study drug and attend visits every 12 weeks (± 6 days of the protocol specified visit date) until the End of Blinded Treatment Visit.
e. Once the last subject completes the Week 48 visit and Gilead completes the Week 48 analysis, all subjects will return to the clinic (preferably within 30 days) for an End of Blinded Treatment Visit. At the End of Blinded Treatment Visit, if safety and efficacy of B/F/TAF is demonstrated following review of unblinded data, subjects in a country where B/F/TAF FDC is not available, will be given the option to receive B/F/TAF FDC in an OL extension phase for up to 96 weeks, or until the product becomes accessible to subjects through an access program, or until Gilead elects to discontinue the study in that country, whichever occurs first. Treatment assignments will be provided to the investigators within 30 days of the last subject completing the End of Blinded Treatment Visit.
f. Study visits are to be completed within ± 6 days of the protocol specified visit date based on the End of Blinded Treatment Visit date, unless otherwise specified.
g. Before the OL extension period, 30-Day Follow-up is required for subjects not enrolling in the OL extension, or those who prematurely discontinue study drugs and do not continue in the study through at least one subsequent visit after the Early Study Drugs Discontinuation Visit.

During the OL extension period, subjects who complete the OL extension, or who permanently discontinue study drugs during the OL extension, will be required to return to the clinic 30 days after the last dose of study drugs, for the 30-Day Follow-Up Visit. For the purpose of scheduling a 30-Day Follow-Up Visit, a ± 6 days window may be used.
h. Before the OL extension period, Early Study Drugs Discontinuation visit is to occur within 72 hours of last dose of study drug. Subjects will be asked to continue attending the scheduled study visits through the End of Blinded Treatment Visit, even if the subject discontinues study drugs.

During the OL extension period, subjects who discontinue study drug will be asked to return to the clinic within 72 hours of stopping study drugs, for the Early Study Drugs Discontinuation Visit, followed by a 30-Day Follow-Up Visit. The subject will not continue attending the scheduled OL study visits.
i. SF-36, HIV Symptoms Distress Module, WPAI, PSQI, to be completed by the subject. Subject is to read questionnaire by himself/herself and write/mark answers directly onto questionnaires.
j. Any AE or test showing abnormal results that is believed to have a possible or probable causal relationship with the study drug will be repeated weekly (or as often as deemed prudent by the Investigator) until the abnormality is resolved, returns to baseline (Day 1) value, or is otherwise explained.
k. Symptom-directed physical examination, as needed.
l. Post Week 48, complete physical examination and HCV Serology, are to be performed every 48 weeks
m. Blood pressure, pulse, respiration rate, and temperature.

n. Females of childbearing potential only. After the Screening visit, positive urine pregnancy tests will be confirmed with a serum pregnancy test.

o. Chemistry profile: alkaline phosphatase, AST, ALT, total bilirubin, direct and indirect bilirubin, total protein, albumin, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, and amylase (reflex lipase testing is performed in subjects with total amylase > 1.5 x ULN). After Day 1, calcium, phosphorous, and magnesium will not be collected. Analyses of glucose will be done as part of the fasting metabolic assessments, and not as part of the chemistry profile at Day 1, Weeks 12, 24, 48, post Week 48 (every 24 weeks), and End of Blinded Treatment, Week 24OL, Week 48OL, Week 72OL, Week 96OL.

p. CBC with differential and platelet count.

q. Fasting (no food or drinks, except water, at least 8 hours prior to blood collection) glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has not fasted prior to the visit, the visit may proceed, but the subject must return within 72 hours in a fasted state to draw blood for the metabolic assessments.

r. Metabolic assessments during the post Week 48 will be done every 24 weeks.
s. Hepatitis C virus serology. Subjects who are HCVAb positive will have a HCV RNA test performed.
t. HBV blood panel will be performed at Screening, Week 48, every 48 weeks through End of Blinded Treatment Visit, and Weeks 48OL, 96OL: HBsAg, HBsAb, HBcAb
u. **For subjects who are HBV co-infected at any visit:** The following HBV Blood panel will be conducted by the central laboratory: HBsAb, HBsAg (qualitative and quantitative), and HBeAg (if negative, reflex HBeAb)

For subjects who are NOT HBV co-infected at any visit: The following HBV Blood panel will be conducted by the central laboratory: HBsAb, HBeAb, and HBsAg.

Subjects who are HBsAg or HBcAb positive will have a reflex test for HBV DNA (viral load)

v. **For subjects who are HBV co-infected at any visit:** Plasma HBV DNA at every visit (including OL extension period [not collected at Screening and 30-day Follow-up])

w. Randomization may be performed up to 3 days prior to the in-clinic Day 1 visit provided that all screening procedures have been completed and subject eligibility has been confirmed.

x. Initiation of the first dose of study drug is to take place in-clinic following completion of study procedures at the Day 1 visit.

y. Open label study drug, B/F/TAF FDC will be dispensed to subjects participating in the OL extension for up to 96 weeks.
Appendix 3. Management of Clinical and Laboratory Adverse Events

Grade 1
- May continue dosing at the discretion of the investigator

Grade 2
- Repeat lab to confirm toxicity grade

Grade 3
- Repeat lab to confirm toxicity grade

Grade 4
- If confirmed, and possibly or probably related to investigational medicinal products:
  1. Withhold investigational medicinal products until ≤ Grade 2
  2. Restart all investigational medicinal products at full dose upon discussion with the Gilead Sciences Medical Monitor

If Grade 3 or 4 recurrence is confirmed, and possibly or probably related to investigational medicinal products, discontinue all investigational medicinal products dosing permanently, and manage the subject according to local practice.

If confirmed, and unrelated to investigational medicinal products, dosing may continue at the discretion of the investigator.

If confirmed, and possibly or probably related to investigational medicinal products, discontinue investigational medicinal products dosing permanently, and manage subject according to local practice. Subject should be followed as clinically indicated until the laboratory abnormality returns to baseline, or is otherwise explained.
### Appendix 4. Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities

**Antiviral Toxicity Grading Scale Version: 01 April 2015**

<table>
<thead>
<tr>
<th>HEMATOLOGY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hemoglobin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>HIV POSITIVE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 57 Days</td>
<td>8.5 to 10.0 g/dL</td>
<td>7.5 to &lt; 8.5 g/dL</td>
<td>6.5 to &lt; 7.5 g/dL</td>
<td>&lt; 6.5 g/dL</td>
</tr>
<tr>
<td></td>
<td>85 to 100 g/L</td>
<td>75 to &lt; 85 g/L</td>
<td>65 to &lt; 75 g/L</td>
<td>&lt; 65 g/L</td>
</tr>
<tr>
<td>HIV NEGATIVE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 57 Days</td>
<td>10.0 to 10.9 g/dL</td>
<td>9.0 to &lt; 10.0 g/dL</td>
<td>7.0 to &lt; 9.0 g/dL</td>
<td>&lt; 7.0 g/dL</td>
</tr>
<tr>
<td></td>
<td>100 to 109 g/L</td>
<td>90 to &lt; 100 g/L</td>
<td>70 to &lt; 90 g/L</td>
<td>&lt; 70 g/L</td>
</tr>
<tr>
<td></td>
<td>OR</td>
<td>OR</td>
<td>OR</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any decrease from Baseline</td>
<td>Any decrease from Baseline</td>
<td>Any decrease from Baseline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.5 to &lt; 3.5 g/dL</td>
<td>3.5 to &lt; 4.5 g/dL</td>
<td>≥ 4.5 g/dL</td>
<td></td>
</tr>
<tr>
<td></td>
<td>25 to &lt; 35 g/L</td>
<td>35 to &lt; 45 g/L</td>
<td>≥ 45 g/L</td>
<td></td>
</tr>
<tr>
<td><strong>Infant, 36–56 Days</strong></td>
<td>8.5 to 9.4 g/dL</td>
<td>7.0 to &lt; 8.5 g/dL</td>
<td>6.0 to &lt; 7.0 g/dL</td>
<td>&lt; 6.0 g/dL</td>
</tr>
<tr>
<td>(HIV POSITIVE OR NEGATIVE)</td>
<td>85 to 94 g/L</td>
<td>70 to &lt; 85 g/L</td>
<td>60 to &lt; 70 g/L</td>
<td>&lt; 60 g/L</td>
</tr>
<tr>
<td><strong>Infant, 22–35 Days</strong></td>
<td>9.5 to 10.5 g/dL</td>
<td>8.0 to &lt; 9.5 g/dL</td>
<td>7.0 to &lt; 8.0 g/dL</td>
<td>&lt; 7.0 g/dL</td>
</tr>
<tr>
<td>(HIV POSITIVE OR NEGATIVE)</td>
<td>95 to 105 g/L</td>
<td>80 to &lt; 95 g/L</td>
<td>70 to &lt; 80 g/L</td>
<td>&lt; 70 g/L</td>
</tr>
<tr>
<td><strong>Infant, 1–21 Days</strong></td>
<td>12.0 to 13.0 g/dL</td>
<td>10.0 to &lt; 12.0 g/dL</td>
<td>9.0 to &lt; 10.0 g/dL</td>
<td>&lt; 9.0 g/dL</td>
</tr>
<tr>
<td>(HIV POSITIVE OR NEGATIVE)</td>
<td>120 to 130 g/L</td>
<td>100 to &lt; 120 g/L</td>
<td>90 to &lt; 100 g/L</td>
<td>&lt; 90 g/L</td>
</tr>
<tr>
<td><strong>Absolute Neutrophil Count</strong></td>
<td>1000 to 1300/mm³</td>
<td>750 to &lt; 1000/mm³</td>
<td>500 to &lt; 750/mm³</td>
<td>&lt; 500/mm³</td>
</tr>
<tr>
<td>Adult and Pediatric, ≥ 7 Months#</td>
<td>1.00 to 1.30 Gi/L</td>
<td>0.75 to &lt; 1.00 Gi/L</td>
<td>0.50 to &lt; 0.75 Gi/L</td>
<td>&lt; 0.50 Gi/L</td>
</tr>
<tr>
<td><strong>Absolute CD4+ Count</strong></td>
<td>300 to 400/mm³</td>
<td>200 to &lt; 300/mm³</td>
<td>100 to &lt; 200/mm³</td>
<td>&lt; 100/mm³</td>
</tr>
<tr>
<td>HIV NEGATIVE ONLY</td>
<td>300 to 400/μL</td>
<td>200 to &lt; 300/μL</td>
<td>100 to &lt; 200/μL</td>
<td>&lt; 100/μL</td>
</tr>
<tr>
<td>Adult and Pediatric &gt; 13 Years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td><strong>Absolute Lymphocyte Count</strong></td>
<td>600 to 650/mm³</td>
<td>500 to &lt; 600/mm³</td>
<td>350 to &lt; 500/mm³</td>
<td>&lt; 350/mm³</td>
</tr>
<tr>
<td>HIV NEGATIVE ONLY</td>
<td>0.60 to 0.65 GI/L</td>
<td>0.50 to &lt; 0.60 GI/L</td>
<td>0.35 to &lt; 0.50 GI/L</td>
<td>&lt; 0.35 GI/L</td>
</tr>
<tr>
<td><strong>Adult and Pediatric</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>&gt; 13 Years</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Platelets</strong></td>
<td>100,000 to &lt; 125,000/mm³</td>
<td>50,000 to &lt; 100,000/mm³</td>
<td>25,000 to &lt; 50,000/mm³</td>
<td>&lt; 25,000/mm³</td>
</tr>
<tr>
<td></td>
<td>100 to &lt; 125 GI/L</td>
<td>50 to &lt; 100 GI/L</td>
<td>25 to &lt; 50 GI/L</td>
<td>&lt; 25 GI/L</td>
</tr>
<tr>
<td><strong>WBCs</strong></td>
<td>2000/mm³ to 2500/mm³</td>
<td>1,500 to &lt; 2,000/mm³</td>
<td>1000 to &lt; 1,500/mm³</td>
<td>&lt; 1000/mm³</td>
</tr>
<tr>
<td></td>
<td>2.00 GI/L to 2.50 GI/L</td>
<td>1.50 to &lt; 2.00 GI/L</td>
<td>1.00 to &lt; 1.50 GI/L</td>
<td>&lt; 1.00 GI/L</td>
</tr>
<tr>
<td><strong>Hypofibrinogenemia</strong></td>
<td>100 to 200 mg/dL</td>
<td>75 to &lt; 100 mg/dL</td>
<td>50 to &lt; 75 mg/dL</td>
<td>&lt; 50 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.00 to 2.00 g/L</td>
<td>0.75 to &lt; 1.00 g/L</td>
<td>0.50 to &lt; 0.75 g/L</td>
<td>&lt; 0.50 g/L</td>
</tr>
<tr>
<td><strong>Hyperfibrinogenemia</strong></td>
<td>&gt; ULN to 600 mg/dL</td>
<td>&gt; 600 mg/dL</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>&gt; ULN to 6.0 g/L</td>
<td>&gt; 6.0 g/L</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Fibrin Split Product</strong></td>
<td>20 to 40 µg/mL</td>
<td>&gt; 40 to 50 µg/mL</td>
<td>&gt; 50 to 60 µg/mL</td>
<td>&gt; 60 µg/mL</td>
</tr>
<tr>
<td></td>
<td>20 to 40 mg/L</td>
<td>&gt; 40 to 50 mg/L</td>
<td>&gt; 50 to 60 mg/L</td>
<td>&gt; 60 mg/L</td>
</tr>
<tr>
<td><strong>Prothrombin Time (PT)</strong></td>
<td>&gt; 1.00 to 1.25 × ULN</td>
<td>&gt; 1.25 to 1.50 × ULN</td>
<td>&gt; 1.50 to 3.00 × ULN</td>
<td>&gt; 3.00 × ULN</td>
</tr>
<tr>
<td><strong>International Normalized Ratio</strong></td>
<td>1.1 to 1.5 x ULN</td>
<td>&gt;1.5 to 2.0 x ULN</td>
<td>&gt;2.0 to 3.0 x ULN</td>
<td>&gt;3.0 x ULN</td>
</tr>
<tr>
<td>of prothrombin time (INR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Activated Partial</strong></td>
<td>&gt; 1.00 to 1.66 × ULN</td>
<td>&gt; 1.66 to 2.33 × ULN</td>
<td>&gt; 2.33 to 3.00 × ULN</td>
<td>&gt; 3.00 × ULN</td>
</tr>
<tr>
<td>Thromboplastin Time (APTT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Methemoglobin</strong></td>
<td>5.0 to 10.0%</td>
<td>&gt; 10.0 to 15.0%</td>
<td>&gt; 15.0 to 20.0%</td>
<td>&gt; 20.0%</td>
</tr>
</tbody>
</table>

# An overlap between the Grade 1 scale and the Lab’s normal range for absolute neutrophils may result for pediatric subjects. Please follow the Gilead convention of grading any result within the lower limit of the normal range (LLN) and ULN a 0.
<table>
<thead>
<tr>
<th>CHEMISTRY</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyponatremia</td>
<td>130 to &lt;LLN mEq/L</td>
<td>125 to &lt; 130 mEq/L</td>
<td>121 to &lt; 125 mEq/L</td>
<td>&lt; 121 mEq/L</td>
</tr>
<tr>
<td></td>
<td>130 to &lt;LLN mmol/L</td>
<td>125 to &lt; 130 mmol/L</td>
<td>121 to &lt; 125 mmol/L</td>
<td>&lt; 121 mmol/L</td>
</tr>
<tr>
<td>Hypernatremia</td>
<td>&gt;ULN to 150 mEq/L</td>
<td>&gt; 150 to 154 mEq/L</td>
<td>&gt; 154 to 159 mEq/L</td>
<td>&gt; 159 mEq/L</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN to 150 mmol/L</td>
<td>&gt; 150 to 154 mmol/L</td>
<td>&gt; 154 to 159 mmol/L</td>
<td>&gt; 159 mmol/L</td>
</tr>
<tr>
<td>Hypokalemia Adult and Pediatric ≥ 1 Year</td>
<td>3.0 to &lt;LLN mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
<td>&lt; 2.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>3.0 to &lt;LLN mmol/L</td>
<td>2.5 to &lt; 3.0 mmol/L</td>
<td>2.0 to &lt; 2.5 mmol/L</td>
<td>&lt; 2.0 mmol/L</td>
</tr>
<tr>
<td>Infant &lt;1 Year</td>
<td>3.0 to 3.4 mEq/L</td>
<td>2.5 to &lt; 3.0 mEq/L</td>
<td>2.0 to &lt; 2.5 mEq/L</td>
<td>&lt; 2.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>3.0 to 3.4 mmol/L</td>
<td>2.5 to &lt; 3.0 mmol/L</td>
<td>2.0 to &lt; 2.5 mmol/L</td>
<td>&lt; 2.0 mmol/L</td>
</tr>
<tr>
<td>Hyperkalemia Adult and Pediatric ≥ 1 Year</td>
<td>5.6 to 6.0 mEq/L</td>
<td>&gt; 6.0 to 6.5 mEq/L</td>
<td>&gt; 6.5 to 7.0 mEq/L</td>
<td>&gt; 7.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>5.6 to 6.0 mmol/L</td>
<td>&gt; 6.0 to 6.5 mmol/L</td>
<td>&gt; 6.5 to 7.0 mmol/L</td>
<td>&gt; 7.0 mmol/L</td>
</tr>
<tr>
<td>Infant &lt;1 Year</td>
<td>&gt;ULN to 6.0 mEq/L</td>
<td>&gt; 6.0 to 6.5 mEq/L</td>
<td>&gt; 6.5 to 7.0 mEq/L</td>
<td>&gt; 7.0 mEq/L</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN to 6.0 mmol/L</td>
<td>&gt; 6.0 to 6.5 mmol/L</td>
<td>&gt; 6.5 to 7.0 mmol/L</td>
<td>&gt; 7.0 mmol/L</td>
</tr>
<tr>
<td>Hypoglycemia Adult and Pediatric ≥ 1 Month</td>
<td>55 to 64 mg/dL</td>
<td>40 to &lt; 55 mg/dL</td>
<td>30 to &lt; 40 mg/dL</td>
<td>&lt; 30 mg/dL</td>
</tr>
<tr>
<td></td>
<td>3.03 to 3.58 mmol/L</td>
<td>2.20 to &lt; 3.03 mmol/L</td>
<td>1.64 to &lt; 2.20 mmol/L</td>
<td>&lt; 1.64 mmol/L</td>
</tr>
<tr>
<td>Infant, &lt; 1 Month</td>
<td>50 to 54 mg/dL</td>
<td>40 to &lt; 50 mg/dL</td>
<td>30 to &lt; 40 mg/dL</td>
<td>&lt; 30 mg/dL</td>
</tr>
<tr>
<td></td>
<td>2.8 to 3.0 mmol/L</td>
<td>2.2 to &lt; 2.8 mmol/L</td>
<td>1.7 to &lt; 2.2 mmol/L</td>
<td>&lt; 1.7 mmol/L</td>
</tr>
<tr>
<td>CHEMISTRY</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Hyperglycemia, Nonfasting</strong></td>
<td>116 to 160 mg/dL</td>
<td>&gt; 160 to 250 mg/dL</td>
<td>&gt; 250 to 500 mg/dL</td>
<td>&gt; 500 mg/dL</td>
</tr>
<tr>
<td></td>
<td>6.42 to 8.91 mmol/L</td>
<td>&gt; 8.91 to 13.90 mmol/L</td>
<td>&gt; 13.90 to 27.79 mmol/L</td>
<td>&gt; 27.79 mmol/L</td>
</tr>
<tr>
<td><strong>Hyperglycemia, Fasting</strong></td>
<td>110 to 125 mg/dL</td>
<td>&gt;125 to 250 mg/dL</td>
<td>&gt;250 to 500 mg/dL</td>
<td>&gt;500 mg/dL</td>
</tr>
<tr>
<td></td>
<td>6.08 to 6.96 mmol/L</td>
<td>&gt;6.96 to 13.90 mmol/L</td>
<td>&gt;13.90 to 27.79 mmol/L</td>
<td>&gt;27.79 mmol/L</td>
</tr>
<tr>
<td><strong>Hypocalcemia</strong></td>
<td>7.8 &lt;LLN mg/dL</td>
<td>7.0 to &lt; 7.8 mg/dL</td>
<td>6.1 to &lt; 7.0 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
</tr>
<tr>
<td>(corrected for albumin if appropriate*)</td>
<td>1.94 to &lt;LLN mmol/L</td>
<td>1.74 to &lt; 1.94 mmol/L</td>
<td>1.51 to &lt; 1.74 mmol/L</td>
<td>&lt; 1.51 mmol/L</td>
</tr>
<tr>
<td><strong>Pediatric ≥7 days -2 Years</strong></td>
<td>7.8 to 8.4 mg/dL</td>
<td>7.0 to &lt; 7.8 mg/dL</td>
<td>6.1 to &lt; 7.0 mg/dL</td>
<td>&lt; 6.1 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.94 to 2.10 mmol/L</td>
<td>1.74 to &lt; 1.94 mmol/L</td>
<td>1.51 to &lt; 1.74 mmol/L</td>
<td>&lt; 1.51 mmol/L</td>
</tr>
<tr>
<td><strong>Adult and Pediatric ≥2 Years</strong></td>
<td>7.0 to &lt; 7.8 mg/dL</td>
<td>1.74 to &lt; 1.94 mmol/L</td>
<td>1.51 to &lt; 1.74 mmol/L</td>
<td>&lt; 1.51 mmol/L</td>
</tr>
<tr>
<td><strong>Infant, &lt; 7 Days</strong></td>
<td>6.5 to 7.5 mg/dL</td>
<td>6.0 to &lt; 6.5 mg/dL</td>
<td>5.5 to &lt; 6.0 mg/dL</td>
<td>&lt; 5.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.61 to 1.88 mmol/L</td>
<td>1.49 to &lt; 1.61 mmol/L</td>
<td>1.36 to &lt; 1.49 mmol/L</td>
<td>&lt; 1.36 mmol/L</td>
</tr>
<tr>
<td><em><em>Hypercalcemia (corrected for albumin if appropriate</em>)</em>*</td>
<td>&gt;ULN to 11.5 mg/dL</td>
<td>&gt; 11.5 to 12.5 mg/dL</td>
<td>&gt; 12.5 to 13.5 mg/dL</td>
<td>&gt; 13.5 mg/dL</td>
</tr>
<tr>
<td>Adult and Pediatric ≥7 Days</td>
<td>&gt;ULN to 2.88 mmol/L</td>
<td>&gt; 2.88 to 3.13 mmol/L</td>
<td>&gt; 3.13 to 3.38 mmol/L</td>
<td>&gt; 3.38 mmol/L</td>
</tr>
<tr>
<td><strong>Infant, &lt; 7 Days</strong></td>
<td>&gt; 11.5 to 12.9 mg/dL</td>
<td>&gt; 12.4 to 12.9 mg/dL</td>
<td>&gt; 12.9 to 13.5 mg/dL</td>
<td>&gt; 13.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; 2.86 to 3.30 mmol/L</td>
<td>&gt; 3.10 to 3.23 mmol/L</td>
<td>&gt; 3.23 to 3.38 mmol/L</td>
<td>&gt; 3.38 mmol/L</td>
</tr>
<tr>
<td><strong>Hypocalcemia (ionized)</strong></td>
<td>3.0 mg/dL to &lt; LLN</td>
<td>2.5 to &lt; 3.0 mg/dL</td>
<td>2.0 to &lt; 2.5 mg/dL</td>
<td>&lt; 2.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>0.74 mmol/L to &lt; LLN</td>
<td>0.62 to &lt; 0.74 mmol/L</td>
<td>0.49 to &lt; 0.62 mmol/L</td>
<td>&lt; 0.49 mmol/L</td>
</tr>
<tr>
<td>CHEMISTRY</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Hypercalcemia (ionized)</td>
<td>&gt; ULN to 6.0 mg/dL</td>
<td>&gt; 6.0 to 6.5 mg/dL</td>
<td>&gt; 6.5 to 7.0 mg/dL</td>
<td>&gt; 7.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; ULN to 1.50 mmol/L</td>
<td>&gt; 1.50 to 1.63 mmol/L</td>
<td>&gt; 1.63 to 1.75 mmol/L</td>
<td>&gt; 1.75 mmol/L</td>
</tr>
<tr>
<td>Hypomagnesemia</td>
<td>1.40 to &lt;LLN mg/dL</td>
<td>1.04 to &lt; 1.40 mg/dL</td>
<td>0.67 to &lt; 1.04 mg/dL</td>
<td>&lt; 0.67 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.2 to &lt;LLN mmol/L</td>
<td>0.9 to &lt; 1.2 mmol/L</td>
<td>0.6 to &lt; 0.9 mmol/L</td>
<td>&lt; 0.6 mgEq/L</td>
</tr>
<tr>
<td></td>
<td>0.58 to &lt;LLN mmol/L</td>
<td>0.43 to &lt; 0.58 mmol/L</td>
<td>0.28 to &lt; 0.43 mmol/L</td>
<td>&lt; 0.28 mmol/L</td>
</tr>
<tr>
<td>Hypophosphatemia</td>
<td>2.0 to &lt; LLN mg/dL</td>
<td>1.5 to &lt; 2.0 mg/dL</td>
<td>1.0 to &lt; 1.5 mg/dL</td>
<td>&lt; 1.0 mg/dL</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>0.63 to &lt; LLN mmol/L</td>
<td>0.47 to &lt; 0.63 mmol/L</td>
<td>0.31 to &lt; 0.47 mmol/L</td>
<td>&lt; 0.31 mmol/L</td>
</tr>
<tr>
<td>&gt; 14 Years</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pediatric 1 Year–14 Years</td>
<td>3.0 to &lt;LLN mg/dL</td>
<td>2.5 to &lt; 3.0 mg/dL</td>
<td>1.5 to &lt; 2.5 mg/dL</td>
<td>&lt; 1.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>0.96 to &lt;LLN mmol/L</td>
<td>0.80 to &lt; 0.96 mmol/L</td>
<td>0.47 to &lt; 0.80 mmol/L</td>
<td>&lt; 0.47 mmol/L</td>
</tr>
<tr>
<td>Pediatric &lt; 1 Year</td>
<td>3.5 to &lt;LLN mg/dL</td>
<td>2.5 to &lt; 3.5 mg/dL</td>
<td>1.5 to &lt; 2.5 mg/dL</td>
<td>&lt; 1.5 mg/dL</td>
</tr>
<tr>
<td></td>
<td>1.12 to &lt;LLN mmol/L</td>
<td>0.80 to &lt; 1.12 mmol/L</td>
<td>0.47 to &lt; 0.80 mmol/L</td>
<td>&lt; 0.47 mmol/L</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.5 × ULN</td>
<td>&gt; 2.5 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 14 Days</td>
<td>NA</td>
<td>20.0 to 25.0 mg/dL</td>
<td>&gt; 25.0 to 30.0 mg/dL</td>
<td>&gt; 30.0 mg/dL</td>
</tr>
<tr>
<td>(non-hemolytic)</td>
<td></td>
<td>342 to 428 μmol/L</td>
<td>&gt; 428 to 513 μmol/L</td>
<td>&gt; 513 μmol/L</td>
</tr>
<tr>
<td>Infant, ≤ 14 Days (hemolytic)</td>
<td>NA</td>
<td>NA</td>
<td>20.0 to 25.0 mg/dL</td>
<td>&gt; 25.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>342 to 428 μmol/L</td>
<td>&gt; 428 μmol/L</td>
</tr>
<tr>
<td>Blood Urea Nitrogen</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>CHEMISTRY</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Hyperuricemia</strong></td>
<td>&gt;ULN to 10.0 mg/dL</td>
<td>&gt; 10.0 to 12.0 mg/dL</td>
<td>&gt; 12.0 to 15.0 mg/dL</td>
<td>&gt; 15.0 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt;ULN to 597 μmol/L</td>
<td>&gt; 597 to 716 μmol/L</td>
<td>&gt; 716 to 895 μmol/L</td>
<td>&gt; 895 μmol/L</td>
</tr>
<tr>
<td><strong>Hypouricemia</strong></td>
<td>1.5 mg/dL to &lt; LLN</td>
<td>1.0 to &lt; 1.5 mg/dL</td>
<td>0.5 to &lt; 1.0 mg/dL</td>
<td>&lt; 0.5 mg/dL</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>87 μmol/L to &lt; LLN</td>
<td>57 to &lt; 87 μmol/L</td>
<td>27 to &lt; 57 μmol/L</td>
<td>&lt; 27 μmol/L</td>
</tr>
<tr>
<td>≥ 1 year</td>
<td>N/A</td>
<td>1.0 mg/dL to &lt; LLN</td>
<td>0.5 to &lt; 1.0 mg/dL</td>
<td>&lt; 0.5 mg/dL</td>
</tr>
<tr>
<td>Infant &lt; 1 Year</td>
<td>57 μmol/L to &lt; LLN</td>
<td>27 to &lt; 57 μmol/L</td>
<td>&lt; 27 μmol/L</td>
<td></td>
</tr>
<tr>
<td><strong>Creatinine</strong></td>
<td>&gt; 1.50 to 2.00 mg/dL</td>
<td>&gt; 2.00 to 3.00 mg/dL</td>
<td>&gt; 3.00 to 6.00 mg/dL</td>
<td>&gt; 6.00 mg/dL</td>
</tr>
<tr>
<td></td>
<td>&gt; 133 to 177 μmol/L</td>
<td>&gt; 177 to 265 μmol/L</td>
<td>&gt; 265 to 530 μmol/L</td>
<td>&gt; 530 μmol/L</td>
</tr>
<tr>
<td><strong>Bicarbonate</strong></td>
<td>16.0 mEq/L to &lt; LLN</td>
<td>11.0 to &lt; 16.0 mEq/L</td>
<td>&gt; 8.0 to &lt; 11.0 mEq/L</td>
<td>&lt; 8.0 mEq/L</td>
</tr>
<tr>
<td>Adult and Pediatric</td>
<td>16.0 mmol/L to &lt; LLN</td>
<td>11.0 to &lt; 16.0 mmol/L</td>
<td>&gt; 8.0 to &lt; 11.0 mmol/L</td>
<td>&lt; 8.0 mmol/L</td>
</tr>
<tr>
<td>≥ 4 Years</td>
<td>NA</td>
<td>11.0 mEq/L to &lt; LLN</td>
<td>8.0 to &lt; 11.0 mEq/L</td>
<td>&lt; 8.0 mEq/L</td>
</tr>
<tr>
<td>Pediatric &lt; 4 Years</td>
<td>11.0 mmol/L to &lt; LLN</td>
<td>8.0 to &lt; 11.0 mmol/L</td>
<td>&lt; 8.0 mmol/L</td>
<td></td>
</tr>
<tr>
<td><strong>Triglycerides</strong></td>
<td>NA</td>
<td>500 to 750 mg/dL</td>
<td>&gt; 750 to 1200 mg/dL</td>
<td>&gt; 1200 mg/dL</td>
</tr>
<tr>
<td>(Fasting)</td>
<td></td>
<td>5.64–8.47 mmol/L</td>
<td>&gt; 8.47–13.55 mmol/L</td>
<td>&gt; 13.55 mmol/L</td>
</tr>
<tr>
<td><strong>LDL (Fasting)</strong></td>
<td>130 to 160 mg/dL</td>
<td>&gt;160 to 190 mg/dL</td>
<td>&gt; 190 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Adult</td>
<td>3.35 to 4.15 mmol/L</td>
<td>&gt;4.15 to 4.92 mmol/L</td>
<td>&gt;4.92 mmol/L</td>
<td>NA</td>
</tr>
<tr>
<td><strong>LDL (Fasting)</strong></td>
<td>110 to 130 mg/dL</td>
<td>&gt;130 to 190 mg/dL</td>
<td>&gt; 190 mg/dL</td>
<td></td>
</tr>
<tr>
<td>Pediatric &gt;2 to &lt;18 years</td>
<td>2.84 to 3.37 mmol/L</td>
<td>&gt;3.37 to 4.92 mmol/L</td>
<td>&gt;4.92 mmol/L</td>
<td>NA</td>
</tr>
</tbody>
</table>
## CHEMISTRY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hypercholesterolemia</strong> (Fasting)</td>
<td>200 to 239 mg/dL 5.16 to 6.19 mmol/L</td>
<td>&gt; 239 to 300 mg/dL 6.19 to 7.77 mmol/L</td>
<td>&gt; 300 mg/dL 7.77 mmol/L</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Pediatric &lt; 18 Years</strong></td>
<td>170 to 199 mg/dL 4.39 to 5.15 mmol/L</td>
<td>&gt; 199 to 300 mg/dL 5.15 to 7.77 mmol/L</td>
<td>&gt; 300 mg/dL 7.77 mmol/L</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Creatine Kinase</strong></td>
<td>3.0 to &lt; 6.0 × ULN</td>
<td>6.0 to &lt; 10.0 × ULN</td>
<td>10.0 to &lt; 20.0 × ULN</td>
<td>≥ 20.0 × ULN</td>
</tr>
</tbody>
</table>

* Calcium should be corrected for albumin if albumin is < 4.0 g/dL

** An overlap between the Grade 1 scale and the Lab’s normal range for creatinine may result for Male subjects >70 yrs. Please follow the Gilead convention of grading any result within the LLN and ULN a 0.

## ENZYMES

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (SGOT)</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>ALT (SGPT)</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>GGT</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>Alkaline Phosphatase</td>
<td>1.25 to 2.50 × ULN</td>
<td>&gt; 2.50 to 5.00 × ULN</td>
<td>&gt; 5.00 to 10.00 × ULN</td>
<td>&gt; 10.00 × ULN</td>
</tr>
<tr>
<td>Total Amylase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.0 × ULN</td>
<td>&gt; 2.0 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Pancreatic Amylase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 2.0 × ULN</td>
<td>&gt; 2.0 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td>Lipase</td>
<td>&gt; 1.0 to 1.5 × ULN</td>
<td>&gt; 1.5 to 3.0 × ULN</td>
<td>&gt; 3.0 to 5.0 × ULN</td>
<td>&gt; 5.0 × ULN</td>
</tr>
<tr>
<td><strong>Albumin</strong>&lt;br&gt;Pediatrics &lt;16 years</td>
<td><strong>-</strong>&lt;br&gt;2.0 to &lt; LLN g/dL 20 to &lt; LLN g/L</td>
<td><strong>&lt; 2.0 g/dL</strong>&lt;br&gt;&lt; 20 g/L</td>
<td><strong>NA</strong>&lt;br&gt;NA</td>
<td><strong>NA</strong>&lt;br&gt;NA</td>
</tr>
<tr>
<td><strong>≥ 16 years</strong></td>
<td>3.0 g/dL to &lt; LLN 30 g/L to &lt; LLN</td>
<td>2.0 to &lt; 3.0 g/dL 20 to &lt; 30 g/L</td>
<td>&lt; 2.0 g/dL 20 g/L</td>
<td>NA</td>
</tr>
</tbody>
</table>
## URINALYSIS

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematuria (Dipstick)</td>
<td>1+</td>
<td>2+</td>
<td>3-4+</td>
<td>NA</td>
</tr>
<tr>
<td>Hematuria (Quantitative)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td>&gt;ULN - 10 RBC/HPF</td>
<td>&gt; 10-75 RBC/HPF</td>
<td>&gt; 75 RBC/HPF</td>
<td>NA</td>
</tr>
<tr>
<td>Males</td>
<td>6-10 RBC/HPF</td>
<td>&gt; 10-75 RBC/HPF</td>
<td>&gt; 75 RBC/HPF</td>
<td>NA</td>
</tr>
<tr>
<td>Proteinuria (Dipstick)</td>
<td>1+</td>
<td>2-3+</td>
<td>4+</td>
<td>NA</td>
</tr>
<tr>
<td>Proteinuria, 24 Hour Collection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult and Pediatric ≥ 10 Years</td>
<td>200 to 999 mg/24 h</td>
<td>&gt;999 to 1999 mg/24 h</td>
<td>&gt;1999 to 3500 mg/24 h</td>
<td>&gt; 3500 mg/24 h</td>
</tr>
<tr>
<td>Pediatric &gt; 3 Mo to &lt; 10 Years</td>
<td>201 to 499 mg/m²/24 h</td>
<td>&gt;499 to 799 mg/m²/24 h</td>
<td>&gt;799 to 1000 mg/m²/24 h</td>
<td>&gt; 1000 mg/m²/24 h</td>
</tr>
<tr>
<td>Glycosuria (Dipstick)</td>
<td>1+</td>
<td>2-3+</td>
<td>4+</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Notes:**
- Toxicity grades for Quantitative and Dipstick Hematuria will be assigned by Covance Laboratory, however for other laboratories, toxicity grades will only be assigned to Dipstick Hematuria.
- With the exception of lipid tests, any graded laboratory test with a result that is between the LLN and ULN should be assigned Grade 0.
- If the severity of a clinical AE could fall under either one of two grades (eg, the severity of an AE could be either Grade 2 or Grade 3), select the higher of the two grades for the AE.
<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cardiac Arrhythmia (general) (By ECG or physical exam)</td>
<td>Asymptomatic AND No intervention indicated</td>
<td>Asymptomatic AND Non-urgent medical intervention indicated</td>
<td>Symptomatic, non-life-threatening AND Non-urgent medical intervention indicated</td>
<td>Life-threatening arrhythmia OR Urgent intervention indicated</td>
</tr>
<tr>
<td>Cardiac-ischemia/Infarction</td>
<td>NA</td>
<td>NA</td>
<td>Symptomatic ischemia (stable angina) OR Testing consistent with ischemia</td>
<td>Unstable angina OR Acute myocardial infarction</td>
</tr>
<tr>
<td>Hemorrhage (significant acute blood loss)</td>
<td>NA</td>
<td>Symptomatic AND No transfusion indicated</td>
<td>Symptomatic AND Transfusion of ≤ 2 units packed RBCs (for children ≤ 10 cc/kg) indicated</td>
<td>Life-threatening hypotension OR Transfusion of &gt; 2 units packed RBCs indicated (for children ≤ 10 cc/kg) indicated</td>
</tr>
<tr>
<td>Hypertension (with repeat testing at same visit)</td>
<td>140–159 mmHg systolic OR 90–99 mmHg diastolic</td>
<td>&gt; 159–179 mmHg systolic OR &gt; 99–109 mmHg diastolic</td>
<td>&gt; 179 mmHg systolic OR &gt; 109 mmHg diastolic</td>
<td>Life-threatening consequences (eg, malignant hypertension) OR Hospitalization (other than ER visit) indicated Life-threatening consequences (eg, malignant hypertension) OR Hospitalization indicated (other than emergency room visit)</td>
</tr>
<tr>
<td><strong>Pediatric ≤ 17 Years</strong> (with repeat testing at same visit)</td>
<td>NA</td>
<td>91st–94th percentile adjusted for age, height, and gender (systolic and/or diastolic)</td>
<td>≥ 95th percentile adjusted for age, height, and gender (systolic and/or diastolic)</td>
<td>Life-threatening consequences (eg, malignant hypertension) OR Hospitalization (other than ER visit) indicated Life-threatening consequences (eg, malignant hypertension) OR Hospitalization indicated (other than emergency room visit)</td>
</tr>
<tr>
<td>Hypotension</td>
<td>NA</td>
<td>Symptomatic, corrected with oral fluid replacement</td>
<td>Symptomatic, IV fluids indicated</td>
<td>Shock requiring use of vasopressors or mechanical assistance to maintain blood pressure</td>
</tr>
<tr>
<td>Pericardial Effusion</td>
<td>Asymptomatic, small effusion requiring no intervention</td>
<td>Asymptomatic, moderate or larger effusion requiring no intervention</td>
<td>Effusion with non-life-threatening physiologic consequences OR Effusion with nonurgent intervention indicated</td>
<td>Life-threatening consequences (eg, tamponade) OR Urgent intervention indicated</td>
</tr>
<tr>
<td>CARDIOVASCULAR</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>----------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Prolonged PR Interval</strong></td>
<td>PR interval 0.21 to 0.25 sec</td>
<td>PR interval &gt; 0.25 sec</td>
<td>Type II 2nd degree AV block OR Ventricular pause &gt; 3.0 sec</td>
<td>Complete AV block</td>
</tr>
<tr>
<td><strong>Pediatric ≤ 16 Years</strong></td>
<td>1st degree AV block (PR &gt; normal for age and rate)</td>
<td>Type I 2nd degree AV block</td>
<td>Type II 2nd degree AV block</td>
<td>Complete AV block</td>
</tr>
<tr>
<td><strong>Prolonged QTc</strong></td>
<td>Asymptomatic, QTc interval 0.45 to 0.47 sec OR Increase interval &lt; 0.03 sec above baseline</td>
<td>Asymptomatic, QTc interval 0.48 to 0.49 sec OR Increase in interval 0.03 to 0.05 sec above baseline</td>
<td>Asymptomatic, QTc interval ≥ 0.50 sec OR Increase in interval ≥ 0.06 sec above baseline</td>
<td>Life-threatening consequences, eg, Torsade de pointes or other associated serious ventricular dysrhythmia</td>
</tr>
<tr>
<td><strong>Pediatric ≤ 16 Years</strong></td>
<td>Asymptomatic, QTc interval 0.450 to 0.464 sec</td>
<td>Asymptomatic, QTc interval 0.465 to 0.479 sec</td>
<td>Asymptomatic, QTc interval ≥ 0.480 sec</td>
<td>Life-threatening consequences, eg, Torsade de pointes or other associated serious ventricular dysrhythmia</td>
</tr>
<tr>
<td><strong>Thrombosis/Embolism</strong></td>
<td>NA</td>
<td>Deep vein thrombosis AND No intervention indicated (eg, anticoagulation, lysis filter, invasive procedure)</td>
<td>Deep vein thrombosis AND Intervention indicated (eg, anticoagulation, lysis filter, invasive procedure)</td>
<td>Embolic event (eg, pulmonary embolism, life-threatening thrombus)</td>
</tr>
<tr>
<td><strong>Vasovagal Episode (associated with a procedure of any kind)</strong></td>
<td>Present without loss of consciousness</td>
<td>Present with transient loss of consciousness</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Ventricular Dysfunction (congestive heart failure, CHF)</strong></td>
<td>NA</td>
<td>Asymptomatic diagnostic finding AND intervention indicated</td>
<td>New onset with symptoms OR Worsening symptomatic CHF</td>
<td>Life-threatening CHF</td>
</tr>
</tbody>
</table>
### RESPIRATORY

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bronchospasm (acute)</td>
<td>FEV1 or peak flow reduced to 70% to 80%</td>
<td>FEV1 or peak flow 50% to 69%</td>
<td>FEV1 or peak flow 25% to 49%</td>
</tr>
<tr>
<td>Dyspnea or Respiratory Distress</td>
<td>Dyspnea on exertion with no or minimal interference with usual social &amp; functional activities</td>
<td>Dyspnea on exertion causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Dyspnea at rest causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Pediatric &lt; 14 Years</td>
<td>Wheezing OR minimal increase in respiratory rate for age</td>
<td>Nasal flaring OR Intercostal retractions OR Pulse oximetry 90% to 95%</td>
<td>Respiratory failure with ventilatory support indicated</td>
</tr>
<tr>
<td>Dyspnea at rest causing inability to perform usual social &amp; functional activities</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### OCULAR/VISUAL

<table>
<thead>
<tr>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uveitis</td>
<td>Asymptomatic but detectable on exam</td>
<td>Symptomatic anterior uveitis OR Medical intervention indicated</td>
<td>Posterior or pan-uveitis OR Operative intervention indicated</td>
</tr>
<tr>
<td>Visual Changes (from baseline)</td>
<td>Visual changes causing no or minimal interference with usual social &amp; functional activities</td>
<td>Visual changes causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Visual changes causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Disabling visual loss in affected eye(s)</td>
</tr>
<tr>
<td>SKIN</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>----------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alopecia</td>
<td>Thinning detectable by study participant or caregiver (for disabled adults)</td>
<td>Thinning or patchy hair loss detectable by health care provider</td>
<td>Complete hair loss</td>
</tr>
<tr>
<td>Cutaneous Reaction – Rash</td>
<td>Localized macular rash</td>
<td>Diffuse macular, maculopapular, or morbilliform rash OR Target lesions</td>
<td>Diffuse macular, maculopapular, or morbilliform rash with vesicles or limited number of bullae OR Superficial ulcerations of mucous membrane limited to one site</td>
</tr>
<tr>
<td>Hyperpigmentation</td>
<td>Slight or localized</td>
<td>Marked or generalized</td>
<td>NA</td>
</tr>
<tr>
<td>Hypopigmentation</td>
<td>Slight or localized</td>
<td>Marked or generalized</td>
<td>NA</td>
</tr>
<tr>
<td>Pruritis (itching – no skin lesions)</td>
<td>Itching causing no or minimal interference with usual social &amp; functional activities</td>
<td>Itching causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Itching causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>(See also Injection Site Reactions: Pruritis associated with injection)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condition</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Anorexia</td>
<td>Loss of appetite without decreased oral intake</td>
<td>Loss of appetite associated with decreased oral intake without significant weight loss</td>
<td>Loss of appetite associated with significant weight loss</td>
</tr>
<tr>
<td>Ascites</td>
<td>Asymptomatic</td>
<td>Symptomatic AND Intervention indicated (eg, diuretics or therapeutic paracentesis)</td>
<td>Symptomatic despite intervention</td>
</tr>
<tr>
<td>Cholecystitis</td>
<td>NA</td>
<td>Symptomatic AND Medical intervention indicated</td>
<td>Radiologic, endoscopic, or operative intervention indicated</td>
</tr>
<tr>
<td>Constipation</td>
<td>NA</td>
<td>Persistent constipation requiring regular use of dietary modifications, laxatives, or enemas</td>
<td>Obstipation with manual evacuation indicated</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>Transient or intermittent episodes of unformed stools OR Increase of ≤ 3 stools over baseline/24 hr OR Increase of 4–6 stools over baseline per 24 hrs.</td>
<td>Persistent episodes of unformed to watery stools OR Increase of 4–6 stools over baseline per 24 hrs.</td>
<td>Bloody diarrhea OR Increase of ≥ 7 stools per 24-hour period OR IV fluid replacement indicated</td>
</tr>
<tr>
<td></td>
<td>Liquid stools (more unformed than usual) but usual number of stools</td>
<td>Liquid stools with increased number of stools OR Mild dehydration</td>
<td>Liquid stools with moderate dehydration</td>
</tr>
<tr>
<td>dysphagia-Odynophagia</td>
<td>Symptomatic but able to eat usual diet</td>
<td>Symptoms causing altered dietary intake without medical intervention indicated</td>
<td>Symptoms causing severely altered dietary intake with medical intervention indicated</td>
</tr>
<tr>
<td>GASTROINTESTINAL</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Mucositis/Stomatitis (clinical exam)</td>
<td>Erythema of the mucosa</td>
<td>Patchy pseudomembranes or ulcerations</td>
<td>Confluent pseudomembranes or ulcerations OR Mucosal bleeding with minor trauma</td>
</tr>
<tr>
<td>See also Proctitis, Dysphagia-Odynophagia</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>Transient (&lt; 24 hours) or intermittent nausea with no or minimal interference with oral intake</td>
<td>Persistent nausea resulting in decreased oral intake for 24–48 hours</td>
<td>Persistent nausea resulting in minimal oral intake for &gt; 48 hours OR Aggressive rehydration indicated (eg, IV fluids)</td>
</tr>
<tr>
<td>Pancreatitis</td>
<td>NA</td>
<td>Symptomatic AND Hospitalization not indicated (other than ER visit)</td>
<td>Symptomatic AND Hospitalization indicated (other than ER visit)</td>
</tr>
<tr>
<td>Proctitis (functional-symptomatic)</td>
<td>Rectal discomfort AND No intervention indicated</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities OR Medical intervention indicated</td>
<td>Symptoms causing inability to perform usual social/functional activities OR Operative intervention indicated</td>
</tr>
<tr>
<td>Also see Mucositis/Stomatitis for Clinical Exam</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>Transient or intermittent vomiting with no or minimal interference with oral intake</td>
<td>Frequent episodes of vomiting with no or mild dehydration</td>
<td>Persistent vomiting resulting in orthostatic hypotension OR Aggressive rehydration indicated</td>
</tr>
<tr>
<td>NEUROLOGICAL</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Alteration in Personality-</td>
<td>Alteration causing no or minimal interference with usual social &amp; functional activities</td>
<td>Alteration causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Alteration causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Behavior or in Mood (eg, agitation, anxiety, depression, mania, psychosis)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Altered Mental Status</td>
<td>Changes causing no or minimal interference with usual social &amp; functional activities</td>
<td>Mild lethargy or somnolence causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Confusion, memory impairment, lethargy, or somnolence causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>For Dementia, see Cognitive and Behavioral/Attentional Disturbance (including dementia and ADD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ataxia</td>
<td>Asymptomatic ataxia detectable on exam OR Minimal ataxia causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptomatic ataxia causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptomatic ataxia causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Cognitive and Behavioral/Attentional Disturbance (including dementia and Attention Deficit Disorder)</td>
<td>Disability causing no or minimal interference with usual social &amp; functional activities OR Specialized resources not indicated</td>
<td>Disability causing greater than minimal interference with usual social &amp; functional activities OR Specialized resources on part-time basis indicated</td>
<td>Disability causing inability to perform usual social &amp; functional activities OR Specialized resources on a full-time basis indicated</td>
</tr>
<tr>
<td>Central nervous system Ischemia (acute)</td>
<td>NA</td>
<td>NA</td>
<td>Transient ischemic attack</td>
</tr>
<tr>
<td>Developmental delay – Pediatric ≤ 16 Years</td>
<td>Mild developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Moderate developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
<td>Severe developmental delay, either motor or cognitive, as determined by comparison with a developmental screening tool appropriate for the setting</td>
</tr>
<tr>
<td>Neurological</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Headache</td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Insomnia</td>
<td>NA</td>
<td>Difficulty sleeping causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Difficulty sleeping causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Neuromuscular Weakness (including myopathy &amp; neuropathy)</td>
<td>Asymptomatic with decreased strength on exam OR Minimal muscle weakness causing no or minimal interference with usual social &amp; functional activities</td>
<td>Muscle weakness causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Muscle weakness causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Neurosensory Alteration (including paresthesia and painful neuropathy)</td>
<td>Asymptomatic with sensory alteration on exam or minimal paresthesia causing no or minimal interference with usual social &amp; functional activities</td>
<td>Sensory alteration or paresthesia causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Sensory alteration or paresthesia causing inability to perform usual social &amp; functional activities</td>
</tr>
<tr>
<td>Seizure: (new onset)</td>
<td>NA</td>
<td>1 seizure</td>
<td>2–4 seizures</td>
</tr>
<tr>
<td>Neurological Event</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Seizure: (pre-existing)</td>
<td>NA</td>
<td>Increased frequency of pre-existing seizures (non-repetitive) without change in seizure character OR infrequent breakthrough seizures while on stable meds in a previously controlled seizure disorder</td>
<td>Change in seizure character from baseline either in duration or quality (eg, severity or focality)</td>
</tr>
<tr>
<td>For Worsening of Existing Epilepsy the Grades Should Be Based on an Increase from Previous Level of Control to Any of These Levels</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seizures</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting &lt; 5 minutes with &lt; 24 hours post ictal state</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting 5–20 minutes with &lt; 24 hours post ictal state</td>
<td>Seizure, generalized onset with or without secondary generalization, lasting &gt; 20 minutes</td>
</tr>
<tr>
<td>Syncope (not associated with a procedure)</td>
<td>NA</td>
<td>Present</td>
<td>NA</td>
</tr>
<tr>
<td>Vertigo</td>
<td>Vertigo causing no or minimal interference with usual social &amp; functional activities</td>
<td>Vertigo causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Vertigo causing inability to perform usual social &amp; functional activities</td>
</tr>
</tbody>
</table>
## MUSCULOSKELETAL

<table>
<thead>
<tr>
<th>Condition</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthralgia</td>
<td>Joint pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Joint pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Joint pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling joint pain causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Arthritis</td>
<td>Stiffness or joint swelling causing no or minimal interference with usual social &amp; functional activities</td>
<td>Stiffness or joint swelling causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Stiffness or joint swelling causing inability to perform usual social &amp; functional activities</td>
<td>Disabling joint stiffness or swelling causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Bone Mineral Loss</td>
<td>BMD t-score or z-score –2.5 to –1.0</td>
<td>BMD t-score or z-score &lt; –2.5</td>
<td>Pathological fracture (including loss of vertebral height)</td>
<td>Pathologic fracture causing life-threatening consequences</td>
</tr>
<tr>
<td>Pediatric &lt; 21 Years</td>
<td>BMD z-score –2.5 to –1.0</td>
<td>BMD z-score &lt; –2.5</td>
<td>Pathological fracture (including loss of vertebral height)</td>
<td>Pathologic fracture causing life-threatening consequences</td>
</tr>
<tr>
<td>Myalgia</td>
<td>Muscle pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Muscle pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Muscle pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling muscle pain causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td>Osteonecrosis</td>
<td>NA</td>
<td>Asymptomatic with radiographic findings AND No operative intervention indicated</td>
<td>Symptomatic bone pain with radiographic findings OR Operative intervention indicated</td>
<td>Disabling bone pain with radiographic findings causing inability to perform basic self-care functions</td>
</tr>
</tbody>
</table>
### SYSTEMIC

<table>
<thead>
<tr>
<th>Grade</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute Systemic Allergic Reaction</strong></td>
<td>Localized urticaria (wheals) with no medical intervention indicated</td>
<td>Localized urticaria with medical intervention indicated OR Mild angioedema with no medical intervention indicated</td>
<td>Generalized urticaria OR Angioedema with medical intervention indicated OR Symptomatic mild bronchospasm</td>
<td>Acute anaphylaxis OR Life-threatening bronchospasm OR laryngeal edema</td>
</tr>
<tr>
<td><strong>Chills</strong></td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>NA</td>
</tr>
<tr>
<td><strong>Fatigue Malaise</strong></td>
<td>Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities</td>
<td>Incapacitating fatigue/malaise symptoms causing inability to perform basic self-care functions</td>
</tr>
<tr>
<td><strong>Fever (nonaxillary)</strong></td>
<td>37.7°C to 38.6°C 99.8°F to 101.5°F</td>
<td>38.7°C to 39.3°C 101.6°F to 102.8°F</td>
<td>39.4°C to 40.5°C 102.9°F to 104.9°F</td>
<td>&gt; 40.5°C &gt; 104.9°F</td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td>Pain causing no or minimal interference with usual social &amp; functional activities</td>
<td>Pain causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Pain causing inability to perform usual social &amp; functional activities</td>
<td>Disabling pain causing inability to perform basic self-care functions OR Hospitalization (other than ER visit) indicated</td>
</tr>
<tr>
<td><strong>Unintentional Weight Loss</strong></td>
<td>NA</td>
<td>5% to 9% loss in body weight from baseline</td>
<td>10% to 19% loss in body weight from baseline</td>
<td>≥ 20% loss in body weight from baseline OR Aggressive intervention indicated [eg, tube feeding or total parenteral nutrition]</td>
</tr>
<tr>
<td>INJECTION SITE REACTION</td>
<td>Grade 1</td>
<td>Grade 2</td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>-------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Injection Site Pain (pain without touching) Or Tenderness (pain when area is touched)</td>
<td>Pain/tenderness causing no or minimal limitation of use of limb</td>
<td>Pain/tenderness limiting use of limb OR Pain/tenderness causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Pain/tenderness causing inability to perform usual social &amp; functional activities</td>
<td>Pain/tenderness causing inability to perform basic self-care function OR Hospitalization (other than ER visit) indicated for management of pain/tenderness</td>
</tr>
<tr>
<td>Injection Site Reaction (Localized), &gt; 15 Years</td>
<td>Erythema OR Induration of 5 × 5 cm to 9 × 9 cm (or 25–81 × cm²)</td>
<td>Erythema OR Induration OR Edema &gt; 9 cm any diameter (or &gt; 81 cm²)</td>
<td>Erythema OR Induration OR Edema &gt; 2.5 cm diameter but &lt; 50% surface area of the extremity segment (eg, upper arm/thigh)</td>
<td>Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage</td>
</tr>
<tr>
<td>Pediatric ≤ 15 Years</td>
<td>Erythema OR Induration OR Edema present but ≤ 2.5 cm diameter</td>
<td>Erythema OR Induration OR Edema &gt; 9 cm any diameter (or &gt; 81 cm²)</td>
<td>Erythema OR Induration OR Edema &gt; 2.5 cm diameter but &lt; 50% surface area of the extremity segment (eg, upper arm/thigh)</td>
<td>Ulceration OR Secondary infection OR Phlebitis OR Sterile abscess OR Drainage</td>
</tr>
<tr>
<td>Pruritis Associated with Injection See also Skin: Pruritis (itching—no skin lesions)</td>
<td>Itching localized to injection site AND Relieved spontaneously or with &lt; 48 h treatment</td>
<td>Itching beyond the injection site but not generalized OR Itching localized to injection site requiring ≥ 48 h treatment</td>
<td>Generalized itching causing inability to perform usual social &amp; functional activities</td>
<td>NA</td>
</tr>
</tbody>
</table>

NA
<table>
<thead>
<tr>
<th>Condition</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipodystrophy (eg, back of neck, breasts, abdomen)</td>
<td>Detectable by study participant or caregiver (for young children and disabled adults)</td>
<td>Detectable on physical exam by health care provider</td>
<td>Disfiguring OR Obvious changes on casual visual inspection</td>
<td>NA</td>
</tr>
<tr>
<td>Diabetes Mellitus</td>
<td>NA</td>
<td>New onset without need to initiate medication OR Modification of current meds to regain glucose control</td>
<td>New onset with initiation of indicated med OR Diabetes uncontrolled despite treatment modification</td>
<td>Life-threatening consequences (eg, ketoacidosis, hyperosmolar non-ketotic coma)</td>
</tr>
<tr>
<td>Gynecomastia</td>
<td>Detectable by study participant or caregiver (for young children and disabled adults)</td>
<td>Detectable on physical exam by health care provider</td>
<td>Disfiguring OR Obvious on casual visual inspection</td>
<td>NA</td>
</tr>
<tr>
<td>Hyperthyroidism</td>
<td>Asymptomatic</td>
<td>Symptomatic causing greater than minimal interference with usual social &amp; functional activities OR Thyroid suppression therapy indicated</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities OR Uncontrolled despite treatment modification</td>
<td>Life-threatening consequences (eg, thyroid storm)</td>
</tr>
<tr>
<td>Hypothyroidism</td>
<td>Asymptomatic</td>
<td>Symptomatic causing greater than minimal interference with usual social &amp; functional activities OR Thyroid replacement therapy indicated</td>
<td>Symptoms causing inability to perform usual social &amp; functional activities OR Uncontrolled despite treatment modification</td>
<td>Life-threatening consequences (eg, myxedema coma)</td>
</tr>
<tr>
<td>Lipoatrophy (eg, fat loss from the face, extremities, buttocks)</td>
<td>Detectable by study participant or caregiver (for young children and disabled adults)</td>
<td>Detectable on physical exam by health care provider</td>
<td>Disfiguring OR Obvious on casual visual inspection</td>
<td>NA</td>
</tr>
</tbody>
</table>
### GENITOURINARY

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermenstrual Bleeding (IMB)</td>
<td>Spotting observed by participant OR Minimal blood observed during clinical or colposcopic exam</td>
<td>Intermenstrual bleeding not greater in duration or amount than usual menstrual cycle</td>
<td>Intermenstrual bleeding greater in duration or amount than usual menstrual cycle</td>
<td>Hemorrhage with life-threatening hypotension OR Operative intervention indicated</td>
</tr>
<tr>
<td>Urinary Tract obstruction (eg, stone)</td>
<td>NA</td>
<td>Signs or symptoms of urinary tract obstruction without hydronephrosis or renal dysfunction</td>
<td>Signs or symptoms of urinary tract obstruction with hydronephrosis or renal dysfunction</td>
<td>Obstruction causing life-threatening consequences</td>
</tr>
</tbody>
</table>

### INFECTION

<table>
<thead>
<tr>
<th></th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infection (any other than HIV infection)</td>
<td>Localized, no systemic antiμbial treatment indicated AND Symptoms causing no or minimal interference with usual social &amp; functional activities</td>
<td>Systemic antiμbial treatment indicated OR Symptoms causing greater than minimal interference with usual social &amp; functional activities</td>
<td>Systemic antiμbial treatment indicated AND Symptoms causing inability to perform usual social &amp; functional activities OR Operative intervention (other than simple incision and drainage) indicated</td>
<td>Life-threatening consequences (eg, septic shock)</td>
</tr>
</tbody>
</table>

**Basic Self-care Functions:** Activities such as bathing, dressing, toileting, transfer/movement, continence, and feeding.

**Usual Social & Functional Activities:** Adaptive tasks and desirable activities, such as going to work, shopping, cooking, use of transportation, pursuing a hobby, etc.
Appendix 5. Definitions of Stage 3 Opportunistic Illnesses in HIV (CDC Guidelines)

1. Candidiasis of bronchi, trachea, or lungs
2. Candidiasis of esophagus
3. Cervical cancer, invasive
4. Coccidioidomycosis, disseminated or extrapulmonary
5. Cryptococcosis, extrapulmonary
6. Cryptosporidiosis, chronic intestinal (> 1 month duration)
7. Cytomegalovirus disease (other than liver, spleen or nodes)
8. Cytomegalovirus retinitis (with loss of vision)
9. Encephalopathy, HIV-related
10. Herpes simplex: chronic ulcer(s) (> 1 month duration); or bronchitis, pneumonitis or esophagitis
11. Histoplasmosis, disseminated or extrapulmonary
12. Isosporiasis, chronic intestinal (> 1 month duration)
13. Kaposi’s sarcoma
14. Lymphoma, Burkitt’s (or equivalent term)
15. Lymphoma, immunoblastic (or equivalent term)
16. Lymphoma, primary, of brain
17. Mycobacterium avium complex or Mycobacterium kansasii, disseminated or extrapulmonary
18. Mycobacterium tuberculosis, of any site, pulmonary, disseminated or extrapulmonary
19. Mycobacterium, other species or unidentified species, disseminated or extrapulmonary
20. Pneumocystis jirovecii (previously known as “Pneumocystis carinii) pneumonia
21. Pneumonia, recurrent
22. Progressive multifocal leukoencephalopathy
23. *Salmonella* septicemia, recurrent

24. Toxoplasmosis of brain

25. Wasting syndrome attributed to HIV infection

CDC Stage-3-Defining Opportunistic Illnesses in HIV Infection - 2014 {Schneider 2008}
Appendix 6. Pregnancy Precautions, Definition for Female of Childbearing Potential, and Contraceptive Requirements

1) Definitions

a. Definition of Childbearing Potential

For the purposes of this study, a female born subject is considered of childbearing potential following the initiation of puberty (Tanner stage 2) until becoming post-menopausal, unless permanently sterile or with medically documented ovarian failure.

Women are considered to be in a postmenopausal state when they are ≥ 54 years of age with cessation of previously occurring menses for ≥ 12 months without an alternative cause.

Permanent sterilization includes hysterectomy, bilateral oophorectomy, or bilateral salpingectomy in a female subject of any age.

b. Definition of Male Fertility

For the purposes of this study, a male born subject is considered to be fertile after the initiation of puberty unless permanently sterile by bilateral orchidectomy or medical documentation.

2) Contraception Requirements for Female Subjects

a. Study Drug Effects on Pregnancy and Hormonal Contraception

The data on B/F/TAF in pregnant women is limited or not available. There is no suspicion of human teratogenicity based on class effects or genotoxic potential. Relevant non-clinical reproductive studies for human pregnancy do not indicate a strong suspicion of human teratogenicity/fetotoxicity. Data from clinical pharmacokinetic interaction studies of BIC and F/TAF have demonstrated that there is no reduction in the clinical efficacy of hormonal contraception or that the effect on hormonal contraception is insignificant. Please refer to the latest version of the B/F/TAF investigator’s brochure and the current Prescribing Information and local product labeling.

Serious cases of neural tube birth defects involving the brain, spine, and spinal cord have been reported in babies born to women treated with dolutegravir. Preliminary results from an ongoing observational study in Botswana found that women who received dolutegravir at the time of becoming pregnant or early in the first trimester appear to be at higher risk for these defects.

Please refer to the latest local product labeling for DTG for additional information.

b. Contraception Requirements for Female Subjects of Childbearing Potential

The inclusion of female subjects of childbearing potential requires the use of highly effective contraceptive measures. They must have a negative serum pregnancy test at Screening and a negative pregnancy test on the Baseline/Day 1 visit prior to randomization. At minimum, a pregnancy test will be performed 7 days after the last study drug dose. In the event of a delayed
menstrual period (over one month between menstruations), a pregnancy test must be performed
to rule out pregnancy. This is true even for women of childbearing potential with infrequent or
irregular periods. Female subjects must also agree to one of the following from Screening until
30 days after the last dose of study drug.

- Complete abstinence from intercourse of reproductive potential. Abstinence is an acceptable
  method of contraception only when it is in line with the subject’s preferred and usual
  lifestyle.

Or

- Consistent and correct use of 1 of the following methods of birth control listed below.
  - Intrauterine device (IUD) with a failure rate of <1% per year
  - Intrauterine hormone-releasing system (IUS) with a failure rate of <1% per year
  - Tubal sterilization
  - Essure micro-insert system (provided confirmation of success by hysterosalpingogram
    three months after procedure and where permitted and used per local prescribing label)
  - Vasectomy in the male partner (provided that the partner is the sole sexual partner and
    had confirmation of surgical success 3 months after procedure)

Female subjects who wish to use a hormonally based method must use it in conjunction with a
barrier method, preferably a male condom. Female subjects who utilize a hormonal
contraceptive as one of their birth control methods must have consistently used the same method
for at least three months prior to study dosing. Hormonally-based contraceptives and barrier
methods permitted for use in this protocol are as follows:

- Barrier methods (each method must be used with a hormonal method)
  - Male condom (with or without spermicide)
  - Female condom (with or without spermicide)
  - Diaphragm with spermicide
  - Cervical cap with spermicide
  - Sponge with spermicide

- Hormonal methods (each method must be used with a barrier method, preferably male
  condom)
  - Oral contraceptives (either combined or progesterone only)
- Injectable progesterone
- Subdermal contraceptive implant
- Transdermal contraceptive patch
- Contraceptive vaginal ring

Female subjects must also refrain from egg donation and in vitro fertilization during treatment and until at least 30 days after the end of relevant systemic exposure.

3) Contraception Requirements for Male Subjects

During the study, male subjects with female partners of childbearing potential should use condoms when engaging in intercourse of reproductive potential.

4) Unacceptable Birth Control Methods

Birth control methods that are unacceptable include periodic abstinence (eg, calendar, ovulation, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method (LAM). Female condom and male condom should not be used together.

5) Procedures to be Followed in the Event of Pregnancy

Subjects will be instructed to notify the investigator if they become pregnant, or are concerned they may be pregnant at any time during the study, or if they become pregnant within 30 days of last study drug dose. Subjects who become pregnant or who suspect that they are pregnant during the study must report the information to the investigator and discontinue study drug immediately. Subjects who become pregnant will be discontinued from the study and their study treatment assignment will be unblinded by the Investigator and provided to the subject.

Subjects who become pregnant while on study should receive appropriate monitoring and care until the conclusion of the pregnancy. Subjects who become pregnant while on study who are not engaged in pre-natal care that includes a routine second trimester ultrasound will be referred for ultrasonography as part of study follow-up. Instructions for reporting pregnancy and pregnancy outcome are outlined in Section 7.6.2.1.
ELECTRONIC SIGNATURES

<table>
<thead>
<tr>
<th>Signed by</th>
<th>Meaning of Signature</th>
<th>Server Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Erin Quirk</td>
<td>Clinical Research eSigned</td>
<td>28-Jun-2018 23:26:45</td>
</tr>
</tbody>
</table>